---
document_datetime: 2024-02-02 15:08:28
document_pages: 104
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0138-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-003820-ii-0138-epar-assessment-report-variation_en.pdf
version: success
processing_time: 198.5485463
conversion_datetime: 2025-12-30 00:05:45.079132
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
09 November 2023 EMA/534959/2023

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Invented name: Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0138

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................                                 | 6                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation .................................................................................................. | 6                                                                                                          |
| 1.2. Steps taken for the assessment of the product                                                                        | ........................................................ 7                                                 |
| 2. Scientific discussion                                                                                                  | ................................................................................ 7                         |
| 2.1. Introduction                                                                                                         | ........................................................................................................ 7 |
| 2.1.1. Problem statement                                                                                                  | ............................................................................................ 7             |
| 2.1.2. About the product                                                                                                  | ............................................................................................. 9            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                          | ........ 9                                                                                                 |
| 2.1.4. General comments on compliance with GCP                                                                            | .......................................................... 9                                               |
| 2.2. Non-clinical aspects                                                                                                 | .............................................................................................. 9           |
| 2.3. Clinical aspects                                                                                                     | .................................................................................................. 10      |
| 2.3.1. Introduction                                                                                                       | .................................................................................................... 10    |
| 2.3.2. Pharmacokinetics                                                                                                   | ............................................................................................ 10            |
| 2.3.3. Pharmacodynamics ..........................................................................................        | 15                                                                                                         |
| 2.3.4. PK/PD modelling                                                                                                    | ............................................................................................. 16           |
| 2.3.5. Discussion on clinical pharmacology                                                                                | ................................................................... 16                                     |
| 2.3.6. Conclusions on clinical pharmacology                                                                               | ................................................................. 16                                       |
| 2.4. Clinical efficacy                                                                                                    | .................................................................................................. 17      |
| 2.4.1. Dose response study(ies) .................................................................................         | 17                                                                                                         |
| 2.4.2. Main study                                                                                                         | ..................................................................................................... 17   |
| 2.4.3. Discussion on clinical efficacy ............................................................................       | 62                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................          | 66                                                                                                         |
| 2.5. Clinical safety                                                                                                      | .................................................................................................... 66    |
| 2.5.1. Discussion on clinical safety ..............................................................................       | 95                                                                                                         |
| 2.5.2. Conclusions on clinical safety ............................................................................        | 98                                                                                                         |
| 2.5.3. PSUR cycle                                                                                                         | ..................................................................................................... 98   |
| 2.6. Risk management plan                                                                                                 | ....................................................................................... 98                 |
| 2.7. Update of the Product information ......................................................................             | 100                                                                                                        |
| 2.7.1. User consultation                                                                                                  | .......................................................................................... 100             |
| 3. Benefit-Risk Balance ...........................................................................                       | 100                                                                                                        |
| 3.1. Therapeutic Context .........................................................................................        | 100                                                                                                        |
| 3.1.1. Disease or condition                                                                                               | ...................................................................................... 100                 |
| 3.1.2. Available therapies and unmet medical need                                                                         | ..................................................... 101                                                  |
| 3.1.3. Main clinical studies .......................................................................................      | 101                                                                                                        |
| 3.2. Favourable effects ............................................................................................      | 101                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects ...........................................                   | 101                                                                                                        |
| 3.4. Unfavourable effects .........................................................................................       | 102                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects                                                             | ....................................... 102                                                                |
| 3.6. Effects Table ....................................................................................................   | 102                                                                                                        |
| 3.7. Benefit-risk assessment and discussion                                                                               | ............................................................... 103                                        |
| 3.7.1. Importance of favourable and unfavourable effects ............................................                     | 103                                                                                                        |
| 3.7.2. Balance of benefits and risks ..........................................................................           | 104                                                                                                        |
| 3.7.3. Additional considerations on the benefit risk balance                                                              | .......................................... 104                                                             |

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions ..................................................................................................... 104

## 4. Recommendations ............................................................................... 104

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                            |
|----------------|-------------------------------------------------------|
| 1L             | First-line                                            |
| ADA            | Antidrug antibodies                                   |
| AE             | Adverse event(s)                                      |
| AEOSI          | Adverse events of special interest                    |
| ALT            | Alanine transaminase                                  |
| APaT           | All Participants as Treated                           |
| AST            | Aspartate aminotransferase                            |
| BICR           | Blinded Independent Central Review                    |
| BTC            | Biliary tract carcinoma                               |
| CCA            | Cholangiocarcinoma                                    |
| CI             | Confidence interval                                   |
| CL             | Clearance                                             |
| CPS            | Combined positive score                               |
| CR             | Complete response                                     |
| CSR            | Clinical study report                                 |
| CTCAE          | Common Terminology Criteria for Adverse Events        |
| DCO            | Data cutoff                                           |
| DDI            | Drug-drug interaction                                 |
| dMMR           | Mismatch repair deficient                             |
| DOR            | Duration of response                                  |
| EC 50          | half-maximal effective concentration                  |
| ECOG PS        | Eastern Cooperative Oncology Group Performance Status |
| EMA            | European Medicines Agency                             |
| ENSCCA         | European Network for the Study of Cholangiocarcinoma  |
| ePRO           | Electronic Patient Reported Outcomes                  |
| ESMO           | European Society for Medical Oncology                 |
| E-R            | Exposure-response                                     |
| EU             | European Union                                        |
| FA             | Final analysis                                        |
| FAS            | Full analysis set                                     |
| FDA            | Food and Drug Administration                          |
| GBC            | Gallbladder cancer                                    |
| GHS            | Global Health Status                                  |
| HBV            | Hepatitis B virus                                     |
| HCC            | Hepatocellular carcinoma                              |
| HCV            | Hepatitis C virus                                     |
| HECI           | Hepatic events of clinical interest                   |
| HNSCC          | Head and neck squamous cell carcinoma                 |
| HR             | Hazard ratio                                          |
| HRQoL          | Health-related Quality of Life                        |
| IA1            | Interim analysis 1                                    |
| IFN            | Interferon                                            |
| IgG            | Immunoglobulin G                                      |
| IL-2           | Interleukin-2                                         |
| ITT            | Intention-to-treat                                    |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                   |
|----------------|----------------------------------------------|
| KM             | Kaplan-Meier                                 |
| LSM            | Least squares mean                           |
| mAb            | Monoclonal antibody                          |
| MMS            | Microsatellite Stable                        |
| MSI-H          | Microsatellite instability-high              |
| NCCN           | National Comprehensive Cancer Network        |
| NSCLC          | Non-small cell lung cancer                   |
| NTRK           | Neurotrophic tyrosine receptor kinase        |
| ORR            | Objective response rate                      |
| OS             | Overall survival                             |
| PD-1           | Programmed death receptor 1                  |
| PD-L1 and -L2  | Programmed cell death ligands 1 and 2        |
| PFS            | Progression-free survival                    |
| PK             | Pharmacokinetic                              |
| PR             | Partial response                             |
| PRO            | Patient-reported outcomes                    |
| PT             | Preferred term                               |
| Q3W            | Every 3 weeks                                |
| Q6W            | Every 6 weeks                                |
| QoL            | Quality of Life                              |
| RCC            | Renal cell carcinoma                         |
| RECIST         | Response Evaluation Criteria in Solid Tumors |
| RSD            | Reference safety data                        |
| SAE            | Serious adverse event                        |
| SAP            | Statistical analysis plan                    |
| SOC            | Standard of care                             |
| TIL            | Tumor-infiltrating lymphocytes               |
| TNBC           | Triple negative breast cancer                |
| TNFα           | Tumor necrosis factor-α                      |
| TTD            | Time-to-deterioration                        |
| TTR            | Time to response                             |
| US             | United States                                |
| WBC            | White blood cell count                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 1 June 2023 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include KEYTRUDA in combination with gemcitabine-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, based on final results from study KEYNOTE-966; this is a Phase 3 randomized, double blind study of Pembrolizumab plus Gemcitabine/Cisplatin versus Placebo plus Gemcitabine/Cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. As a consequence, sections 4.1, 4.4 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 43.1 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP was completed.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Paolo Gasparini

Co-Rapporteur:

N/A

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 1 June 2023       |
| Start of procedure:                                  | 17 June 2023      |
| CHMP Rapporteur Assessment Report                    | 11 August 2023    |
| PRAC Rapporteur Assessment Report                    | 16 August 2023    |
| PRAC members comments                                | 23 August 2023    |
| Updated PRAC Rapporteur Assessment Report            | 24 August 2023    |
| PRAC Outcome                                         | 31 August 2023    |
| CHMP members comments                                | 4 September 2023  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 8 September 2023  |
| Request for supplementary information (RSI)          | 14 September 2023 |
| PRAC Rapporteur Assessment Report                    | 12 October 2023   |
| CHMP Rapporteur Assessment Report                    | 25 October 2023   |
| PRAC Outcome                                         | 26 October 2023   |
| CHMP members comments                                | 30 October 2023   |
| Updated CHMP Rapporteur Assessment Report            | 3 November 2023   |
| Opinion                                              | 9 November 2023   |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The biliary tract carcinoma (BTC) comprises a heterogeneous group of malignancies affecting the biliary tree that are distinguished based on the anatomical localisation (gallbladder, intrahepatic, perihilar, and distal/periampullary). Given the rare frequency of these tumours, the different subtypes are generally pooled together although carrying different epidemiology, risk factors, clinical presentation, molecular features, and prognosis (Manne et al , 2021) 1 .

1 Manne, A., Woods, E., Tsung, A. and Mittra, A. (2021) 'Biliary tract cancers: treatment updates and future directions in the era of precision medicine and immuno-oncology', Frontiers in Oncology, 11, pp. 1-16. doi: 10.3389/fonc.2021.768009.

<div style=\"page-break-after: always\"></div>

## State the claimed the therapeutic indication

The initially applied indication was: KEYTRUDA, in combination with gemcitabine-based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.

## Epidemiology and risk factors, screening tools/prevention

BTC is rare accounting for &lt;1% of all human malignancies. The incidence ranges from 0.35 cases per 100,000 in high-income countries to 40-fold in endemic parts of Asia and South America. Risk factors vary between subtypes and geographical regions. Primary sclerosing cholangitis, inflammatory bowel disease, gallstones, liver cirrhosis, hepatitis B and C, primary sclerosing cholangitis (PSC), and (in endemic areas) liver fluke infections, are associated with increased risk of BTC. Gallbladder cancer is also associated with obesity and female sex. Recently, diabetes, obesity and use of hormonal contraceptives have been identified as new risk factors for intrahepatic cholangiocarcinoma (Valle et al. , 2021) 2 (Rahman et al. , 2021) 3 .

Guidelines for imaging-based surveillance of patients with PSC are available (Berry et al ., 2022) 4 . For the other at-risk clinical conditions, screening has not yet been established.

Risk factors for BTC vary between regions depending on the prevailing etiopathogenesis. However, chronic inflammation of the biliary epithelium is a key feature characterising the different subtypes (Lazcano-Ponce et al ., 2001) 5 .

## Clinical presentation, diagnosis and stage/prognosis

Diffuse symptomatology and high-risk invasive diagnostics make biliary tract cancer challenging to diagnose and tumours are often advanced at diagnosis, contributing to the poor overall 5-year relative survival of only 14-16%. Despite variations in geographic distribution and risk factors, the approach to diagnosis and treatment remains the same. The majority of patients are diagnosed in advanced stage and are treated with systemic therapy. Patients presenting with earlier stage disease may undergo curative surgical resection; however, postoperative recurrence is reported in more than half of the patients. Overall, most patients are treated with systemic therapy and prognosis remains poor highlighting the unmet medical need for this condition (Kang et al., 2022) 6 .

## Management

Chemotherapy has long been the SoC for first-line treatment of advanced BTC, and the cisplatin gemcitabine doublet is the most commonly adopted therapy in the advanced stage of cancer, with a demonstrated survival advantage compared to gemcitabine alone. Oxaliplatin may be substituted for cisplatin in case of kidney disease, and gemcitabine monotherapy may be preferred in patients with poor

2 Valle, J.W., Kelley, R.K., Nervi, B., Oh, D.Y. and Zhu, A.X. (2021) 'Biliary tract cancer', Lancet, 397(10269), 428-44. https://doi.org/10.1016/S0140-6736(20)32167-7

3 Rahman, R., Ludvigsson, J.F., von Seth, E., Lagergren, J., Bergquist, A. and Radkiewicz, C., 2021. Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study. Cancer Epidemiology, 70, p.101855.

4 Berry PA, Kotha S. Surveillance imaging in primary sclerosing cholangitis (PSC): evidence, patient preference and physician autonomy. Transl Gastroenterol Hepatol. 2022 Oct 25;7:43. doi: 10.21037/tgh-21-87. PMID: 36300155; PMCID: PMC9468984.

5 Lazcano-Ponce, E.C., Miquel, J.F., Muñoz, N., Herrero, R., Ferrecio, C., Wistuba, I.I., Alonso de Ruiz, P., Aristi Urista, G. and Nervi, F. (2001) 'Epidemiology and molecular pathology of gallbladder cancer', CA: A Cancer Journal for Clinicians, 51(6), 349364. https://doi.org/10.3322/canjclin.51.6.349

6 Kang MJ, Lim J, Han SS, Park HM, Kim SW, Lee WJ, Woo SM, Kim TH, Won YJ, Park SJ. Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep. 2022 Jun 17;12(1):10206. doi: 10.1038/s41598-022-13605-3. PMID: 35715440; PMCID: PMC9205970.

<div style=\"page-break-after: always\"></div>

clinical performance (i.e. PS of 2 or other factors of fragility). The recently concluded TOPAZ-1 study provided evidence for improvement in OS with the immune checkpoint inhibitor durvalumab in addition to cisplatin-gemcitabine compared to chemotherapy alone. This combination has been included in the most up-to-date clinical guidance as recommended first-line treatment for advanced BTC (ESMO 2023) 7 . Alternative therapeutic schemes, including triplet regimens, are currently under investigation.

## 2.1.2. About the product

Pembrolizumab is a humanised mAb which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

Since its first approval within Europe for the treatment of advanced melanoma in 2015, pembrolizumab has been licensed for a number of different malignancies, both as monotherapy or in association to chemotherapy.

The recommended dose of KEYTRUDA in adults is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

No Scientific Advice was sought by the EMA during the development program of pembrolizumab for the BTC indication.

## 2.1.4. General comments on compliance with GCP

The MAH claimed that the clinical studies were conducted in accordance with current standard research approaches with regard to the design, conduct, and analysis of such studies including the archiving of essential documents. All studies were conducted following appropriate Good Clinical Practice standards and considerations for the ethical treatment of human participants that were in place at the time the studies were performed.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

7 ESMO Congress 2023 (2023) Madrid, Spain, 20-24 October 2023. Available at: https://www.esmo.org/meetingcalendar/esmo-congress-2023 (Accessed: 26 October 2023). Valle, J.W., Kelley, R.K., Nervi, B., Oh, D.-Y. and Zhu, A.X. (2021) 'Biliary tract cancer', The Lancet, 397(10272), pp. 428-444. doi: 10.1016/S0140-6736(21)00153-7

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Study Number/Status                          | Design                                                                   | Population                                                                                                                                 | Dosage, Regimen                                                                                                                                                                                          | Primary Efficacy Endpoint                    |
|----------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| KEYNOTE-966 Ongoing                          | Randomized, double-blind, placebo- controlled, parallel group, multisite | Participants with advanced/unresectable biliary carcinoma (intrahepatic, extrahepatic, or gallbladder, excluding ampulla of vater cancers) | Arm A: pembrolizumab 200 mg Q3W + gemcitabine 1000 mg/m 2 + cisplatin 25 mg/m 2 on Day 1 and 8 of each cycle Arm B: placebo + gemcitabine 1000 mg/m 2 + cisplatin 25 mg/m 2 on Day 1 and 8 of each cycle | OS                                           |
| OS=overall survival; Q3W=once every 3 weeks. | OS=overall survival; Q3W=once every 3 weeks.                             | OS=overall survival; Q3W=once every 3 weeks.                                                                                               | OS=overall survival; Q3W=once every 3 weeks.                                                                                                                                                             | OS=overall survival; Q3W=once every 3 weeks. |

## 2.3.2. Pharmacokinetics

The recommended dose of KEYTRUDA in adults is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.

PK data form study KEYNOTE-966 were used in support of 200 mg Q3W as the recommended dose of pembrolizumab in combination with chemotherapy in participants with advanced BTC.

Substantial characterization of the PK and immunogenicity of pembrolizumab have been provided in previous submissions. In particular, pembrolizumab PK disposition has been characterized via pooled population PK analyses using serum concentration-time data contributed from subjects across various clinical studies using a time-dependent PK (TDPK) model. The PK reference dataset for monotherapy includes all available PK data from subjects enrolled on KEYNOTE-001, KEYNOTE-002, KEYNOTE-006, KEYNOTE-010, and KEYNOTE-024, with an overall sample size of 2993. This serves as the PK reference analysis to support descriptions of pembrolizumab pharmacokinetics in the USPI and EU SmPC.

<div style=\"page-break-after: always\"></div>

In addition to the dosing regimens of 200 mg Q3W or 2 mg/kg Q3W, the 400 mg Q6W dosing regimen was also approved in the EU for all adult monotherapy indications (procedure number EMEA/H/C/003820/II/0062) and for all adult indications in combination with other anticancer agents (procedure number EMEA/H/C/003820/II/0102).

## Absorption

Pembrolizumab is dosed via the intravenous route and therefore is immediately and completely bioavailable.

## Distribution

Consistent with a limited extravascular distribution, the volume of distribution of pembrolizumab at steady state is small (6.0 L; coefficient of variation [CV]: 20%). As expected for an antibody, pembrolizumab does not bind to plasma proteins in a specific manner.

## Elimination

Pembrolizumab clearance (CL) is approximately 23% lower (geometric mean, 195 mL/day [CV%: 40%]) after achieving maximal change at steady state compared with the first dose (252 mL/day [CV%: 37%]). The geometric mean value (CV%) for the terminal half-life is 22 days (32%) at steady-state.

## Pharmacokinetic target population

Considering that an extensive characterization of the PK and immunogenicity profile of pembrolizumab have been provided in previous submissions, in this submission the focus is on the data related to the characterization of the pharmacology for the combination of pembrolizumab with chemotherapy (gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2) in participants with advanced BTC.

## PK Data KEYNOTE-966

KEYNOTE-966 is a randomized, double-blind, placebo-controlled, parallel group, multisite, Phase 3 study, designed to evaluate the efficacy and safety of pembrolizumab plus chemotherapy (gemcitabine and cisplatin) in participants with previously untreated advanced BTC.

## PK Analysis Pembrolizumab

The objectives of the PK analysis were:

- To evaluate pembrolizumab concentrations obtained from subjects in the study of KEYNOTE-966.
- To compare pembrolizumab PK data in KEYNOTE-966 observed in the pembrolizumab plus
- gemcitabine/cisplatin treatment arm with reference (TDPK) model-predicted pembrolizumab PK.
- To compare KEYNOTE-966 observed pembrolizumab PK data with historical monotherapy data.

<div style=\"page-break-after: always\"></div>

Table 1 Overview of cohorts included in KEYNOTE-966 pembrolizumab PK analysis

| Study/Cohort                                                         | Cancer Type                                                          | Treatment                                                            | Numberofsubjects providing PKa                                       |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| KEYNOTE-966 Global Study                                             | Biliary tract carcimoma                                              | Pembrolizumab (200 mg Q3W) plus gemcitabine/cisplatin                | 523                                                                  |
| a Unique subjects providing an evaluable PK sample; Q3W=Every3weeks. | a Unique subjects providing an evaluable PK sample; Q3W=Every3weeks. | a Unique subjects providing an evaluable PK sample; Q3W=Every3weeks. | a Unique subjects providing an evaluable PK sample; Q3W=Every3weeks. |

PK sampling schedule in KEYNOTE-966 for pembrolizumab: pre-infusion pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycle 1, 2, 4 and 8 and every 4 cycles thereafter. Post-dose samples (Cmax) were drawn at Cycle 1 and 8, approximately 30 minutes after the end of pembrolizumab infusion.

Phoenix™ WinNonlin® (Version 8.1.1.279) software was used for pharmacokinetic analysis.

Summary descriptive statistics of the pre-dose and post-dose concentrations by cycle are presented in the following table:

Table 2 Summary statistics of pembrolizumab predose (Ctrough) and postdose (Cmax) serum concentration values from the treatment arm of pembrolizumab plus gemcitabine/cisplatin following administration of multiple I.V. doses of 200 mg Q3W pembrolizumab in KEYNOTE-966

<!-- image -->

| Cycle                                                                                                                                                                                                                                     | NOMTAFD                                                                                                                                                                                                                                   | N                                                                                                                                                                                                                                         | GM (%CV)                                                                                                                                                                                                                                  | AM (SD)                                                                                                                                                                                                                                   | Min                                                                                                                                                                                                                                       | Median                                                                                                                                                                                                                                    | Max                                                                                                                                                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                           | (day)                                                                                                                                                                                                                                     | (g/mL)                                                                                                                                                                                                                                    | (g/mL)                                                                                                                                                                                                                                    | (g/mL)                                                                                                                                                                                                                                    | (g/mL)                                                                                                                                                                                                                                    | (g/mL)                                                                                                                                                                                                                                    | (g/mL)                                                                                                                                                                                                                                    |
| Predose (Ctrough)                                                                                                                                                                                                                         | Predose (Ctrough)                                                                                                                                                                                                                         | Predose (Ctrough)                                                                                                                                                                                                                         | Predose (Ctrough)                                                                                                                                                                                                                         | Predose (Ctrough)                                                                                                                                                                                                                         | Predose (Ctrough)                                                                                                                                                                                                                         | Predose (Ctrough)                                                                                                                                                                                                                         | Predose (Ctrough)                                                                                                                                                                                                                         |
| Cycle 1 (Week 0)                                                                                                                                                                                                                          | 0.00                                                                                                                                                                                                                                      | 496                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                           | 0.00 (0.0)                                                                                                                                                                                                                                | 0.00                                                                                                                                                                                                                                      | 0.00                                                                                                                                                                                                                                      | 0.00                                                                                                                                                                                                                                      |
| Cycle 2 (Week 3)                                                                                                                                                                                                                          | 21.0                                                                                                                                                                                                                                      | 49                                                                                                                                                                                                                                        | 12.2 (33.4)                                                                                                                                                                                                                               | 12.8 (4.0)                                                                                                                                                                                                                                | 5.04                                                                                                                                                                                                                                      | 12.0                                                                                                                                                                                                                                      | 22.4                                                                                                                                                                                                                                      |
| Cycle 4 (Week 9)                                                                                                                                                                                                                          | 63.0                                                                                                                                                                                                                                      | 38                                                                                                                                                                                                                                        | 22.6 (32.0)                                                                                                                                                                                                                               | 23.7 (6.9)                                                                                                                                                                                                                                | 10.5                                                                                                                                                                                                                                      | 24.1                                                                                                                                                                                                                                      | 39.8                                                                                                                                                                                                                                      |
| Cycle 8 (Week 21)                                                                                                                                                                                                                         | 147                                                                                                                                                                                                                                       | 269                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                           | 36.2 (12.8)                                                                                                                                                                                                                               | 0.00                                                                                                                                                                                                                                      | 36.0                                                                                                                                                                                                                                      | 90.9                                                                                                                                                                                                                                      |
| Cycle 12 (Week 33)                                                                                                                                                                                                                        | 231                                                                                                                                                                                                                                       | 182                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                           | 37.2 (14.9)                                                                                                                                                                                                                               | 0.00                                                                                                                                                                                                                                      | 36.5                                                                                                                                                                                                                                      | 92.6                                                                                                                                                                                                                                      |
| Cycle 16 (Week 45)                                                                                                                                                                                                                        | 315                                                                                                                                                                                                                                       | 96                                                                                                                                                                                                                                        | 35.5 (53.9)                                                                                                                                                                                                                               | 39.3 (16.3)                                                                                                                                                                                                                               | 3.01                                                                                                                                                                                                                                      | 37.2                                                                                                                                                                                                                                      | 91.7                                                                                                                                                                                                                                      |
| Cycle20(Week57)                                                                                                                                                                                                                           | 399                                                                                                                                                                                                                                       | 48                                                                                                                                                                                                                                        | 38.2 (41.9)                                                                                                                                                                                                                               | 41.1 (15.4)                                                                                                                                                                                                                               | 11.7                                                                                                                                                                                                                                      | 38.8                                                                                                                                                                                                                                      | 86.2                                                                                                                                                                                                                                      |
| Cycle 24 (Week 69)                                                                                                                                                                                                                        | 483                                                                                                                                                                                                                                       | 29                                                                                                                                                                                                                                        | 35.2 (78.5)                                                                                                                                                                                                                               | 42.3 (22.7)                                                                                                                                                                                                                               | 4.21                                                                                                                                                                                                                                      | 39.3                                                                                                                                                                                                                                      | 104                                                                                                                                                                                                                                       |
| Cycle 28 (Week 81)                                                                                                                                                                                                                        | 567                                                                                                                                                                                                                                       | 15                                                                                                                                                                                                                                        | 35.7 (57.0)                                                                                                                                                                                                                               | 39.6 (15.2)                                                                                                                                                                                                                               | 9.79                                                                                                                                                                                                                                      | 44.0                                                                                                                                                                                                                                      | 65.6                                                                                                                                                                                                                                      |
| Cycle32(Week93)                                                                                                                                                                                                                           | 651                                                                                                                                                                                                                                       | 10                                                                                                                                                                                                                                        | 36.2 (54.4)                                                                                                                                                                                                                               | 40.1 (17.8)                                                                                                                                                                                                                               | 11.7                                                                                                                                                                                                                                      | 36.3                                                                                                                                                                                                                                      | 77.7                                                                                                                                                                                                                                      |
| Postdose (Cmx)                                                                                                                                                                                                                            | Postdose (Cmx)                                                                                                                                                                                                                            | Postdose (Cmx)                                                                                                                                                                                                                            | Postdose (Cmx)                                                                                                                                                                                                                            | Postdose (Cmx)                                                                                                                                                                                                                            | Postdose (Cmx)                                                                                                                                                                                                                            | Postdose (Cmx)                                                                                                                                                                                                                            | Postdose (Cmx)                                                                                                                                                                                                                            |
| Cycle 1 (Week 0)                                                                                                                                                                                                                          | 0.021                                                                                                                                                                                                                                     | 483                                                                                                                                                                                                                                       | 60.3 (28.8)                                                                                                                                                                                                                               | 62.5 (16.0)                                                                                                                                                                                                                               | 8.37                                                                                                                                                                                                                                      | 62.2                                                                                                                                                                                                                                      | 120                                                                                                                                                                                                                                       |
| Cycle8(Week 21)                                                                                                                                                                                                                           | 147                                                                                                                                                                                                                                       | 268                                                                                                                                                                                                                                       | 91.6 (31.5)                                                                                                                                                                                                                               | 95.7 (27.1)                                                                                                                                                                                                                               | 20.1                                                                                                                                                                                                                                      | 92.3                                                                                                                                                                                                                                      | 192                                                                                                                                                                                                                                       |
| AM =Arithmetic Mean; CV% = Geometric Coefficient ofVariation; GM = Geometric Mean; Min = Minimum; Max = Maximum; NOMTAFD = Nominal time after first administration; SD = Standard Deviation; Results reported for time points with N ≥ 3. | AM =Arithmetic Mean; CV% = Geometric Coefficient ofVariation; GM = Geometric Mean; Min = Minimum; Max = Maximum; NOMTAFD = Nominal time after first administration; SD = Standard Deviation; Results reported for time points with N ≥ 3. | AM =Arithmetic Mean; CV% = Geometric Coefficient ofVariation; GM = Geometric Mean; Min = Minimum; Max = Maximum; NOMTAFD = Nominal time after first administration; SD = Standard Deviation; Results reported for time points with N ≥ 3. | AM =Arithmetic Mean; CV% = Geometric Coefficient ofVariation; GM = Geometric Mean; Min = Minimum; Max = Maximum; NOMTAFD = Nominal time after first administration; SD = Standard Deviation; Results reported for time points with N ≥ 3. | AM =Arithmetic Mean; CV% = Geometric Coefficient ofVariation; GM = Geometric Mean; Min = Minimum; Max = Maximum; NOMTAFD = Nominal time after first administration; SD = Standard Deviation; Results reported for time points with N ≥ 3. | AM =Arithmetic Mean; CV% = Geometric Coefficient ofVariation; GM = Geometric Mean; Min = Minimum; Max = Maximum; NOMTAFD = Nominal time after first administration; SD = Standard Deviation; Results reported for time points with N ≥ 3. | AM =Arithmetic Mean; CV% = Geometric Coefficient ofVariation; GM = Geometric Mean; Min = Minimum; Max = Maximum; NOMTAFD = Nominal time after first administration; SD = Standard Deviation; Results reported for time points with N ≥ 3. | AM =Arithmetic Mean; CV% = Geometric Coefficient ofVariation; GM = Geometric Mean; Min = Minimum; Max = Maximum; NOMTAFD = Nominal time after first administration; SD = Standard Deviation; Results reported for time points with N ≥ 3. |

Observed pembrolizumab concentration data in KEYNOTE-966 for pembrolizumab plus chemotherapy group are overlaid on the simulated profile using the reference PK model as shown in Figure 1.

<div style=\"page-break-after: always\"></div>

Figure 1 Observed pembrolizumab concentration data in KEYNOTE-966 from the treatment arm of pembrolizumab plus gemcitabine/cisplatin receiving 200 mg Q3W with reference model-predicted pharmacokinetic profile for 200 mg Q3W dose regimen at Cycle 1 and Steady state (at and after Cycle 8), Global study

<!-- image -->

KEYNOTE-966 Steady State

10

15

Time since last dose (day)

Tabular summaries of descriptive statistics and boxplots from early drug treatment at Cycle 1 end of infusion (post-dose) and at pre-dose Cycle 2 and Cycle 8, comparing observed pembrolizumab concentrations of 200 mg (Q3W) from participants with advanced BTC in KEYNOTE-966 and monotherapy trials in non-small cell lung cancer (NSCLC, KEYNOTE-024), urothelial cancer (UC, KEYNOTE-045 and KEYNOTE- 052), head and neck squamous cell cancer (HNSCC, KEYNOTE-048 and KEYNOTE-055), classical Hodgkin Lymphoma (HL, KEYNOTE-087), microsatellite instability-high cancer (MSI-H, KEYNOTE158) and MSI-H colorectal cancer (MSI-H-CRC, KEYNOTE-164 and KEYNOTE-177), are presented in Table 3 and Figure 2 reported below.

100

Pembrolizumab Concentration (μg/mL)

20

Relative Time

Predose

Postdose

<div style=\"page-break-after: always\"></div>

Table 3 Summary statistics of observed pembrolizumab concentrations at Cycle 1 postdose, Cycle 2 and Cycle 8 predose in various monotherapy trials (KEYNOTE-024, -045, -048, -052, -055, -087, 158 MSIH non CRC, -164, -177) and KEYNOTE-966 advanced/unresectable biliary tract carcinoma

| Time point       |   Dose (mg) | Study/Indieation   |   N | GM(CV%) (μg/mL)   | AM(SD) (ng/mL)   |   Min (μg/mL) |   Median (μg/mL) |   Max (μg/mL) |
|------------------|-------------|--------------------|-----|-------------------|------------------|---------------|------------------|---------------|
| Cycle 1 Postdose |         200 | KN024NSCLC         | 147 | 67.5 (23.1)       | 69.3 (16.2)      |        36.6   |             66.8 |         132   |
|                  |         200 | KN045 UC           | 247 | 65.7 (26.2)       | 67.9 (18.2)      |        33.9   |             65.9 |         144   |
|                  |         200 | KN048 1L HNSCC     | 495 | 61.8 (28.7)       | 64.2(17.6)       |         9.48  |             61.7 |         165   |
|                  |         200 | KN052 UC           | 867 | 58.0 (27.9)       | 60.2(17.3)       |        22.8   |             57.4 |         148   |
|                  |         200 | KN055 HNSCC        |  43 | 56.5 (27.8)       | 58.9 (20.7)      |        33.1   |             54.9 |         162   |
|                  |         200 | KN087 HL           | 195 | 60.7 (28.0)       | 63.1(18.3)       |        31.2   |             61.3 |         183   |
|                  |         200 | KN158 MSIH- NonCRC |  90 | 64.4 (27.0)       | 66.7 (18.3)      |        31.2   |             65.2 |         133   |
|                  |         200 | KN164MSIH-CRC      |  56 | 62.2 (27.8)       | 64.6 (19.1)      |        34.9   |             61.2 |         150   |
|                  |         200 | KN177MSIH-CRC      | 115 | 65.0 (25.7)       | 67.1 (17.1)      |        36.4   |             65.7 |         113   |
|                  |         200 | KN966-BTC          | 483 | 60.3 (28.8)       | 62.5 (16)        |         8.37  |             62.2 |         120   |
| Cycle 2 Predose  |         200 | KN024NSCLC         | 132 | 11.1 (54.1)       | 12.3 (4.7)       |         0.535 |             12.2 |          28.5 |
|                  |         200 | KN045 UC           | 233 | 13.1 (47.2)       | 14.2 (4.9)       |         0.475 |             13.9 |          29.3 |
|                  |         200 | KN048 1L HNSCC     | 458 |                   | 13.4 (4.6)       |         0     |             13.2 |          29.6 |
|                  |         200 | KN052 UC           | 286 | 11.1 (42.3)       | 11.9 (4.4)       |         2.07  |             11.5 |          26.2 |
|                  |         200 | KN055HNSCC         |  40 | 10.7 (47.2)       | 11.8 (5.2)       |         3.45  |             11.6 |          33.1 |
|                  |         200 | KN087HL            | 200 | 14.4 (39.5)       | 15.4 (5.1)       |         3.06  |             15.3 |          30   |
|                  |         200 | KN164MSIH-CRC      |  56 | 12.5 (35.3)       | 13.2 (4.6)       |         5.44  |             12.4 |          25.6 |
|                  |         200 | KN177MSIH-CRC      |  96 | 13.2 (45.7)       | 14.4 (5.9)       |         3.64  |             13.9 |          35.5 |
|                  |         200 | KN966-BTC          |  49 | 12.2 (33.4)       | 12.8 (4)         |         5.04  |             12   |          22.4 |
| Cycle 8 Predose  |         200 | KN024NSCLC         |  82 | 30.6 (49.6)       | 33.6(13.3)       |         5.26  |             32.7 |          64.1 |
|                  |         200 | KN045 UC           | 104 | 33.4 (63.7)       | 37.8 (16.5)      |         1.13  |             37.5 |          95.6 |
|                  |         200 | KN048 1L HNSCC     | 235 | 34.2 (50.3)       | 37.5 (15.1)      |         1.77  |             34.8 |         127   |
|                  |         200 | KN052 UC           |  59 | 28.0 (38.4)       | 29.9(10.4)       |         8.15  |             27.9 |          59.8 |
|                  |         200 | KN055HNSCC         |   7 | 27.8 (41.0)       | 29.6 (11.4)      |        16.8   |             24.5 |          43.3 |
|                  |         200 | KN087HL            |  68 | 43.9 (43.5)       | 47.4 (17)        |        13.9   |             47.5 |          92.4 |
|                  |         200 | KN164MSIH-CRC      |  34 | 33.6 (43.1)       | 36.2 (13.8)      |         8.4   |             33.7 |          78.8 |
|                  |         200 | KN177MSIH-CRC      |  53 | 32.9 (49.2)       | 36.2 (15.1)      |         9.76  |             34.7 |          68.5 |
|                  |         200 | KN966-BTC          | 269 |                   | 36.2 (12.8)      |         0     |             36   |          90.9 |

GM=GeometricMean;%CV=GeometricCoefficientofVariation;AM=ArithmeticMean;SD=Standard Deviation;NSCLC=non-small cell lungcancer;UC=urothelial cancer;HNSCC=headandnecksquamous cell carcinoma;HL=Hodgkin lymphoma;MSIH CRC=micro satelliteinstabilityhigh cancer colorectal cancer;BTC = Biliary tract carcinoma.

Figure 2 Pembrolizumab observed concentrations at Cycle 1 postdose, Cycle 2 and Cycle 8 predose in various monotherapy trials (KEYNOTE-024, -045, -048, -052, -055 -087, 158 MSIH non CRC, -164, -177) and KEYNOTE-966

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

## 2.3.3. Pharmacodynamics

## Mechanism of action

Keytruda is an antibody that binds to the programmed death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Keytruda potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

## Primary and secondary pharmacology

## Immunogenicity

The existing immunogenicity assessment for pembrolizumab for the monotherapy setting is based on a sufficiently large dataset of patients across several indications, with very low observed rates of total treatment ADA across different pembrolizumab regimens (1.4 - 3.8%) as well as of neutralizing antibodies (0.4 - 1.6%). This analysis has not demonstrated impact on efficacy or safety, as currently

<div style=\"page-break-after: always\"></div>

summarized in the EU SmPC and USPI. This low rate of immunogenicity has been shown to be consistent across tumour type and no clinically meaningful consequences have been observed in the subjects with a positive immunogenicity reading. Additionally, incidence of ADA has not been impacted by the presence of another small molecule or chemotherapy in combination with pembrolizumab.

## 2.3.4. PK/PD modelling

No new information regarding PK/PD modelling for pembrolizumab is available within this application.

## 2.3.5. Discussion on clinical pharmacology

In this application, the focus is on PK data related to the combination of pembrolizumab with chemotherapy (gemcitabine/cisplatin) from study KEYNOTE-966.

## Absorption

The dosing regimen of 400 mg Q6W is applicable across all adult indications regardless of the combination treatment type, thus, the 400 mg Q6W dosing regimen would have a similar benefit-risk profile as the 200 mg Q3W (or 2 mg/kg Q3W) dosing regimen in the clinical use of pembrolizumab in participants with BTC.

## Elimination

Pembrolizumab clearance (CL) is approximately 23% lower (geometric mean, 195 mL/day [CV%: 40%]) after achieving maximal change at steady state compared with the first dose (252 mL/day [CV%: 37%]); this decrease in CL with time is not considered clinically meaningful. The geometric mean value (CV%) for the terminal half-life is 22 days (32%) at steady-state.

## Pharmacokinetic

PK data from KEYNOTE-966 show that the observed pembrolizumab serum concentration values in subjects with advanced BTC are contained within the 90% CI of the reference PK model, which indicate consistency with the historical data, in both Cycle 1 postdose and Cycle 8 predose (at steady state).

In addition, tabular summaries of descriptive statistics and boxplots from early drug treatment at Cycle 1 end of infusion (post-dose) and at pre-dose Cycle 2 and Cycle 8 show that observed pembrolizumab concentrations of 200 mg (Q3W) in combination with chemotherapy (gemcitabine/cisplatin) from participants with advanced BTC in KEYNOTE-966 are similar to the observed pembrolizumab concentration when administered as monotherapy in other trials in different cancer indications.

No new data on immunogenicity have been submitted within this application and this is acceptable considering that the incidence of antidrug antibodies (ADA) has been already evaluated in the presence of chemotherapy in combination with pembrolizumab.

In conclusion, pembrolizumab PK disposition is not affected by the co-administration with chemotherapy, in particular by the co-administration of gemcitabine plus cisplatin.

## 2.3.6. Conclusions on clinical pharmacology

Pembrolizumab PK disposition is not affected by the co-administration with chemotherapy (gemcitabine plus cisplatin) for advanced BTC. Observed concentrations from KEYNOTE-966 overlaid on the reference

<div style=\"page-break-after: always\"></div>

model predicted median concentrations both at Cycle 1 and at steady state and are consistent with other globally approved studies in different cancer indications.

## 2.4. Clinical efficacy

The current submission is based on a single pivotal study (KEYNOTE-966).

This is a randomised, placebo-controlled, parallel-group, multisite, double-blind study of pembrolizumab plus chemotherapy (gemcitabine plus cisplatin) versus placebo plus chemotherapy (gemcitabine plus cisplatin) in participants with advanced (metastatic) and/or unresectable (locally advanced) BTC (intra- or extrahepatic cholangiocarcinoma or gallbladder) (hereafter referred to as advanced BTC).

The report is based on the final analysis (FA data cut-off date 15-DEC-2022).

## 2.4.1. Dose response study(ies)

No dose-response studies were submitted as part of this application.

## 2.4.2. Main study

## Title of Study

KEYNOTE-966: A Phase 3 Randomized, Double-Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

Figure 3 KEYNOTE-966 Study design

<!-- image -->

ECOG=Eastern Cooperative Oncology Group:IV=intravenous;max=maximum;N=number ofparticipants; PD=progressive disease;Q3W=every3weeks.

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

## Inclusion criteria

Participants were eligible for inclusion in the study if they met all of the following key inclusion criteria:

1. Had histologically confirmed diagnosis of advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer).
2. Had measurable disease based on RECIST 1.1, as determined by the site investigator.
3. Participants with past or ongoing HCV infection were eligible for the study. Treated participants must have completed their treatment at least 1 month prior to starting study intervention. Untreated or incompletely treated HCV participants could have initiated antiviral therapy for HCV if liver function remained stable for at least 3 months on study intervention.

4. Participants with controlled HBV infection were eligible if they met the following criteria:

- Participants with chronic HBV infection, defined as HBsAg positive and/or detectable HBV DNA, must have been given antiviral therapy for HBV for at least 4 weeks prior to the first dose of study intervention and HBV viral load must have been less than 100 IU/mL prior to first dose of study intervention. Participants on active HBV therapy with viral loads under 100 IU/mL were to stay on the same therapy throughout study intervention. Antiviral therapy after completion of study intervention was to follow local guidelines.

- Participants with clinically resolved HBV infection, defined as HBsAg negative and anti-HBc positive, and who had an undetectable HBV viral load at screening were to be checked Q6W for HBV viral load and treated for HBV if viral load was over 100 IU/mL. Antiviral therapy after completion of study intervention was to follow local guidelines.

5. Was male or female, from at least 18 years of age inclusive, at the time of signing the informed consent.

6. Had a performance status of 0 or 1 on the ECOG performance scale within 3 days prior to the first dose of study intervention.
7. Had a life expectancy of greater than 3 months.
8. Patients were required to have adequate organ function as defined in the following table:

<div style=\"page-break-after: always\"></div>

Table 4 Inclusion criteria KEYNOTE-966: organ function requirements

| System                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Laboratory Value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hematological                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Absolute neutrophil count (ANC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ≥1500/μL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Platelets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ≥100 000/μL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Hemoglobin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | ≥9.0 g/dL or ≥5.6 mmol/La                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Creatinine OR Measured or calculatedbcreatinine clearance (GFR can also be used in place of creatinine or CrCl)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ≤1.5 x ULN OR ≥60 mL/min for participant with creatinine levels >1.5×institutionalULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Total bilirubin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ≤1.5 xULN OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 x ULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| AST (SGOT) and ALT (SGPT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ≤2.5 x ULN (≤5 x ULN for participants with liver metastases)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Coagulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Intemationalnormalizedratio(INR)OR prothrombin time (PT) Activated partial thromboplastin time (aPTT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | ≤1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range ofintendeduseofanticoagulants                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal. aCriteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusionwithinlast 2weeks. bCreatinine clearance (CrCl) should be calculated using the Cockcroft-Gault Method: Refer to Appendix 10 for appropriate calculation. Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value | ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal. aCriteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusionwithinlast 2weeks. bCreatinine clearance (CrCl) should be calculated using the Cockcroft-Gault Method: Refer to Appendix 10 for appropriate calculation. Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value |

## Exclusion criteria

Participants were excluded from the study if they met one of the following key exclusion criteria:

1. Had previous systemic therapy for advanced (metastatic) or unresectable (locally advanced) BTC (intra-or extra hepatic cholangiocarcinoma or gallbladder cancer), with the exception of neoadjuvant/adjuvant therapy which was allowed. Neoadjuvant/adjuvant therapy should have been completed at least 6 months prior to diagnosis of advanced and/or unresectable disease, and participants should not have received gemcitabine and/or cisplatin in the neoadjuvant/adjuvant setting. Participants who received prior neoadjuvant/adjuvant therapy with R2 postoperative pathology of the oncologic resection were excluded.
2. Had ampullary cancer.
3. Had small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology and/or mucinous cystic neoplasms.
4. Had an active autoimmune disease that required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
5. Had received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).

<div style=\"page-break-after: always\"></div>

6. Had received prior anticancer therapy (e.g., TACE, palliative surgery) for advanced unresectable biliary tract cancer (intra-or extra hepatic cholangiocarcinoma or gallbladder cancer), including investigational agents within 4 weeks prior to randomization.

7. Had dual active HBV infection (HBsAg (+) and /or detectable HBV DNA) and HCV infection (anti-HCV Ab (+) and detectable HCV RNA) at study entry.

## Treatments

Table 5 Study interventions

| Arm Name   | Arm Type          | Intervention Name       | Intervention Type   | Dose Formulation          | Unit Dose Strength(s)                   | Dosage Level(s)   | Route of Administration   | Regimen/Treatment Period/Vaccination Regimen                    | Use                  | IMP/ NIMP   | Sourcing         |
|------------|-------------------|-------------------------|---------------------|---------------------------|-----------------------------------------|-------------------|---------------------------|-----------------------------------------------------------------|----------------------|-------------|------------------|
| Arm A      | Experimental      | Pembrolizumab           | Drug                | Sterile Suspension (Vial) | 25 mg/mL                                | 200 mg            | IV Infusion               | Day 1 of each cycle, up to 35 administrations                   | Experimental         | IMP         | Central          |
| Arm A      | Experimental      | Cisplatin               | Drug                | Vial                      | 1 mg/mL vial, 20 mg vial, or 50 mg vial | 25 mg/m²          | IV Infusion               | Day1 and Day8of each cycle,up to 8 cycles                       | Background Treatment | NIMP        | Local or Central |
| Arm A      | Experimental      | Gemcitabine             | Drug                | Vial                      | 1 g/vial                                | 1000 mg/m²        | IV Infusion               | Day 1 andDay8of eachcycle,untilPD  or unacceptable toxicity     | Background Treatment | NIMP        | Local or Central |
| Arm B      | Active Comparator | Placebo (Normal Saline) | Drug                | Sterile Suspension (Vial) | N/A                                     | N/A               | IV Infusion               | Day 1 of each cycle, upto35 administrations                     | Placebo              | IMP         | Local            |
| Arm B      | Active Comparator | Cisplatin               | Drug                | Vial                      | 1 mg/mL vial, 20 mg vial, or 50 mg vial | 25 mg/m²          | IVInfusion                | Day 1 and Day 8of each cycle, up to 8 cycles                    | Background Treatment | NIMP        | Local or Central |
| Arm B      | Active Comparator | Gemcitabine             | Drug                | Vial                      | 1 g/ vial                               | 1000 mg/m²        | IV Infusion               | Day 1 and Day 8of each cycle, until PD or unacceptable toxicity | Background Treatment | NIMP        | Local or Central |

Definitions ofIMPand NIMParebased on guidance issued by the EuropeanCommission.Regional and/or Country differences of the definition ofIMP/NIMPmay exist.In these circumstances,locallegislation isfollowed.RefertoSection10.7(Appendix 7)of the study protocol[16.1.1]for country-specific requirements.

IMP=Investigational Medicinal Product;IV=intravenous;N/A=Not applicable;NIMP=Non-Investigational Medicinal Product;PD=progressive disease.

<div style=\"page-break-after: always\"></div>

## Objectives/endpoints

## Table 6 Objectives and endpoints

| Objectives                                                                                                                                                                                                                                                                                                                                                                   | Endpoints                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                        |
| Objective: To compare overall survival (OS) between pembrolizumab plus gemcitabine/cisplatin and placebo plus gemcitabine/cisplatin Hypothesis (Hl): Pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to OS                                                                                                           | OS: the time from randomization to death due to any cause                                                                                                                              |
| Secondary                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                        |
| Objective: To compare progression-free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR) between pembrolizumab plus gemcitabine/cisplatin and placebo plus gemcitabine/cisplatin Hypothesis (H2): Pembrolizumab plus gemcitabine/cisplatin is superior to placcbo plus gemcitabine/cisplatin with respect to PFS per RECIST 1.1 by BICR | PFS: the time from randomization to the first documented PD per RECIST 1.1 by BICR, or death due to any cause, whichever occurs fiist                                                  |
| Objective: To compare objective response rate (ORR) per RECIST 1.1 as assessed by BICR between pembrolizumab plus gemcitabine/cisplatin and placebo plus gemcitabine/cisplatin Hypothesis (H3): Pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to ORR per RECIST 1.1 as assessed by BICR                            | Objective Response (OR): complete response (CR) or partial response (PR)                                                                                                               |
| Objective: To evaluate duration of response (DOR) per RECIST 1.1 as assessed by BICR                                                                                                                                                                                                                                                                                         | DOR: for participants who show confirmed CR or PR, the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first |

<div style=\"page-break-after: always\"></div>

| Objectives                                                                                                                                                                                                                                                                                    | Endpoints                                                                                                                                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective: To evaluate the safety and tolerability profile of pembrolizumab plus gemcitabine/cisplatin                                                                                                                                                                                        | Adveise events (AEs) Study intervention discontinuations due to AEs                                                                                                                                                                           |
| Tertiary/Exploratory                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                               |
| Objective: To evaluate disease control rate (DCR) per RECIST 1.1 as assessed by BICR                                                                                                                                                                                                          | Disease Control (DC): a best overall response of CR, PR, or stable disease (SD). SD must be achieved at ≥6 weeks after randomization tobe considered best overall response                                                                    |
| Objective: To evaluate efficacy outcomes per RECIST 1.1 modified for immune-based therapeutics (iRECIST) as assessed by the investigator                                                                                                                                                      | PFS, OR, DOR, DC                                                                                                                                                                                                                              |
| Objective: To evaluate efficacy outcomes per RECIST 1.1 as assessed by the investigator                                                                                                                                                                                                       | PFS, OR,DOR, DC                                                                                                                                                                                                                               |
| Objective: To compare time to deterioration (TTD) and score change firom baseline in global quality of life using the EORTC Quality of Life (QOL) Questionnaire (EORTC QLQ) -C30 and EORTC QLQ-BIL21 between pembrolizumab plus  gemcitabine/cisplatin and placebo plus gemcitabine/cisplatin | Scores from the global health status/QOL scale on the EORTC QLQ- C30 and EORTC QLQ-BIL21 TTD: the time to first onset of a 10 point or more decrease from baseline. TTDevaluatedforEORTC QLQ-C30 and EORTC QLQ-BIL21 global health status/QOL |
| Objective: To characterize health utilities using the EuroQoL-5 Dimension Questionnaire, 5-Level (EQ-5D-5L) healthy utility scores                                                                                                                                                            | EQ-5D-5L health utility score                                                                                                                                                                                                                 |

## Sample size

Approximately 1048 participants were expected to be randomized 1:1 into pembrolizumab plus gemcitabine plus cisplatin or placebo plus gemcitabine plus cisplatin. After enrollment of the global portion was complete, the study remained open to enrolment in China alone for the China extension cohort of 46 participants until a total of 158 participants had been enrolled across the global and extension parts to meet local regulatory requirements in China. This report describes the global portion of the study. OS was the sole primary endpoint for the study, with PFS and ORR as the key secondary endpoints. The working model in evaluating the power of both OS and PFS analyses and projecting event accumulation with time assumed that both OS and PFS had an approximately 2-month delay in treatment effect.

<div style=\"page-break-after: always\"></div>

Specifically, the model assumed that the OS curves for the pembrolizumab plus gemcitabine/cisplatin arm and placebo plus gemcitabine/cisplatin arm coincided over the first 2 months with HR=1 and diverged when the treatment effect with constant HR=0.75 starts at 2 months. Based on a 11-month control median, under the delayed treatment effect model, the median of the pembrolizumab plus gemcitabine/cisplatin arm was estimated approximately 14.0 months (~3-month increment). For the OS endpoint, based on a target number of 818 events and 2 interim analyses, assuming HR=1 for the first 2 months and HR=0.75 after 2 months, the study had approximately 93% power to reject the null hypothesis under the alternative hypothesis at an overall alpha level of 0.025 (1-sided).

Regarding the PFS curves, the model assumes that for the pembrolizumab plus gemcitabine/cisplatin arm and placebo plus gemcitabine/cisplatin arm coincided over the first 2 months with HR=1 and diverge when the treatment effect with constant HR=0.7 starts at 2 months. Based on a 6-month control median, under the delayed treatment effect model, the median of pembrolizumab plus gemcitabine/cisplatin arm was estimated approximately 7.7 months (~1.6-month increment). For the PFS endpoint, if OS endpoint was successful, based on the expected number of 786 events at PFS final analysis, assuming HR=1 for the first 2 months and HR=0.7 after 2 months, the study had approximately 92% power to reject the null hypothesis under the alternative hypothesis at an overall alpha level of 0.0125 (1-sided).

The sample size and power calculations for PFS and OS assumed the following: 1) PFS follows an exponential distribution with a median of 6 months for the control group; HR=1 for the first 2 months and HR=0.7 after 2 months; 2) OS follows an exponential distribution with a median of 11 months for the control group; HR=1 for the first 2 months and HR=0.75 after 2 months; 3) Enrollment period of 20 months with a ramp-up period of 6 months; 4) A monthly drop-out rate of 2% and 0.1% for PFS and OS, respectively; 5) The interim and final analyses were planned at ~26, ~32 and ~38 months after the start of randomization and the minimum alpha spending approach is employed.

If OS endpoint was successful, the ORR power calculation was based on the following assumptions: 1) under an overall alpha level of 0.0125; 2) the underlying ORR was 25% in the placebo +gemcitabine/cisplatin arm. The study had ~91% power to detect a true ORR rate difference of 10% (pembrolizumab + gemcitabine/cisplatin versus placebo +gemcitabine/cisplatin).

The sample size and power calculations were performed using R ('gsDesign' and 'simtrial' packages).

## Randomisation

Treatment allocation/randomization occurred centrally using an interactive response technology (IRT) system. There are 2 study treatment arms. Participants were randomized in a 1:1 ratio to receive either pembrolizumab or placebo each in combination with chemotherapy. Treatment randomization was stratified based on the following criteria:

- 1) Region (Asia versus non-Asia);
- 2) Locally Advanced versus Metastatic (in the event the participant has locally advanced and metastatic BTC, the participant should be stratified as metastatic);
- 3) Site of Origin (gallbladder, intrahepatic, or extrahepatic).

## Blinding (masking)

A double-blinding technique with in-house blinding will be used. Pembrolizumab and placebo (normal saline) will be packaged identically so that blind is maintained. The participant, the investigator, and Sponsor personnel or delegate(s) who are involved in the study intervention administration or clinical evaluation of the participants are unaware of the intervention assignments.

<div style=\"page-break-after: always\"></div>

As of the data cutoff for the FA, a total of 31 participants were prematurely unblinded as emergency unblindings and 1 of those emergency unblindings was inadvertent. A total of 62 nonemergency unblindings occurred for purposes of selection of subsequent therapy. Nonemergency unblindings required SCF approval and all critical data to be entered to decrease risk of bias. A total of 4 second course unblindings occurred to determine second course eligibility. Second course unblinding required centrally verified disease progression. The premature unblinding of these participants did not have a major impact on study conduct or on the outcome of the study, and none of these premature unblindings led to exclusion from the analysis. These unblinding events were reviewed via the Sponsor's Significant Quality Issues process and were determined to have no impact on the quality of the data.

## Statistical methods

## Protocol Amendments involving statistical methods

The protocol was subject to six general amendments, of which Amendment 2 (08-DEC-2020), Amendment 4 (26-AUG-2021) and Amendment 5 (18-NOV-2021) modified the statistical analysis plan (SAP) language as follows. Statistical methods were reported in the protocol section and in the Amendment 04 of supplemental SAP (sSAP) dated 13-JUN-2022.

Amendment 2 (08-DEC-2020): The protocol was revised to make OS the sole primary endpoint and to change PFS from a primary to a secondary endpoint. A more conservative hazard ratio assumption for OS was made accounting for possible delayed treatment effect; as consequence the sample size was increased from initial 788 to 1048 participants, to maintain study timelines and statistical power. The futility analysis was removed since early results are not informative in the presence of a delayed treatment effect. The interim and final analyses timing was updated from calendar-based to event-based and the multiple strategy was also updated to allocate all initial alpha to OS as a single primary endpoint and split the alpha equally between ORR and PFS when OS demonstrated superiority. Two interim analyses (IAs) were planned at ~500 OS events (~29 months) and ~616 OS events (~35 months), respectively. The FA was planned after the occurring of ~725 OS events (~41 moths from the start of randomization).

Amendment 4 (26-AUG-2021): The SAP was updated to account for faster event accumulation than initially projected by increasing the number of events at final analysis and specifying time and event triggers for analyses to ensure sufficient minimum follow-up time for a longer potential delayed effect. The first IA was removed and the number of OS events at each analysis was increased. The IA was planned after ~695 OS events (~32 months) and the FA was planned after ~818 OS events (~38 months). The analyses were triggered by required time and OS events, the minimum alpha spending approach for OS analysis was used and the group-sequential analysis of PFS and ORR was changed to a single analysis at the time of OS interim analysis.

Amendment 5 (18-NOV-2021): A new, earlier interim analysis (IA1) for OS was added to take into account the emerging external data showing positive results for immunotherapy plus chemotherapy as first-line therapy for patients with advanced biliary tract carcinoma. The IA1 was planned at ~585 OS events (~26 months), the IA2 was planned at ~695 OS events (~32 months) and the FA was planned after ~818 OS events (~38 months).

Additional details on protocol amendments can be found under 'conduct of the study' below.

<div style=\"page-break-after: always\"></div>

## Interim analysis

Two interim analyses (IA) were planned in addition to the final analysis (FA) for this study. The efficacy analyses in this submission are based on FA. The timing and the purpose of each analysis are summarized in the table below.

Table 7 KEYNOTE-966: Purpose of Interim Analyses and Final Analysis

| Analyses                                                                                               | Key Endpoints                                                                                          | Timing                                                                                                 | Primary Purpose of Analysis                                                                            |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| IA1                                                                                                    | OS                                                                                                     | ~585 OS events have been observedand~26months passed since the start of randomization.                 | Interim OS analysis Final PFS and ORR analyses ifos superiority is established                         |
| IA2                                                                                                    | OS                                                                                                     | ~695 OS events have been observedand~32months passed since the start of randomization.                 | Interim OS analysis                                                                                    |
| FA                                                                                                     | OS                                                                                                     | ~818 OS events have been observedand~38months passed since the start of randomization.                 | Final OS analysis                                                                                      |
| Abbreviations: IAl=interim analysis 1; IA2=interim analysis 2; FA=final analysis; OS=overall survival. | Abbreviations: IAl=interim analysis 1; IA2=interim analysis 2; FA=final analysis; OS=overall survival. | Abbreviations: IAl=interim analysis 1; IA2=interim analysis 2; FA=final analysis; OS=overall survival. | Abbreviations: IAl=interim analysis 1; IA2=interim analysis 2; FA=final analysis; OS=overall survival. |

## Type I error and multiplicity control

The trial used the graphical method of Maurer and Bretz to control for multiple hypotheses as well as interim analyses. According to this approach, study hypotheses may be tested more than once, and when a particular null hypothesis is rejected, the alpha allocated to that hypothesis can be reallocated to other hypotheses. Figure below shows the multiplicity diagram for type I error control.

Figure 4 KEYNOTE-966: Multiplicity diagram for Type I error control

<!-- image -->

Initial one-sided α allocation for each hypothesis in the ellipse representing the hypothesis. The weights for reallocation from each hypothesis to the others were represented in the boxes on the lines connecting

<div style=\"page-break-after: always\"></div>

hypotheses. The initial α assigned to OS will be 0.025. If OS hypothesis was rejected, the corresponding alpha was reallocated equally to PFS and ORR. If the PFS hypothesis was rejected, the corresponding alpha was reallocated to ORR. If the ORR hypothesis was rejected, the corresponding alpha was reallocated to PFS. Within each endpoint, the Type I error control across the interim and final analyses has been maintained by the use of the Lan-DeMets spending function approach with O'Brien-Fleming boundaries.

## OS

The initial α-level for testing OS is 0.025. Under the alternative hypothesis, the treatment effect were delayed by 2 months, with OS HR=1 in the first 2 months, and HR=0.75 after 2 months. Table below shows the boundary properties for OS hypothesis testing based on the minimum alpha spending strategy using a Lan-DeMets spending function approximating O'Brien-Fleming boundaries.

Table 8 KEYNOTE-966: Boundary properties for OS hypothesis testing based on the minimum alpha spending strategy

<!-- image -->

| Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | α=0.025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA1: 72%* N: 1069 Events: 585 Month:~26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Z                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 2.4072                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA1: 72%* N: 1069 Events: 585 Month:~26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | p(l-sided)a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.0080                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA1: 72%* N: 1069 Events: 585 Month:~26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | HR at boundb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.8199                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA1: 72%* N: 1069 Events: 585 Month:~26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | P(Cross)if HR =1c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.0080                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA1: 72%* N: 1069 Events: 585 Month:~26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | P(Cross) under the alternative hypothesisde                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.6170                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA2 : 85%* N: 1069 Events: 695 Month:~32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Z                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 2.2409                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA2 : 85%* N: 1069 Events: 695 Month:~32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | p (l-sided)a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.0125                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA2 : 85%* N: 1069 Events: 695 Month:~32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | HR at boundb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.8451                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA2 : 85%* N: 1069 Events: 695 Month:~32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | P(Cross)if HR =1c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.0150                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA2 : 85%* N: 1069 Events: 695 Month:~32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | P(Cross) under the alternative hypothesisde                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.8154                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| FA N: 1069 Events: 818 Month:~38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Z                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 2.0438                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| FA N: 1069 Events: 818 Month:~38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | p (l-sided)a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.0205                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| FA N: 1069 Events: 818 Month:~38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | HR at boundb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.8669                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| FA N: 1069 Events: 818 Month:~38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | P(Cross)if HR = 1c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.0250                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| FA N: 1069 Events: 818 Month:~38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | P(Cross) under the alternative hypothesisd,e                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.9266                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Abbreviations: HR=hazard ratio; IA1=interim analysis 1; IA2=interim analysis 2; FA=final analysis. The number ofevents is approximate. *Percentage of total planned events at the interim analysis. a The nominal a for testing. b The approximate HR required to reach an efficacy bound. * P(Cross if HR = 1) is the cumulative probability of crossing a bound under the null hypothesis. d The alternative hypothesis is HR=1 for the first 2 months and HR=0.75 after 2 months. e P(Cross) under the alternative hypothesis is the cumulative probability of crossing a bound under the | Abbreviations: HR=hazard ratio; IA1=interim analysis 1; IA2=interim analysis 2; FA=final analysis. The number ofevents is approximate. *Percentage of total planned events at the interim analysis. a The nominal a for testing. b The approximate HR required to reach an efficacy bound. * P(Cross if HR = 1) is the cumulative probability of crossing a bound under the null hypothesis. d The alternative hypothesis is HR=1 for the first 2 months and HR=0.75 after 2 months. e P(Cross) under the alternative hypothesis is the cumulative probability of crossing a bound under the | Abbreviations: HR=hazard ratio; IA1=interim analysis 1; IA2=interim analysis 2; FA=final analysis. The number ofevents is approximate. *Percentage of total planned events at the interim analysis. a The nominal a for testing. b The approximate HR required to reach an efficacy bound. * P(Cross if HR = 1) is the cumulative probability of crossing a bound under the null hypothesis. d The alternative hypothesis is HR=1 for the first 2 months and HR=0.75 after 2 months. e P(Cross) under the alternative hypothesis is the cumulative probability of crossing a bound under the |

The bounds provided were based on the assumption that the number of OS events at IA1, IA2 and FA are 585, 695 and 818, respectively. At the time of an analysis, the observed number of events may differ substantially from the expected. To avoid overspending at an interim analysis and leave reasonable alpha for the FA, the minimum alpha spending strategy has been adopted. At an IA, the information fraction

<div style=\"page-break-after: always\"></div>

used in Lan-DeMets spending function to determine the alpha spending at the IA was based on the minimum of the expected information fraction and the actual information fraction at each analysis. Specifically, the information fraction was calculated as the observed number of events at the IA over the target number of events at the FA, if the observed number of events was less than the expected, or as the expected number of events at the IA over the target number of events at FA, if the observed number of events exceeded the expected number. The FA used the remaining Type I error that has not been spent at the earlier analyses. The event counts for all analyses were used to compute the correlations.

## PFS

The PFS hypothesis was not allocated any alpha initially and might only be tested when the OS was successful. The study tested PFS at IA1 (final PFS analysis). The p-value based on PFS data observed at IA1 was calculated and compared to its corresponding p-value bound when OS demonstrated superiority and alpha for PFS test became available. At IA2 and FA data cutoff a descriptive analysis of PFS might also be provided when superiority in OS was demonstrated. Following the outlined multiplicity strategy, the PFS hypothesis might be tested at α=0.0125 (if the OS null hypothesis was rejected), or at α=0.025 (if both the OS and ORR null hypotheses were rejected). Under the alternative, the treatment effect was delayed by 2 months, with PFS HR=1 in the first 2 months, and HR=0.7 after 2 months. The boundary properties and power for each of these alpha levels are shown below.

Table 9 KEYNOTE-966: Boundary properties and power for each alpha level (PFS)

<!-- image -->

| Analysis                 | Value                                        |   α = 0.0125 |   =0.025 |
|--------------------------|----------------------------------------------|--------------|----------|
| IA1 (Final PFS analysis) | Z                                            |       2.2414 |   1.96   |
| N: 1069                  | p (l-sided)a                                 |       0.0125 |   0.025  |
| Events: 786              | HR at boundb                                 |       0.8554 |   0.8695 |
| Month: ~26               | P(Cross) if HR = 1c                          |       0.0125 |   0.025  |
|                          | P(Cross) under the alternative hypothesisd,e |       0.9176 |   0.9518 |

- d The altemative hypothesis is HR=1 for the first 2 months and HR=0.7 after 2 months.

é P(Cross) under the alternative hypothesis is the probability of crossing a bound under the alternative hypothesis.

## ORR

The ORR hypothesis was not allocated any alpha initially and might only be tested when the OS was successful. The study tested ORR at IA1 (final ORR analysis). The p-value based on ORR data observed at IA1 was calculated and compared to its corresponding p-value bound when OS demonstrated superiority and alpha for ORR test becomes available. At IA2 and FA data cutoff a descriptive analysis of ORR might also be provided when superiority in OS was demonstrated. Table below shows the boundary properties for 2 possible 1-sided α-levels as well as the approximate treatment difference required to reach the boundary (ORR difference) which were derived using a Lan-DeMets O'Brien-Fleming spending function.

<div style=\"page-break-after: always\"></div>

Table 10 KEYNOTE-966: Boundary properties and power for each alpha level (ORR)

| Analysis   | Value                  |   αlevel=0.0125 |   αlevel=0.025 |
|------------|------------------------|-----------------|----------------|
| IA1        | Z                      |          2.2414 |         1.96   |
| N: 1069    | p (l-sided) a          |          0.0125 |         0.025  |
|            | delta at bound b       |          0.0627 |         0.0548 |
|            | P(Cross) if delta=0 c  |          0.0125 |         0.025  |
|            | P(Cross) if delta=0.1d |          0.9088 |         0.947  |

## Efficacy analyses

The Intention-to-Treat (ITT) population, which consisted of all 1069 randomized participants, served as the population for primary efficacy analyses. All randomized participants were included in this population. Participants were included in the treatment group to which they were randomized, regardless of whether they received study treatment. The duration of response (DOR) analysis was based on the population of responders (participants that achieved complete or partial response). A summary of the analysis strategy for key efficacy endpoints as well as censoring rules for primary and sensitivity analyses of PFS and DOR are presented in the following tables:

Table 11 Analysis Strategy for Key Efficacy Endpoints

| Endpoint/Variable          | Statistical Method*                                                                                  | Analysis Population   | Missing Data Approach                                                       |
|----------------------------|------------------------------------------------------------------------------------------------------|-----------------------|-----------------------------------------------------------------------------|
| Primary Analyses           | Primary Analyses                                                                                     | Primary Analyses      | Primary Analyses                                                            |
| OS                         | Testing: Stratified Log- rank test Estimation: Stratified Cox model withEfron's tie handling method  | ITT                   | Censoredatlastknownalivedate or data cutoff date, whichever is the earliest |
| Key SecondaryAnalyses      | Key SecondaryAnalyses                                                                                | Key SecondaryAnalyses | Key SecondaryAnalyses                                                       |
| PFS per RECIST 1.1 by BICR | Testing: Stratified Log- rank test Estimation: Stratified Cox model with Efron's tie handling method | ITT                   | Censored according to rules in [Table 1]                                    |
| ORR per RECIST 1.1 by BICR | Testing  and estimation: stratified 1Miettinen and Nurminen method                                   | ITT                   | Participants with missing response data are considered nonresponders.       |

Abbreviations: BICR=blinded independent central review; ITT=intention-to-treat; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; RECIST 1.1=Response Evaluation Criteria in Solid Tumors 1.1.

F:Statistical models are described infurther detail in the text.For stratified analyses, the stratification factors used for randomization (See Section 3.6.1 for strata collapsing strategy) will be applied to the analysis model.

<div style=\"page-break-after: always\"></div>

Table 12 Censoring Rules for Primary and Sensitivity Analyses of PFS

<!-- image -->

| Situation                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                         | Sensitivity Analysis 1                                                | Sensitivity Analysis 2                                                                                                                                                                       |
|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PD or death documented afler ≤1 missed disease asscssment, and before new anticancer therapy, if any             | Progressed at date of documented PD or death                                                                                                                                                                                                                                                                                                                                                                                             | Progressed at date of documented PD Or death                          | Progressedatdate of documented PD or death                                                                                                                                                   |
| Death or progression immediately aftar 22 consecutive missed disease assessments, or aftur new anticanca therapy | Censored at the carliest date of 1) last discase asscssment prior to the earlier date of ≥2 consecutive missed disease assessment and 2) the last discase assessment prior to new anticancer therapy. if any. In a special case of participants without post- randomization scans who diedlatarthan after 22 consecutive missed disease assessments or started new anticancer therapy,the PFS will be censoredon the randomization date. | Progressed at date of documentedPD OT death                           | Progressedat date of documentedPD ordeath                                                                                                                                                    |
| No PD and no death; and new anticancur trealment is not initiated                                                | Censored at last disease assessment. In a special case of participants without post-randomization scans, the PFS will be censored on the randomization date.                                                                                                                                                                                                                                                                             | at last disease assessment                                            | Progressed at treatment discontinuation dueto reasons other than complete response, otherwise censored at last disease asscssment if still on study treatment 101 completed study treatment. |
| No PD and no death; new anticancur trealment is initiated                                                        | Censored at last discase asscssment before new anticancertherapy.In a special case of participants without post-randomization scans who started new anticancer therapy, the PFS will be censored on the randomization date.                                                                                                                                                                                                              | Censored at last disease asscssment                                   | Progressed at date of new anticancer trcatment                                                                                                                                               |
| Abbreviations: PD-progressive discase; PFS-progression-fiee survival.                                            | Abbreviations: PD-progressive discase; PFS-progression-fiee survival.                                                                                                                                                                                                                                                                                                                                                                    | Abbreviations: PD-progressive discase; PFS-progression-fiee survival. | Abbreviations: PD-progressive discase; PFS-progression-fiee survival.                                                                                                                        |

The non-parametric Kaplan-Meier (KM) method was used to estimate the PFS and OS curve in each treatment group. The treatment difference in PFS and OS was assessed by the stratified log-rank test. For PFS and OS a stratified Cox proportional hazard model with Efron's method of tie handling was used to assess the magnitude of the treatment difference between the treatment arms. The hazard ratio (HR) and its 95% confidence interval (CI) from the stratified Cox model with Efron's method of tie handling and with a single treatment covariate was reported. The same stratification factors used for randomization were applied to both the stratified log-rank test and the stratified Cox model. At FA of SOS, a sensitivity analysis based on the MaxCombo test with logrank FH (0, 1), FH (1, 1) might be performed to account for the potential loss of power with logrank test in case of proportional hazard assumption violation. In order

<div style=\"page-break-after: always\"></div>

to evaluate the robustness of the PFS endpoint, 2 sensitivity analyses with different sets of censoring rules were performed, as described in the table above.

The stratified Miettinen and Nurminen method with weights proportional to the stratum size was used for the comparison of the ORR between the two treatment groups. The point estimate of ORR was provided by treatment group, together with a 95% CI using the exact binomial method proposed by Clopper and Pearson (1934). The stratification factors used for randomization were applied to the analysis. The descriptive analysis of ORR based on all participants was performed after IA1. No formal hypothesis testing was conducted.

DOR was summarised descriptively using Kaplan-Meier medians and quartiles. Only the subset of patients who showed a complete response (CR) or partial response (PR) were included in this analysis. For each DOR analysis, a corresponding summary of the censoring reasons for responding participant were also provided. Responding subjects who were alive, had not progressed, had not initiated new anti-cancer treatment, had not been determined to be lost to follow-up, and had a disease assessment within ~5 months of the data cutoff date were considered ongoing responders at the time of analysis. If a subject met multiple criteria for censoring, the censoring criterion that occurred earliest was applied.

There were 3 stratification factors used for randomization: geographic region (Region 1: Asia versus Region 2: Non-Asia), locally advanced versus metastatic, and site of origin (gallbladder/intrahepatic/extrahepatic). The analysis stratification was based on the value of the randomization factor entered into the IVRS. For the purpose of analysis, some of the small strata among the 12 strata formed by the 3 factors were combined to ensure sufficient number of participants and events in each stratum. The stratification cells were pooled to form the following 10 analysis strata that were used in all stratified analyses:

1. Asia and Locally Advanced and [Extrahepatic or Gallbladder]
2. Asia and Locally Advanced and Intrahepatic
3. Asia and Metastatic and Gallbladder
4. Asia and Metastatic and Extrahepatic
5. Asia and Metastatic and Intrahepatic
6. Non-Asia and Locally Advanced and [Extrahepatic or Gallbladder]
7. Non-Asia and Locally Advanced and Intrahepatic
8. Non-Asia and Metastatic and Gallbladder
9. Non-Asia and Metastatic and Extrahepatic
10. Non-Asia and Metastatic and Intrahepatic

## Subgroup analyses

Subgroup Analyses and Effect of Baseline Factors were planned. To determine whether the treatment effect was consistent across various subgroups, the between-group treatment effect for OS, PFS, and ORR (with a nominal 95% CI) was estimated and plotted by treatment group within each category of the following classification variables: Geographic region (Region 1: Asia versus Region 2: Non-Asia); Locally advanced versus metastatic; Site of origin (gallbladder/intrahepatic/extrahepatic); Age category (&lt;65, ≥ 65 years); Gender (female, male); Biliary stent and or a biliary drain (yes, no); Antibiotics within 1 month of study start (yes, no); Prior radiation (yes, no); Prior chemotherapy (yes, no); Prior PDT (yes, no); Smoking status (never, former, current); Microsatellite instability (MSI) status (microsatellite stable

<div style=\"page-break-after: always\"></div>

(MSS), microsatellite instability-high (MSI-H), indeterminate); PD-L1 CPS1 (CPS ≥ 1, CPS&lt;1, indeterminate); PD-L1 CPS10 (CPS ≥ 10, CPS&lt;10, indeterminate); ECOG performance status at randomization (0 vs. 1).

The consistency of the treatment effect was assessed descriptively via summary statistics by category for the classification variables listed above. If the number of participants in a category of a subgroup variable was less than 5% of the ITT population, the subgroup analysis could not be performed for that category of the subgroup variable. The subgroup analyses for PFS and OS were conducted using an unstratified Cox model, and the subgroup analyses for ORR were conducted using the unstratified Miettinen and Nurminen method.

## Safety analyses

Safety analyses were based on the All Participants as Treated (APaT) population, which included all 1063 randomized participants who received at least 1 dose of study intervention; participants were analyzed according to the study intervention they received. The primary safety analyses will include only events that occurred before the Second Course Treatment. The analysis of safety results followed a tiered approach. There were no Tier 1 endpoints in this study, and Tier 2 parameters were assessed via point estimates with 95% CIs provided for differences in the proportion of participants with events using the Miettinen and Nurminen (M&amp;N) method, an unconditional, asymptotic method. Membership in Tier 2 required that at least 10% of participants in any treatment group exhibit the event. All other adverse experiences belonged to Tier 3; only point estimates by intervention arm were provided for Tier 3 safety parameters. Because many 95% CIs were provided without adjustment for multiplicity, the analysis represents a helpful descriptive measure to be used in review, not a formal method for assessing the statistical significance of the between-group differences.

## ePRO analysis

The patient-reported outcomes (PRO) were tertiary/exploratory objectives in KEYNOTE-966, and thus no formal hypotheses were formulated. Nominal p-value to compare the pembrolizumab plus gemcitabine/cisplatin arm to placebo plus gemcitabine/cisplatin arm might be provided as appropriate. The PRO instruments are EORTC QLQ-C30, EORTC QLQ-BIL21 and EQ-5D-5L. The PRO analyses were based on the PRO full analysis set (FAS) population, defined as participants who had received at least 1 dose of study intervention and had completed at least 1 PRO assessment.  Participants were analyzed in the intervention group to which they were randomized. PRO FAS populations might be different across EORTC QLQ-C30, EORTC QLQ-BIL21, and EQ-5D-5L.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 5 KEYNOTE-966: Participant flow

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 13 Disposition of participants (ITT population)

|                                                               | Pembrolizumab+ Chemotherapy                                   | Pembrolizumab+ Chemotherapy                                   | Placcbo + Chemotherapy                                        | Placcbo + Chemotherapy                                        | Total                                                         | Total                                                         |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                               | 11                                                            | (%)                                                           |                                                               | (%)                                                           | 11                                                            | (%)                                                           |
| Participants in population                                    | 533                                                           |                                                               | 536                                                           |                                                               | 1069                                                          |                                                               |
| Status for Trial                                              |                                                               |                                                               |                                                               |                                                               |                                                               |                                                               |
| Started                                                       | 533                                                           |                                                               | 536                                                           |                                                               | 1069                                                          |                                                               |
| Discontinued                                                  | 414                                                           | (77.7)                                                        | 446                                                           | (83.2)                                                        | 860                                                           | (80.4)                                                        |
| Death                                                         | 409                                                           | (76.7)                                                        | 443                                                           | (82.6)                                                        | 852                                                           | (79.7)                                                        |
| Associated with COVID-19                                      | 1                                                             | (0.2)                                                         | 6                                                             | (1.1)                                                         | 7                                                             | (0.7)                                                         |
| Unassociated with COVID-19                                    | 394                                                           | (73.9)                                                        | 426                                                           | (79.5)                                                        | 820                                                           | (76.7)                                                        |
| Unknown associationwithCOVID-19                               | 14                                                            | (2.6)                                                         | 11                                                            | (2.1)                                                         | 25                                                            | (2.3)                                                         |
| Lost To Follow-Up                                             | 0                                                             | (0.0)                                                         | 1                                                             | (0.2)                                                         | 1                                                             | (0.1)                                                         |
| Unknown association with COVID-19                             | 0                                                             | (0.0)                                                         | 1                                                             | (0.2)                                                         | 1                                                             | (0.1)                                                         |
| Withdrawal By Subject                                         | 5                                                             | (0.9)                                                         | 2                                                             | (0.4)                                                         | 7                                                             | (0.7)                                                         |
| Unassociated with COVID-19                                    | 0                                                             | (0.0)                                                         | 2                                                             | (0.4)                                                         | 2                                                             | (0.2)                                                         |
| Unassociated with COVID-19,                                   | 5                                                             | (0.9)                                                         | 0                                                             | (0.0)                                                         | 5                                                             | (0.5)                                                         |
| Subscquently died Participants Ongoing                        | 119                                                           | (22.3)                                                        | 06                                                            | (16.8)                                                        | 209                                                           | (19.6)                                                        |
| StatusforStudyMedicationinTrialSegmentTreatment               | StatusforStudyMedicationinTrialSegmentTreatment               | StatusforStudyMedicationinTrialSegmentTreatment               | StatusforStudyMedicationinTrialSegmentTreatment               | StatusforStudyMedicationinTrialSegmentTreatment               | StatusforStudyMedicationinTrialSegmentTreatment               | StatusforStudyMedicationinTrialSegmentTreatment               |
| Started                                                       | 529                                                           |                                                               | 534                                                           |                                                               | 1063                                                          |                                                               |
| Completeda                                                    | 13                                                            | (2.5)                                                         | 7                                                             | (1.3)                                                         | 20                                                            | (1.9)                                                         |
| Discontinued                                                  | 489                                                           | (92.4)                                                        | 504                                                           | (94.4)                                                        | 993                                                           | (93.4)                                                        |
| Adverse Event                                                 | 67                                                            | (12.7)                                                        | 61                                                            | (11.4)                                                        | 128                                                           | (12.0)                                                        |
| Associated with COVID-19                                      | 0                                                             | (0.0)                                                         | 3                                                             | (0.6)                                                         | 3                                                             | (0.3)                                                         |
| Unassociatedwith COVID-19                                     | 67                                                            | (12.7)                                                        | 57                                                            | (10.7)                                                        | 124                                                           | (11.7)                                                        |
| Unknown association with COVID-19                             | 0                                                             | (0.0)                                                         | 1                                                             | (0.2)                                                         | 1                                                             | (0.1)                                                         |
| Clinical Progression                                          | 35                                                            | (6.6)                                                         | 43                                                            | (8.1)                                                         | 78                                                            | (7.3)                                                         |
| Unassociated with COVID-19                                    | 35                                                            | (6.6)                                                         | 43                                                            | (8.1)                                                         | 78                                                            | (7.3)                                                         |
| Non-Study Anti-Cancer Therapy                                 | 3                                                             | (0.6)                                                         | 6                                                             | (1.1)                                                         | 9                                                             | (0.8)                                                         |
| Unassociated with COVID-19                                    | 3                                                             | (0.6)                                                         | 6                                                             | (1.1)                                                         | 9                                                             | (0.8)                                                         |
| Physician Decision                                            | 32                                                            | (6.0)                                                         | 16                                                            | (3.0)                                                         | 48                                                            | (4.5)                                                         |
| Unassociated with COVID-19                                    | 32                                                            | (6.0)                                                         | 16                                                            | (3.0)                                                         | 48                                                            | (4.5)                                                         |
| Progressive Discase                                           | 324                                                           | (61.2)                                                        | 354                                                           | (66.3)                                                        | 678                                                           | (63.8)                                                        |
| Unassociated with COVID-19                                    | 322                                                           | (60.9)                                                        | 351                                                           | (65.7)                                                        | 673                                                           | (63.3)                                                        |
| Unknown association with COVID-19                             | 2                                                             | (0.4)                                                         | 2                                                             | (0.4)                                                         | 4                                                             | (0.4)                                                         |
| Unreported association with COVID-19                          | 0                                                             | (0.0)                                                         | 1                                                             | (0.2)                                                         | 1                                                             | (0.1)                                                         |
| Withdrawal By Subject                                         | 28                                                            | (5.3)                                                         | 24                                                            | (4.5)                                                         | 52                                                            | (4.9)                                                         |
| Unassociated with COVID-19                                    | 27                                                            | (5.1)                                                         | 24                                                            | (4.5)                                                         | 51                                                            | (4.8)                                                         |
| Unknown association with COVID-19                             | 1                                                             | (0.2)                                                         | 0                                                             | (0.0)                                                         | 1                                                             | (0.1)                                                         |
| Participants Ongoing                                          | 27                                                            | (5.1)                                                         | 23                                                            | (4.3)                                                         | 50                                                            | (4.7)                                                         |
| StatusforStudyMedicationinTrial SegmentSecond CourseTreatment | StatusforStudyMedicationinTrial SegmentSecond CourseTreatment | StatusforStudyMedicationinTrial SegmentSecond CourseTreatment | StatusforStudyMedicationinTrial SegmentSecond CourseTreatment | StatusforStudyMedicationinTrial SegmentSecond CourseTreatment | StatusforStudyMedicationinTrial SegmentSecond CourseTreatment | StatusforStudyMedicationinTrial SegmentSecond CourseTreatment |
| Started                                                       | 2                                                             |                                                               | 0                                                             |                                                               | 2                                                             |                                                               |
| Discontinued                                                  | 2                                                             | (100.0)                                                       | 0                                                             | (0.0)                                                         | 2                                                             | (100.0)                                                       |
| Progressive Disease                                           | 2                                                             | (100.0)                                                       | 0                                                             | (0.0)                                                         | 2                                                             | (100.0)                                                       |

Each participant is counted once for Study Medication Status based on the latest corresponding disposition record.

a Completed: participants completed 35 cycles pembrolizumab/placebo at the time of all treatment discontinuation without alternative reasons for discontinuation of any drugif given beyond 35 cycles of pembrolizumab/placebo in the first course treatment

Database CutoffDate:15DEC2022

Median duration of follow-up for the FA in the ITT population, defined as the time from randomization to death or DCO, whichever was earlier, was 12.7 months (range: 0.2, 37.5 months) and 10.9 months (range: 0.2, 36.2 months) in the pembrolizumab plus chemotherapy group and placebo plus chemotherapy group, respectively.

The median time from randomization to DCO in the ITT population was 25.6 months (range 18.3 to 38.4 months) for the FA. Certain efficacy analyses presented are based on the IA1 DCO (15-DEC-2021) and the median time from randomization to DCO in the ITT population for IA1 was 13.6 months (range 6.3 to 26.4 months).

<div style=\"page-break-after: always\"></div>

## Recruitment

The study was conducted in 185 centres in 24 countries/regions. Clinical investigator study sites were located in the following countries/regions: Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Malaysia, Netherlands, New Zealand, South Korea, Spain, Taiwan, Thailand, Turkey, United Kingdom, and the US.

A total of 1564 participants were screened, and 495 nonrandomized participants were screen failures. Nonrandomized participants who did not meet inclusion criteria or meet exclusion criteria are summarized below:

Table 14 Summary of non-randomized participants who did not meet inclusion criteria or did meet exclusion criteria

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | n   | (%)    |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|--------|
|         | Non-randomized participants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 495 |        |
|         | Non-randomized participants who did not mect inclusion cniteria or did meet exclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 495 |        |
| Code    | Inclusion Criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |     |        |
| IN12_01 | Have adequate organ function, as defined in the following table (Table 3). Spccimens must be collected within 14 days priorto the first dose ofstudy intervention.ReferProtocol forTable 3.                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 99  | (20.0) |
| IN09_01 | Have aperformance status of0 or1 on the ECOG PerformanceScale within 3 days priorto the first dose of study intervention.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 49  | (9.9)  |
| IN12_00 | dose ofstudyintervention.ReferProtocol forTable 3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 42  | (8.5)  |
| IN10_01 | Provide archival tumor tissue sample or newly obtained core or excisional biopsy ofa tumor lesion not previously inradiated (ie, obtained for histological confimmation)for biomarker analysis.The tumor tissue must be reccived by the central vendor and be decmed adcquate for biomarker analysis cvaluation, including but not limited to PD-L1 and MSI biomarker analysis,priorto participant randomization. Formalin-fixed, paraffinembedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue. Note: Details pertaining to tumor tissue submission can be found in the laboratory manual. | 41  | (8.3)  |
| IN08_01 | The participant (orlegally acceptable representative, if applicable) provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may enroll in the main study without participating infuturebiomedical research.                                                                                                                                                                                                                                                                                                                                               | 40  | (8.1)  |
| IN12_02 | Have adequate organ function, as defined in the following table (Table 3).Specimens must be collected within 14 days pnorto the first dose ofstudy intervention.ReferProtocol forTable 3.                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25  | (5.1)  |
| IN01_01 | Has histologically confirmed diagnosis ofadvanced (metastatic) and/orunrescctable(locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer).                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21  | (4.2)  |
| IN08_00 | The participant (or legally acceptable representative, if applicable) provides written informed consent for the study. The participant may also provide consent forfuture biomedical research.However, the participant may enrollin the main study without participating infuturebiomedical research.                                                                                                                                                                                                                                                                                                                                                 | 19  | (3.8)  |
| IN10_00 | Provide archivaltumortissue sample ornewlyobtainedcore orexcisional biopsy ofa tumorlesion not previouslyinadiated (ie, obtained forhistological confimation)for biomarker analysis.The tumor tissue must be reccivedby the central vendor and be deemed adequate for biomarker analysis evaluation prior to participant randomization. Fommalin-fixed, paraffin-embedded (FFPE) tissue blocks are preferred to slides.Newly obtained biopsics are preferred to archived tissue.Note: Details pertaining to tumor tissue submission can be found in the laboratory manual.                                                                            | 18  | (3.0)  |
| IN04_01 | Participants with controlled hepatitis B are cligible for the study,as long as they meetthe following ctiteria: Please refer protocol for furtherdctails.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 13  | (2.6)  |
| IN09_00 | Have aperformance status of0 or1on the ECOGPerformance Scale within3 days priorto the first dose of study intervention.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13  | (2.6)  |
| IN11_01 | Have alife expectancy of greater than 3 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 13  | (2.0)  |
| IN02_01 | Havemeasurable disease based onRECIST 1.1,as determined by thesite investigator.Lesions situatedinapreviouslytreatedarea by citherradiotherapy, photodynamic therapy,orarterial embolization are considered measurable ifprogression has been demonstrated in such lesions and they mect criteria for measurable disease per RECIST 1.1.                                                                                                                                                                                                                                                                                                              | 10  | (2.0)  |
| IN02_00 | Have measurable disease based on RECIST 1.1,as determined by the site investigator.Lesions situated in a previously treated area by citherradiotherapy,photodynamic therapy,orarterial embolization are considered measurable ifprogressionhasbeen demonstrated in suchlesions and they meet criteria for measurable disease.                                                                                                                                                                                                                                                                                                                         |     | (1.4)  |

As of the DCO (15-DEC-2022) for the FA, a total of 1069 participants were randomized in the ITT population (533 in the pembrolizumab plus chemotherapy group and 536 in the placebo plus chemotherapy group).

## Conduct of the study

Changes in the conduct of the study implemented by protocol amendment are summarized in the following table. There were no changes in the planned conduct of the study implemented by protocol amendment due to the COVID-19 pandemic.

<div style=\"page-break-after: always\"></div>

Table 15 KEYNOTE-966: Summary of changes in the conduct of the study implemented by protocol amendment

| Document          | Date of Issue   | Overall Rationale                                                                                                                                                                                                                                                                                                                |
|-------------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 6       | 16-JUN- 2022    | Merck Sharp & Dohme Corp. underwent an entity name and addresschangetoMerckSharp&DohmeLLC, Rahway, NJ, USA. This conversion resulted only in an entityname change and updatetotheaddress.                                                                                                                                        |
| Amendment 5       | 18-NOV- 2021    | To add a new, earlierinterim analysis for OS due to recently emerging external data showing positive results for immunotherapy plus chemotherapy as first-line therapy for patients with advanced biliary tract carcinoma, and to address health agency feedback by clarifying PFS and ORR analyses approach.                    |
| Amendment 4       | 26-AUG- 2021    | To update Statistical Analysis plan accounting for faster event accumulation than initially projected by increasing the number ofevents at final analysis and specifying time and event triggers for analyses to ensure sufficientminimumfollow-uptimefor alonger potential delayed effect.                                      |
| Amendment 3       | 11-MAR- 2021    | The Dose Modification and Toxicity Management Guidelines for irAEs and table were updated to align with the USPI as requested by the FDA. In addition, China-specific updates were made to address a CDE request. Cisplatin unit dose strengths were added.                                                                      |
| Amendment 2       | 08-DEC- 2020    | To revise the primary endpoint to OS only with a more conservativehazardratioassumptionaccountingfor possible delayed treatment effect; to change PFS to a secondary endpoint; and to remove the futility analysis. Also, to update interim and final analysis timing from calendar-based toeventbased.                          |
| Amendment 1       | 23-JAN- 2020    | To limit the second course only to those participants who received pembrolizumab in the first course after unblinding participants individually, to address feedback from regulatory authorities, add additional blood sample required for retrospective MSI testing and minimize unnecessary participant visits and procedures. |
| Original Protocol | 21-JUN- 2019    | Not applicable.                                                                                                                                                                                                                                                                                                                  |

CDE=Center for Drug Evaluation; FDA=Food and Drug Administration; irAE=immune-related adverse event; MSI=microsatellite instability; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; USPI=United States Package Insert.

Important protocol deviations were reported for 95 participants (8.9%). Of these, 30 (2.8%) participants had important protocol deviations that were considered to be clinically important (Table 16). Most of the protocol deviations considered to be clinically important (n=15, 1.4%) were due to improperly stored study intervention.

A listing of important protocol deviations is presented by participant, study site, and clinical importance in the table below. No participant's data were excluded from analyses due to an important protocol deviation. One deviation was classified as a serious GCP compliance issue. This involved the use of incorrect ALT reference ranges caused by a change in equipment in which 1 participant was enrolled but later identified to not meet eligibility ALT criteria based on the correct reference ranges. It was determined that there was no impact to safety.

<div style=\"page-break-after: always\"></div>

Table 16 Summary of important protocol deviations considered to be clinically important (ITT population)

|                                                                                                                                                                                                                                                                                                                                                                                                 | Pembrolizmab+Chemotherapy                                                                                   | Pembrolizmab+Chemotherapy                                                                                   | Placebo + Chemotherapy                                                                                      | Placebo + Chemotherapy                                                                                      | Total                                                                                                       | Total                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                 | n                                                                                                           | (%)                                                                                                         | n                                                                                                           | (%)                                                                                                         | n                                                                                                           | (%)                                                                                                         |
| Participants in population                                                                                                                                                                                                                                                                                                                                                                      | 533                                                                                                         |                                                                                                             | 536                                                                                                         |                                                                                                             | 1,069                                                                                                       |                                                                                                             |
| withoneormoreclinicallyimportantprotocoldeviations                                                                                                                                                                                                                                                                                                                                              | 13                                                                                                          | (2.4)                                                                                                       | 17                                                                                                          | (3.2)                                                                                                       | 30                                                                                                          | (2.8)                                                                                                       |
| with no clinically important protocol deviations                                                                                                                                                                                                                                                                                                                                                | 520                                                                                                         | (97.6)                                                                                                      | 519                                                                                                         | (96.8)                                                                                                      | 1,039                                                                                                       | (97.2)                                                                                                      |
| DiscontinuationCriteria                                                                                                                                                                                                                                                                                                                                                                         | 2                                                                                                           | (0.4)                                                                                                       | 5                                                                                                           | (0.9)                                                                                                       | 7                                                                                                           | (0.7)                                                                                                       |
| Participant developedstudyintervention discontinuation criteria，butwas not discontinuedfrom study intervention.                                                                                                                                                                                                                                                                                 | 2                                                                                                           | (0.4)                                                                                                       | 5                                                                                                           | (0.9)                                                                                                       | 7                                                                                                           | (0.7)                                                                                                       |
| Inclusion/ExclusionCriteria                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                           | (0.0)                                                                                                       | 4                                                                                                           | (0.7)                                                                                                       | 4                                                                                                           | (0.4)                                                                                                       |
| Participant was not receiving anti-viral therapy for Hepatitis B asrequired per protocol atrandomization.                                                                                                                                                                                                                                                                                       | 0                                                                                                           | (0.0)                                                                                                       | 2                                                                                                           | (0.4)                                                                                                       | 2                                                                                                           | (0.2)                                                                                                       |
| Participant who did not demonstrate adequate organ functionduring the screening period prior to the startof study treatment.Totalbilirubin<= 1.5*ULN,Direct bilirubin<=ULN for participants with totalbilirubin levels >1.5*ULN,INR orPT/aPTT <= 1.5*ULN unless participantis receiving anticoagulanttherapy as long as PT orPIT is within therapeutic range of intended use of anticoagulants. | 0                                                                                                           | (0.0)                                                                                                       | 2                                                                                                           | (0.4)                                                                                                       | 2                                                                                                           | (0.2)                                                                                                       |
| StudyIntervention                                                                                                                                                                                                                                                                                                                                                                               | 11                                                                                                          | (2.1)                                                                                                       | 6                                                                                                           | (1.1)                                                                                                       | 17                                                                                                          | (1.0)                                                                                                       |
| Participant was administeredimproperly stored studyinterventionthat was deemed unacceptable foruse.                                                                                                                                                                                                                                                                                             | 9                                                                                                           | (1.7)                                                                                                       | 6                                                                                                           | (1.1)                                                                                                       | 15                                                                                                          | (1.4)                                                                                                       |
| Participant was dispensed study intervention otherthanwhat was assigned in the allocation schedule,ie.incorrectmedication orpotential cross- treatment.                                                                                                                                                                                                                                         | 2                                                                                                           | (0.4)                                                                                                       | 0                                                                                                           | (0.0)                                                                                                       | 2                                                                                                           | (0.2)                                                                                                       |
| TrialProcedures                                                                                                                                                                                                                                                                                                                                                                                 | 0                                                                                                           | (0.0)                                                                                                       | 2                                                                                                           | (0.4)                                                                                                       | 2                                                                                                           | (0.2)                                                                                                       |
| PembrolizumabdosemodificationguidancenotfollowedforSAEs and HECIs(eg,not holding dose fortoxicities as indicatedin the protocol), including when a participant develops an adverse event for which the protocolinstructsstudy treatment discontinuation,buttreatmentwasnot discontinued.                                                                                                        | 0                                                                                                           | (0.0)                                                                                                       | 2                                                                                                           | (0.4)                                                                                                       | 2                                                                                                           | (0.2)                                                                                                       |
| Every participantis counted a single time for each applicable row and column. DatabaseCutoffDate:15DEC2022.                                                                                                                                                                                                                                                                                     | Every participantis counted a single time for each applicable row and column. DatabaseCutoffDate:15DEC2022. | Every participantis counted a single time for each applicable row and column. DatabaseCutoffDate:15DEC2022. | Every participantis counted a single time for each applicable row and column. DatabaseCutoffDate:15DEC2022. | Every participantis counted a single time for each applicable row and column. DatabaseCutoffDate:15DEC2022. | Every participantis counted a single time for each applicable row and column. DatabaseCutoffDate:15DEC2022. | Every participantis counted a single time for each applicable row and column. DatabaseCutoffDate:15DEC2022. |

## Part of this study was conducted during the COVID-19 pandemic.

Table 17 Measures implemented by the sponsor to manage study conduct during the COVID-19 pandemic for KEYNOTE-966

| Process                                          | Measure (DateImplemented/Date Ended:DD-MMM-YYYY)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study site monitoring                            | Modifications to the frequency of onsite and remote monitoring were allowed due to national and local travel restrictions and/or study site restrictions toonsitemonitoring(21-MAR-2020). Redacted/alternatemethodsforsourcedatareviewandverificationfor critical data points in absence ofremote access to electronic medical records were allowed under documented circumstances (06-MAR- 2020). Sourcedatareviewand/orverificationbeforedatabaselockwas/were waived for this study (13-MAR-2020). Critical datapointsforSDVwerereassessed andtheSMPupdated without the usual approval workflow approval for resumption of onsite monitoring(01-MAY-2020) |
| Protocol deviations                              | Study sites were queried as to the relationship of reported deviations to the COVID-19 pandemic; responses were documented (20-MAR-2020).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| AE reporting                                     | COVID-19 infection was to be reported following the protocol's AE and SAE reporting instructions.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Clinical supplies (including study intervention) | Direct shipping of ambient drug, without temperature monitoring, from the study site to study participants was allowed under specific circumstances (eg, stability data support transit time) (30-MAR-2020). An alternate location (eg, primary care center, pharmacy) for injectable and/orinfusion administrationofstudyintervention/otherclinical supplies was allowed when participant travel was impacted, and administration could not be postponed (21-APR-2020).                                                                                                                                                                                    |
| Data management                                  | Alternative procedures were allowed for study sites using shared electronic devices to complete clinical outcome assessments (08-APR- 2020). Study sites were queried, and responses documented about the relationship of the following to the COVID-19 pandemic (O8-APR- 2020): Missing participant study visits and data. Participants who discontinued study intervention and/or the study.                                                                                                                                                                                                                                                              |
| Informed consent                                 | Oral confirmation of participant consent (eg, via telephone) was allowed when in-person discussion and signature was not possible (30- MAR-2020).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 18 Participant characteristics (ITT population)

|                                                                    | Pembrolizumab+ Chemotherapy   | Pembrolizumab+ Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Total    | Total   |
|--------------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------|----------|---------|
|                                                                    |                               | (%)                           | n                        | (%)                      |          | (%)     |
| Participants in population                                         | 533                           |                               | 536                      |                          | 1,069    |         |
| Sex                                                                |                               |                               |                          |                          |          |         |
| Male                                                               | 280                           | (52.5)                        | 272                      | (50.7)                   | 552      | (51.6)  |
| Female                                                             | 253                           | (47.5)                        | 264                      | (49.3)                   | 517      | (48.4)  |
| Age (Years)                                                        |                               |                               |                          |                          |          |         |
| $9>                                                                | 269                           | (50.5)                        | 298                      | (55.6)                   | 567      | (53.0)  |
| >=65                                                               | 264                           | (49.5)                        | 238                      | (44.4)                   | 502      | (47.0)  |
| Mean                                                               | 63.3                          |                               | 61.8                     |                          | 62.5     |         |
| SD                                                                 | 10.3                          |                               | 11.0                     |                          | 10.7     |         |
| Median                                                             | 64.0                          |                               | 63.0                     |                          | 64.0     |         |
| Range                                                              | 23 to 85                      |                               | 28 to 84                 |                          | 23 to 85 |         |
| Race                                                               |                               |                               |                          |                          |          |         |
| American Indian OrAlaska Native                                    | 2                             | (0.4)                         | 1                        | (0.2)                    | 3        | (0.3)   |
| Asian                                                              | 245                           | (46.0)                        | 250                      | (46.6)                   | 495      | (46.3)  |
| Black Or African American                                          | 11                            | (2.1)                         | 3                        | (0.6)                    | 14       | (1.3)   |
| Multiple                                                           | 5                             | (0.9)                         | 2                        | (0.4)                    | 7        | (0.7)   |
| American Indian Or AlaskaNative,Black OrAfrican American           | 1                             | (0.2)                         | 0                        | (0.0)                    | 1        | (0.1)   |
| American Indian Or Alaska Native, Black Or African American, White | 0                             | (0.0)                         |                          | (0.2)                    |          | (0.1)   |
| Black Or AficanAmerican,White                                      | 2                             | (0.4)                         |                          | (0.2)                    | 3        | (0.3)   |
| White, Asian                                                       | 2                             | (0.4)                         | 0                        | (0.0)                    | 2        | (0.2)   |
| NativeHawaiianOr OtherPacificIslander                              | 1                             | (0.2)                         | 0                        | (0.0)                    | 1        | (0.1)   |
| White                                                              | 256                           | (48.0)                        | 268                      | (50.0)                   | 524      | (49.0)  |
| Missing                                                            | 13                            | (2.4)                         | 12                       | (2.2)                    | 25       | (2.3)   |
| Ethnicity                                                          |                               |                               |                          |                          |          |         |
| Hispanic Or Latino                                                 | 59                            | (11.1)                        | 52                       | (9.7)                    | 111      | (10.4)  |
| Not Hispanic Or Latino                                             | 433                           | (81.2)                        | 449                      | (83.8)                   | 882      | (82.5)  |
| Not Reported                                                       | 32                            | (6.0)                         | 31                       | (5.8)                    | 63       | (5.9)   |
| Unknown                                                            | 5                             | (0.9)                         | 3                        | (0.6)                    | 8        | (0.7)   |
| Missing                                                            | 4                             | (0.8)                         | 1                        | (0.2)                    | 5        | (0.5)   |

<div style=\"page-break-after: always\"></div>

|                          | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Total   | Total   |
|--------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|---------|---------|
|                          | n                              | (%)                            |                          | (%)                      | n       | (%)     |
| Asia                     | 242                            | (45.4)                         | 244                      | (45.5)                   | 486     | (45.5)  |
| Non-Asia                 | 291                            | (54.6)                         | 292                      | (54.5)                   | 583     | (54.5)  |
| Geographic Region        |                                |                                |                          |                          |         |         |
| North America            | 45                             | (8.4)                          | 40                       | (7.5)                    | 85      | (8.0)   |
| Westem Europe            | 151                            | (28.3)                         | 151                      | (28.2)                   | 302     | (28.3)  |
| Rest of the World        | 337                            | (63.2)                         | 345                      | (64.4)                   | 682     | (63.8)  |
| Prior Adjuvant Therapy   |                                |                                |                          |                          |         |         |
| Yes                      | 47                             | (8.8)                          | 48                       | (9.0)                    | 95      | (8.9)   |
| No                       | 486                            | (91.2)                         | 488                      | (91.0)                   | 974     | (91.1)  |
| PriorNeo-adjuvantTherapy |                                |                                |                          |                          |         |         |
| Yes                      | 3                              | (0.6)                          | 1                        | (0.2)                    | 4       | (0.4)   |
| No                       | 530                            | (99.4)                         | 535                      | (99.8)                   | 1,065   | (99.6)  |
| Prior Surgery            |                                |                                |                          |                          |         |         |
| Yes                      | 157                            | (29.5)                         | 162                      | (30.2)                   | 319     | (29.8)  |
| No                       | 376                            | (70.5)                         | 374                      | (69.8)                   | 750     | (70.2)  |
| Prior Radiation          |                                |                                |                          |                          |         |         |
| Yes                      | 21                             | (3.9)                          | 28                       | (5.2)                    | 49      | (4.6)   |
| No                       | 512                            | (96.1)                         | 508                      | (94.8)                   | 1,020   | (95.4)  |
| Prior Chemotherapy       |                                |                                |                          |                          |         |         |
| Yes                      | 50                             | (9.4)                          | 48                       | (9.0)                    | 98      | (9.2)   |
| No                       | 483                            | (90.6)                         | 488                      | (91.0)                   | 971     | (90.8)  |
| Prior PDT                |                                |                                |                          |                          |         |         |
| No                       | 533                            | (100.0)                        | 536                      | (100.0)                  | 1,069   | (100.0) |
| PD-L1 Status(CPS>=1)     |                                |                                |                          |                          |         |         |
| CPS<1                    | 113                            | (21.2)                         | 110                      | (20.5)                   | 223     | (20.9)  |
| CPS>=1                   | 363                            | (68.1)                         | 365                      | (68.1)                   | 728     | (68.1)  |
| Indeteminate             | 57                             | (10.7)                         | 61                       | (11.4)                   | 118     | (0'11)  |
| PD-L1 Status (CPS>=10)   |                                |                                |                          |                          |         |         |
| CPS<10                   | 273                            | (51.2)                         | 289                      | (53.9)                   | 562     | (52.6)  |

<div style=\"page-break-after: always\"></div>

|                                          | Pembrolizumab +   | Pembrolizumab +   | Placcbo +   | Placcbo +        | Total   | Total   |
|------------------------------------------|-------------------|-------------------|-------------|------------------|---------|---------|
|                                          | n                 | Chemotherapy (%)  | n           | Chemotherapy (%) | n       | (%)     |
| CPS>=10                                  | 203               | (38.1)            | 186         | (34.7)           | 389     | (36.4)  |
| Indeteminate                             | 57                | (10.7)            | 61          | (11.4)           | 118     | (11.0)  |
| MSIStatus                                |                   |                   |             |                  |         |         |
| MSI-H                                    | 6                 | (1.1)             | 4           | (0.7)            | 10      | (0.9)   |
| MSS                                      | 433               | (81.2)            | 422         | (78.7)           | 855     | (80.0)  |
| Indeteminate                             | 94                | (17.6)            | 110         | (20.5)           | 204     | (19.1)  |
| ECOGPerformanceStatus                    |                   |                   |             |                  |         |         |
| 0                                        | 258               | (48.4)            | 228         | (42.5)           | 486     | (45.5)  |
| 1                                        | 274               | (51.4)            | 308         | (57.5)           | 582     | (54.4)  |
| >=2                                      | 1                 | (0.2)             | 0           | (0.0)            | 1       | (0.1)   |
| Site of Origin                           |                   |                   |             |                  |         |         |
| Gallbladder                              | 115               | (21.6)            | 118         | (22.0)           | 233     | (21.8)  |
| Intrahepatic                             | 320               | (60.0)            | 313         | (58.4)           | 633     | (59.2)  |
| Extrahepatic                             | 98                | (18.4)            | 105         | (19.6)           | 203     | (19.0)  |
| Disease Status                           |                   |                   |             |                  |         |         |
| Locally Advanced                         | 60                | (11.3)            | 66          | (12.3)           | 126     | (11.8)  |
| Metastatic                               | 473               | (88.7)            | 470         | (87.7)           | 943     | (88.2)  |
| HepatitisBStatus                         |                   |                   |             |                  |         |         |
| Chronic HBV Infection                    | 14                | (2.6)             | 16          | (3.0)            | 30      | (2.8)   |
| Clinically Resolved HBV Infection        | 150               | (28.1)            | 149         | (27.8)           | 299     | (28.0)  |
| Negative                                 | 366               | (68.7)            | 366         | (68.3)           | 732     | (68.5)  |
| Missing                                  | 3                 | (0.6)             | 5           | (0.9)            | 8       | (0.7)   |
| Any Viral HepatitisB                     |                   |                   |             |                  |         |         |
| HBV Infection                            | 164               | (30.8)            | 165         | (30.8)           | 329     | (30.8)  |
| Negative                                 | 366               | (68.7)            | 366         | (68.3)           | 732     | (68.5)  |
| Missing                                  | 3                 | (0.6)             | 5           | (0.9)            | 8       | (0.7)   |
| Hepatitis C Status                       |                   |                   |             |                  |         |         |
| HCV Infection                            | 1                 | (0.2)             | 1           | (0.2)            | 2       | (0.2)   |
| Prior HCV Infection                      | 18                | (3.4)             | 13          | (2.4)            | 31      | (2.9)   |
| Negative                                 | 514               | (96.4)            | 520         | (97.0)           | 1,034   | (96.7)  |
| Missing                                  | 0                 | (0.0)             | 2           | (0.4)            | 2       | (0.2)   |
| AnyViral Hepatitis C                     |                   |                   |             |                  |         |         |
| HCV Infection                            | 19                | (3.6)             | 14          | (2.6)            | 33      | (3.1)   |
| Negative                                 | 514               | (96.4)            | 520         | (97.0)           | 1,034   | (96.7)  |
| Missing                                  | 0                 | (0.0)             | 2           | (0.4)            | 2       | (0.2)   |
| Smoking Status                           |                   |                   |             |                  |         |         |
| Never Smoker                             | 272               | (51.0)            | 295         | (55.0)           | 567     | (53.0)  |
| Former Smoker                            | 205               | (38.5)            | 191         | (35.6)           | 396     | (37.0)  |
| Current Smoker                           | 56                | (10.5)            | 49          | (9.1)            | 105     | (9.8)   |
| Missing                                  | 0                 | (0.0)             | 1           | (0.2)            | 1       | (0.1)   |
| Alcohol UseStatus                        |                   |                   |             |                  |         |         |
| Never Used Alcohol                       | 282               | (52.9)            | 316         | (59.0)           | 598     | (55.9)  |
| Used/Using Alcohol                       | 251               | (47.1)            | 219         | (40.9)           | 470     | (44.0)  |
| Missing                                  | 0                 | (0.0)             | 1           | (0.2)            | 1       | (0.1)   |
| Disease Overall Stage                    |                   |                   |             |                  |         |         |
| I                                        | 3                 | (0.6)             | 2           | (0.4)            | 5       | (0.5)   |
| II                                       | 19                | (3.6)             | 15          | (2.8)            | 34      | (3.2)   |
| III                                      | 36                | (6.8)             | 47          | (8.8)            | 83      | (7.8)   |
| IV                                       | 475               | (89.1)            | 472         | (88.1)           | 947     | (88.6)  |
| BiliaryStent/BiliaryDrain                |                   |                   |             |                  |         |         |
| Yes                                      | 33                | (6.2)             | 41          | (7.6)            | 74      | (6.9)   |
| No                                       | 500               | (93.8)            | 495         | (92.4)           | 995     | (93.1)  |
| Antibiotics within1 month of study start |                   |                   |             |                  |         |         |
| Yes                                      | 62                | (11.6)            | 43          | (8.0)            | 105     | (9.8)   |

<div style=\"page-break-after: always\"></div>

|    | Pembrolizumab+ Chemotherapy   | Placebo + Chemotherapy   | Total         |
|----|-------------------------------|--------------------------|---------------|
| No | (%) 471 (88.4)                | n (%) 493 (92.0)         | (%) 964(90.2) |

Asia:Korea,Republic of, Taiwan,HongKong,Thailand,Japan,China and Malaysia

Non-Asia:Argentina,Australia,Belgium,Brazil, Canada,Chile,France,Germany,Ireland,Israel,Italy, Netherlands,New Zealand,Spain,Turkey,United Kingdom and UnitedStates

North America:Canada and UnitedStates

Western Europe: Belgium, France, Germany, Ireland, Italy, Netherlands, Spain and United Kingdom

Rest of the World: Argentina,Australia,Brazil, Chile,China,Hong Kong,Israel,Japan,Korea,Republic of, Malaysia, New Zealand, Taiwan, Thailand and Turkey

Chronic HBV Infection: participants hepatitis Bvirus surface antigen positive, and/or hepatitis B DNA is numeric value(excluding\"&lt;20IU/mL\").

ClinicallyResolvedHBVInfection:participants hepatitis Bvirus surface antigen negative,and hepatitisBDNA is not detectable or\"&lt;20 IU/mL\"and (hepatitis B Core IgG and IgM antibodies positive or hepatitis B virus core IgM antibodypositive).

antibody negative).

value

Hepatitis CStatusNegative:participantswithhepatitis CIgG antibodynegative.

HBVInfection:participants witheitherchronicHBVinfection or clinically resolvedHBVinfection.

HCV Infection:participants with either chronic HCV infection or prior HCV infection.

DatabaseCutoffDate:15DEC2022

Table 19 Metastatic sites of disease at Baseline (ITT population)

|                                                     | Pembrolizumab + Chemotherapy     | Pembrolizumab + Chemotherapy     | Placebo + Chemotherapy           | Placebo + Chemotherapy           |
|-----------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                                     | n                                | (%)                              | n                                | (%)                              |
| Participants in population                          | 533                              |                                  | 536                              |                                  |
| Metastatic sites of disease - no. (%)               | 473                              | (88.7)                           | 470                              | (87.7)                           |
| Liver                                               | 314                              | (58.9)                           | 300                              | (56.0)                           |
| Lymph node                                          | 310                              | (58.2)                           | 293                              | (54.7)                           |
| Respiratory                                         | 159                              | (29.8)                           | 146                              | (27.2)                           |
| Peritoneum                                          | 130                              | (24.4)                           | 130                              | (24.3)                           |
| Musculoskeletal and soft tissue                     | 63                               | (11.8)                           | 68                               | (12.7)                           |
| Abdomen wall, cavity and organs ( other than liver) | 42                               | (7.9)                            | 57                               | (10.6)                           |
| Biliary tract and gall bladder                      | 31                               | (5.8)                            | 30                               | (5.6)                            |
| Ascites                                             | 14                               | (2.6)                            | 12                               | (2.2)                            |
| Others                                              | 12                               | (2.3)                            | 16                               | (3.0)                            |
| Database Cutoff Date: 15DEC2022.                    | Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. |

Table 20 Previous modalities of anticancer treatment (ITT population)

|                                                                                                | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                                                                                | n                              | (%)                            | n                        | (%)                      |
| Participants in population                                                                     | 533                            |                                | 536                      |                          |
| Chemotherapy                                                                                   | 50                             | (9.4)                          | 48                       | (9.0)                    |
| Radiotherapy                                                                                   | 21                             | (3.9)                          | 28                       | (5.2)                    |
| Previous surgical therapy related to disease under study (except biliary stenting or drainage) | 140                            | (26.3)                         | 145                      | (27.1)                   |
| Hepatectomy                                                                                    | 71                             | (13.3)                         | 70                       | (13.1)                   |
| Cholecystectomy                                                                                | 45                             | (8.4)                          | 52                       | (9.7)                    |
| Pancreaticoduodenectomy                                                                        | 32                             | (6.0)                          | 36                       | (6.7)                    |
| Biliary tract operation                                                                        | 13                             | (2.4)                          | 16                       | (3.0)                    |

300

(56.0)

293

(54.7)

146

(27.2)

130

(24.3)

68

57

30

(5.6)

12

(2.2)

16

(3.0)

70

52

(9.7)

36

(6.7)

16

(3.0)

<div style=\"page-break-after: always\"></div>

1

4

6

0

0

0

0

0

1

1

1

101

(18.8)

27

(5.0)

8

14

(2.6)

4

0

| Tumour excision                          | 4   | (0.8)   | 1   | (0.2)   |
|------------------------------------------|-----|---------|-----|---------|
| Cancer surgery                           | 4   | (0.8)   | 4   | (0.7)   |
| Hepaticojejunostomy                      | 3   | (0.6)   | 6   | (1.1)   |
| Cholangiojejunostomy                     | 1   | (0.2)   | 0   | (0.0)   |
| Choledochoenterostomy                    | 1   | (0.2)   | 0   | (0.0)   |
| Choledocholithotomy                      | 1   | (0.2)   | 0   | (0.0)   |
| Pancreatectomy                           | 1   | (0.2)   | 0   | (0.0)   |
| Tumour invasion                          | 1   | (0.2)   | 0   | (0.0)   |
| Gallbladder operation                    | 1   | (0.2)   | 1   | (0.2)   |
| Cholangiocarcinoma                       | 0   | (0.0)   | 1   | (0.2)   |
| Liver operation                          | 0   | (0.0)   | 1   | (0.2)   |
| Extent of resection                      |     |         |     |         |
| NEGATIVE (R0)                            | 95  | (17.8)  | 101 | (18.8)  |
| POSITIVE (R1)                            | 26  | (4.9)   | 27  | (5.0)   |
| POSITIVE (R2)                            | 7   | (1.3)   | 8   | (1.5)   |
| Missing                                  | 16  | (3.0)   | 14  | (2.6)   |
| Locoregional Therapy                     | 17  | (3.2)   | 14  | (2.6)   |
| Transcatheter arterial chemoembolisation | 7   | (1.3)   | 4   | (0.7)   |
| High frequency ablation                  | 5   | (0.9)   | 0   | (0.0)   |

<div style=\"page-break-after: always\"></div>

Table 21 Previous modalities of anticancer treatment (ITT population) (continued)

1

5

0

1

1

1

2

1

17

(3.2)

18

(3.4)

6

0

0

0

2

2

2

6

1

2

|                                                                        | Pembrolizumab + Chemotherapy     | Pembrolizumab + Chemotherapy     | Placebo + Chemotherapy           | Placebo + Chemotherapy           |
|------------------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                                                        | n                                | (%)                              | n                                | (%)                              |
| Therapeutic embolisation                                               | 4                                | (0.8)                            | 1                                | (0.2)                            |
| Radioembolisation                                                      | 2                                | (0.4)                            | 5                                | (0.9)                            |
| Alcoholisation procedure                                               | 1                                | (0.2)                            | 0                                | (0.0)                            |
| Liver ablation                                                         | 1                                | (0.2)                            | 1                                | (0.2)                            |
| Microwave therapy                                                      | 1                                | (0.2)                            | 1                                | (0.2)                            |
| Tumour ablation                                                        | 1                                | (0.2)                            | 1                                | (0.2)                            |
| Regional chemotherapy                                                  | 1                                | (0.2)                            | 2                                | (0.4)                            |
| Cryotherapy                                                            | 0                                | (0.0)                            | 1                                | (0.2)                            |
| Previous history of biliary stenting or drainage (previous or ongoing) | 33                               | (6.2)                            | 41                               | (7.6)                            |
| Bile duct stent insertion                                              | 16                               | (3.0)                            | 17                               | (3.2)                            |
| Biliary catheter insertion                                             | 9                                | (1.7)                            | 18                               | (3.4)                            |
| Cholangiostomy                                                         | 5                                | (0.9)                            | 6                                | (1.1)                            |
| Catheter site discharge                                                | 1                                | (0.2)                            | 0                                | (0.0)                            |
| Choledochotomy                                                         | 1                                | (0.2)                            | 0                                | (0.0)                            |
| Device occlusion                                                       | 1                                | (0.2)                            | 0                                | (0.0)                            |
| Biliary catheter removal                                               | 1                                | (0.2)                            | 2                                | (0.4)                            |
| Drain placement                                                        | 1                                | (0.2)                            | 2                                | (0.4)                            |
| Drain removal                                                          | 1                                | (0.2)                            | 2                                | (0.4)                            |
| Stent placement                                                        | 1                                | (0.2)                            | 6                                | (1.1)                            |
| Stent removal                                                          | 0                                | (0.0)                            | 1                                | (0.2)                            |
| Bile duct stent removal                                                | 0                                | (0.0)                            | 2                                | (0.4)                            |
| Database Cutoff Date: 15DEC2022.                                       | Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. |

## Numbers analysed

Table 22 Study populations

|                                                                 | Pembrolizumab+ Chemotherapy   | Placebo+Chemotherapy   | Total   |
|-----------------------------------------------------------------|-------------------------------|------------------------|---------|
| NumberofParticipantsScreened                                    |                               |                        | 1564    |
| Number of Participants Randomized (Planned Treatment)(ITT)      | 533                           | 536                    | 1069    |
| Numberof ParticipantsReceived Treatment(Actual Treatment)(APaT) | 529                           | 534                    | 1063    |
| Numberof ParticipantsRandomized and Did NotReceiveTreatment     | 4                             | 2                      |         |
| DatabaseCutoffDate:15DEC2022.                                   |                               |                        |         |

The efficacy analyses were based on the ITT population of 1069 randomized participants except for the DOR analysis that was based on the population of the responders.

The PRO analyses were based on the PRO FAS population, defined as participants who had received at least 1 dose of study intervention and had completed at least 1 PRO assessment. Participants were analyzed in the intervention group to which they were randomized. PRO FAS populations may be different across EORTC QLQ-C30, EORTC QLQ-BIL21, and EQ-5D-5L.

## Outcomes and estimation

Primary efficacy endpoint of OS was analysed at FA. At DCO for FA, 15-DEC-2022 (38.4 months from start of randomization) a total of 857 OS events were observed. The analyses of PFS, ORR, and DOR (secondary endpoints) were prespecified in the protocol to be based on IA1 data (15-DEC-2021 DCO). Descriptive analyses for secondary endpoints of PFS, ORR and DOR based on FA were also provided.

<div style=\"page-break-after: always\"></div>

## Primary Endpoint

OS

Figure 6 Kaplan-Meier Estimates of Overall Survival (ITT population)

Overall Survival

<!-- image -->

## Numberofparticipantsatrisk

Pembrolizumab+ Chemotherapy

533505469430374326275238204175142108885635211685 0

Placebo+Chemotherapy

0 0

Table 23 Analysis of Overall Survival (ITT population)

| Treatment                                               | N                                                       | Number of Events (%)                                    | Person- month           | Event Rate/ 100 Person- months   | Median OSa (months) (95% CI)   |
|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------|----------------------------------|--------------------------------|
| Pembrolizumab + Chemotherapy                            | 533                                                     | 414 (77.7)                                              | 7473.3                  | 5.5                              | 12.7 (11.5, 13.6)              |
| Placebo + Chemotherapy                                  | 536                                                     | 443 (82.6)                                              | 6799.6                  | 6.5                              | 10.9 (9.9, 11.6)               |
| Pairwise Comparisons                                    | Pairwise Comparisons                                    | Pairwise Comparisons                                    | Hazard Ratiob (95% CI)b | Hazard Ratiob (95% CI)b          | p-Value                        |
| Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy | Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy | Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy | 0.83 (0.72, 0.95)       | 0.83 (0.72, 0.95)                | 0.0034c                        |

<div style=\"page-break-after: always\"></div>

Table 24 Summary of Overall Survival Rate Over Time (ITT population)

|                                         | Pembrolizumab+ Chemotherapy (N=533) % (95% CI)a   | Placebo+Chemotherapy (N=536) % (95% CI)a   |
|-----------------------------------------|---------------------------------------------------|--------------------------------------------|
| SummaryofOverallSurvivalrateattimepoint |                                                   |                                            |
| 6months                                 | 80.7 (77.1,83.8)                                  | 73.7 (69.7, 77.2)                          |
| 12 months                               | 51.6 (47.3,55.7)                                  | 44.1 (39.9, 48.3)                          |
| 18 months                               | 33.0 (29.1,37.0)                                  | 28.0 (24.3, 31.9)                          |
| 24 months                               | 24.9 (21.2,28.8)                                  | 18.1 (14.8, 21.7)                          |

Fromproduct-limit(Kaplan-Meier)methodforcensored data.

DatabaseCutoffDate:15DEC2022.

## Secondary Endpoint

## PFS

At IA1 (15-DEC-2021), the observed point estimate for PFS HR favoured pembrolizumab plus chemotherapy though it did not meet statistical significance when compared with placebo plus chemotherapy (HR=0.86; 95% CI: 0.75, 1.00; p=0.0225); the p-value was greater than the p-value boundary of 0.0125 for statistical significance.

Median PFS was 6.5 months (95% CI: 5.7, 6.9) in the pembrolizumab plus chemotherapy and 5.6 months (95% CI: 5.1, 6.6) in the placebo plus chemotherapy groups, respectively.

<div style=\"page-break-after: always\"></div>

## Results at FA (DCO 15-DEC-2022) are shown below:

Figure 7 Kaplan-Meier Estimates of Progression-free Survival at FA (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT population)

<!-- image -->

## Numberofparticipantsatrisk

Pembrolizumab+ Chemotherapy

53340333724518712699775641342720171173 0 0 0

Placebo+Chemotherapy

53641032422216710076584531221788320 0 0

## DatabaseCutoffDate:15DEC2022.

Table 25 Analysis of Progression-free Survival at FA (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT population)

| Treatment                                               |                                                         | Number of Events (%)                                    | Person- month           | Event Rate/ 100 Person- months   | Median PFS a (months) (95% CI)   |
|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------|----------------------------------|----------------------------------|
| Pembrolizumab + Chemotherapy                            | 533                                                     | 428 (80.3)                                              | 3931.9                  | 10.9                             | 6.5 (5.7, 6.9)                   |
| Placebo+ Chemotherapy                                   | 536                                                     | 448 (83.6)                                              | 3532.2                  | 12.7                             | 5.6 (4.9,6.5)                    |
| Pairwise Comparisons                                    | Pairwise Comparisons                                    | Pairwise Comparisons                                    | Hazard Ratiob (95% CI)b | Hazard Ratiob (95% CI)b          | p-Value                          |
| Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy | Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy | Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy | 0.87 (0.76, 0.99)       | 0.87 (0.76, 0.99)                | 0.0171c                          |

BICR = Blinded independent central review.

Database CutoffDate:15DEC2022.

## ORR

At IA1(15-DEC-2021), ORR based on BICR assessment by RECIST 1.1 was 28.7% (95% CI: 24.9, 32.8) for pembrolizumab plus chemotherapy and 28.5% (95% CI: 24.8, 32.6) for placebo plus chemotherapy

Timein Months

<div style=\"page-break-after: always\"></div>

and did not meet the prespecified criterion for statistical significance (between-group difference=0.2 [95% CI: -5.2, 5.6]; p=0.4735).

Results at FA (DCO 15-DEC-2022) are shown below:

Table 26 Summary of Best Overall Response with Confirmation at FA Based on BICR Assessment per RECIST 1.1 (ITT population)

| Response Evaluation             | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|---------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|
|                                 |                                | (%)                            | (95% C1)a                      | n                        | (%)                      | (95% CI)a                |
| Participants in population      | 533                            |                                |                                | 536                      |                          |                          |
| Complete Response (CR)          | 14                             | 2.6                            | (1.4, 4.4)                     | 9                        | 1.7                      | (0.8, 3.2)               |
| Partial Response (PR)           | 142                            | 26.6                           | (22.9, 30.6)                   | 143                      | 26.7                     | (23.0, 30.6)             |
| Objective Response Rate (CR+PR) | 156                            | 29.3                           | (25.4, 33.3)                   | 152                      | 28.4                     | (24.6,32.4)              |
| Stable Disease (SD)b            | 243                            | 45.6                           | (41.3, 49.9)                   | 253                      | 47.2                     | (42.9, 51.5)             |
| Disease Control (CR+PR+SD)      | 399                            | 74.9                           | (71.0, 78.5)                   | 405                      | 75.6                     | (71.7, 79.1)             |
| Progressive Disease (PD)        | 104                            | 19.5                           | (16.2, 23.1)                   | 97                       | 18.1                     | (14.9, 21.6)             |
| Non-evaluable (NE)              | 8                              | 1.5                            | (0.7, 2.9)                     |                          | 2.1                      | (1.0, 3.6)               |
| No Assessment                   | 22                             | 4.1                            | (2.6, 6.2)                     | 23                       | 4.3                      | (2.7, 6.4)               |

## DoR

At IA1 (15-DEC-2021), among responders median DOR was longer in the pembrolizumab plus chemotherapy group compared with the placebo plus chemotherapy group (9.7 months (1.2+ - 22.7+) vs 6.9 months (0.0+ - 19.2+), respectively).

Results at FA (DCO 15-DEC-2022) are shown below:

Table 27 Summary of Time to Response and Duration of Response Based on BICR Assessment per RECIST 1.1 at FA in Participants With Confirmed Response (ITT population)

|                                                            | Pembrolizumab +Chemotherapy (N=533)   | Placebo+ Chemotherapy (N=536)   |
|------------------------------------------------------------|---------------------------------------|---------------------------------|
| Number of participants with responsea                      | 156                                   | 152                             |
| Time to Response (months)                                  |                                       |                                 |
| Mean (SD)                                                  | 3.4 (3.0)                             | 3.2 (2.0)                       |
| Median (Range)                                             | 2.8 (1.1-26.2)                        | 2.8 (1.2-12.5)                  |
| ResponseDurationb(months)                                  |                                       |                                 |
| Median (Range)                                             | 8.3 (1.2+ - 33.0+)                    | 6.8 (1.1+ -30.0+)               |
| Number(%b) of Participants with Extended ResponseDuration: |                                       |                                 |
| ≥3 months                                                  | 141 (93.5)                            | 134 (90.0)                      |
| ≥6 months                                                  | 93 (64.6)                             | 77 (54.7)                       |
| ≥9 months                                                  | 61 (45.8)                             | 44 (35.5)                       |
| ≥12 months                                                 | 47 (38.0)                             | 33 (27.3)                       |
| ≥15 months                                                 | 34 (27.5)                             | 17 (18.1)                       |
| ≥18 months                                                 | 22 (24.2)                             | 9 (14.4)                        |
| ≥21 months                                                 | 16 (20.5)                             | 4 (7.7)                         |
| ≥24 months                                                 | 10 (17.6)                             | 3 (5.7)                         |

Database CutoffDate:15DEC2022

<div style=\"page-break-after: always\"></div>

Figure 8 Kaplan-Meier Estimates of Duration of Response at FA Based on BICR Assessment per RECIST 1.1 in Participants with Confirmed Response (ITT population)

<!-- image -->

DatabaseCutoffDate:15DEC2022.

## Exploratory endpoints

## Patient-reported outcomes (PRO)

From baseline to Week 18, the prespecified exploratory PRO endpoints using the EORTC QLQ-C30 (global health status (GHS)/quality of life (QoL), physical functioning, role functioning), EORTC QLQ-BIL21 (pain and jaundice scores), and EQ-5D-5L VAS for participants receiving pembrolizumab plus chemotherapy were similar to those treated with placebo plus chemotherapy. From baseline to Week 18, Health-related Quality of Life (HRQoL) was maintained when pembrolizumab was added to chemotherapy.

For the GHS/QoL and functional domains of the EORTC QLQ-C30, a higher score denotes better health. For the symptom domains of the EORTC QLQ-C30 and EORTC QLQ-BIL21, a higher score indicates worsening of symptoms or more symptom burden.

## EORTC QLQ-C30

From baseline to Week 18, LSM changes in the prespecified EORTC QLQ-C30 GHS/QoL, physical functioning, and role functioning scores were similar between the pembrolizumab plus chemotherapy group and the placebo plus chemotherapy group.

<div style=\"page-break-after: always\"></div>

- The Least squares mean (LSM) score difference for GHS/QoL was 0.04 points (95% CI: -2.52, 2.60), with a nominal p value (not adjusted for multiplicity) of 0.9773.
- The LSM score difference for physical functioning was 1.24 (95% CI: -1.42, 3.90), nominal pvalue (not adjusted for multiplicity): 0.3596 and for role functioning was 2.68 (95% CI: -0.76, 6.11), nominal p-value (not adjusted for multiplicity): 0.1264.
- The Time-to-deterioration (TTD) was similar between the pembrolizumab plus chemotherapy group and the placebo plus chemotherapy group for GHS/QoL with the median not reached in the pembrolizumab plus chemotherapy group versus 21.22 months in the placebo plus chemotherapy group (HR=0.86, 95% CI: 0.70, 1.07; nominal p=0.1644), physical functioning (median NR vs 11.99 months; HR=0.95, 95% CI: 0.78, 1.17; nominal p=0.6412), and role functioning (median 6.47 months vs 5.75 months; HR=0.98, 95% CI: 0.81, 1.18; nominal p=0.8326).

## EORTC QLQ-BIL21

- From baseline to Week 18, LSM changes in EORTC QLQ-BIL21 scores were similar between the 2 treatment groups. LSM score differences were as follows: jaundice=0.26 (95% CI: -1.35, 1.87; nominal p=0.7535), and pain= -1.87 (95% CI: -4.26, 0.53; nominal p=0.1265).
- TTD in EORTC QLQ-BIL21 was similar between the 2 groups for jaundice (median TTD was NR for both groups; HR=1.20; 95% CI: 0.94, 1.54; nominal p=0.1468) and pain (median TTD was NR for both groups; HR=0.79; 95% CI: 0.59, 1.05; nominal p=0.1064).

## EQ-5D-5L

Results from the EQ-5D analyses were consistent with the results of EORTC QLQ-C30 analyses. From baseline to Week 18, LSM changes in EQ-5D-5L VAS scores were similar between the pembrolizumab plus chemotherapy group and the placebo plus chemotherapy group. LSM score difference was 0.14 (95% CI: -2.18, 2.46; nominal p=0.9058).

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup analyses

OS

Figure 9 Forest Plot of Overall Survival Hazard Ratio by Subgroup Factors (ITT population)

<!-- image -->

Pem+C = Pembrolizumab + Chemotherapy.

Pbo+C = Placebo + Chemotherapy.

For overall population, analysis is based on the same stratified Cox regression model as conducted for the primary analysis.

Subgroup analyses were conducted using an unstratified Cox model with treatment as a covariate.

If the number of participants in a category of a subgroup variable is less than 5% of the ITT population, the subgroup analysis will not be performed for this category of the subgroup variable. If there is only one category of a subgroup left (meaning other categories of a subgroup variable are all less than 5% of the ITT population), this subgroup variable will not be displayed in the forest plot.

Database Cutoff Date: 15DEC2022.

Pem+CFavor→Pbo+C

<div style=\"page-break-after: always\"></div>

Figure 9 (Continued) Forest Plot of Overall Survival Hazard Ratio by Subgroup Factors (ITT population)

<!-- image -->

Pem+C = Pembrolizumab + Chemotherapy.

Pbo+C = Placebo + Chemotherapy.

For overall population, analysis is based on the same stratified Cox regression model as conducted for the primary analysis.

Subgroup analyses were conducted using an unstratified Cox model with treatment as a covariate.

HBV Infection: Participants with either chronic HBV infection or clinically resolved HBV infection.

Database Cutoff Date: 15DEC2022.

## Ad hoc subgroup analysis for OS

An exploratory ad hoc subgroup analysis of a limited geographic region including participants from Thailand, Japan, Taiwan and South Korea (n= 331) was performed and showed a hazard ratio of 0.92 (95% CI: 0.72, 1.17) for OS, favouring the pembrolizumab plus chemotherapy arm.

A subgroup analysis of participants with a history of HBV infection (n= 329) showed a hazard ratio of 0.86 (95% CI: 0.67, 1.09) for OS, favouring the pembrolizumab plus chemotherapy arm. Similarly, participants with no history of HBV infection (n= 732) showed a hazard ratio of 0.83 (95% CI: 0.70, 0.97) for OS, also favouring the pembrolizumab plus chemotherapy arm.

<div style=\"page-break-after: always\"></div>

## PFS

Figure 10 Forest Plot of Progression-Free Survival Hazard Ratio by Subgroup Factors at IA1 Based on BICR Assessment per RECIST 1.1 (Primary Censoring Rule) (ITT population)

<!-- image -->

Pem+C = Pembrolizumab + Chemotherapy.

Pbo+C = Placebo + Chemotherapy.

For overall population, analysis is based on the same stratified Cox regression model as conducted for the primary analysis.

Subgroup analyses were conducted using an unstratified Cox model with treatment as a covariate.

If the number of participants in a category of a subgroup variable is less than 5% of the ITT population, the subgroup analysis was not performed for this category of the subgroup variable. If there is only one category of a subgroup left (meaning other categories of a subgroup variable are all less than 5% of the ITT population), this subgroup variable was not displayed in the forest plot. Subgroup variables used in the forest plot are from the latest database (i.e., ADSL from FA).

Database Cutoff Date: 15DEC2021.

<div style=\"page-break-after: always\"></div>

## ORR

Figure 11 Forest Plot of Objective Response Rate with Confirmation by Subgroups Factors at IA1 Based on BICR Assessment per RECIST 1.1 (ITT population)

<!-- image -->

Placebo+ChemoFavor→Pembro+Chemo

Pem+C = Pembrolizumab + Chemotherapy.

Pbo+C = Placebo + Chemotherapy.

Analysis (ORR difference and 95% CI) for the overall population is based on the same stratified Miettinen &amp; Nurminen method as conducted for the ORR analysis in ITT population. Subgroup analyses were conducted using the unstratified Miettinen &amp; Nurminen method.

If the number of participants in a category of a subgroup variable is less than 5% of the ITT population, the subgroup analysis was not performed for this category of the subgroup variable. If there is only one category of a subgroup left (meaning other categories of a subgroup variable are all less than 5% of the ITT population), this subgroup variable was not displayed in the forest plot. Subgroup variables used in the forest plot are from the latest database (i.e., ADSL from FA).

Database Cutoff Date: 15DEC2021.

<div style=\"page-break-after: always\"></div>

## Analysis by MSI-H

## MSS (Microsatellite Stable)

OS

Figure 12 Kaplan-Meier Estimates of Overall Survival (Participants with MSS, ITT population)

<!-- image -->

## Numberofparticipantsatrisk

Pembrolizumab+ Chemotherapy

Placebo+Chemotherapy

Table 28 Analysis of Overall Survival (Participants with MSS, ITT population)

| Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Number of Events (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Person- month                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Event Rate/ 100 Person- months                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Median OS a (months) (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 433                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 347 (80.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 5841.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 5.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11.8 (10.7, 13.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Placebo + Chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 422                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 355 (84.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 5313.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 6.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10.9 (9.8, 11.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Pairwise Comparisons                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Pairwise Comparisons                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Pairwise Comparisons                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Hazard Ratiob (95% CI)b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Hazard Ratiob (95% CI)b                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | p-Value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Pembrolizumab + Chemotherapy vs. Placebo + Chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.86 (0.74, 1.00)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.86 (0.74, 1.00)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.0291c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| From product-limit (Kaplan-Meier) method for censored data.                                                                                                                                                                                                                                                                                                                                                                                                                                                  | From product-limit (Kaplan-Meier) method for censored data.                                                                                                                                                                                                                                                                                                                                                                                                                                                  | From product-limit (Kaplan-Meier) method for censored data.                                                                                                                                                                                                                                                                                                                                                                                                                                                  | From product-limit (Kaplan-Meier) method for censored data.                                                                                                                                                                                                                                                                                                                                                                                                                                                  | From product-limit (Kaplan-Meier) method for censored data.                                                                                                                                                                                                                                                                                                                                                                                                                                                  | From product-limit (Kaplan-Meier) method for censored data.                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of origin (gallbladder versus intrahepatic versus extrahepatic) with small strata collapsed as pre- specified in the sSAP. c One-sided p-value based on log-rank test stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of | Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of origin (gallbladder versus intrahepatic versus extrahepatic) with small strata collapsed as pre- specified in the sSAP. c One-sided p-value based on log-rank test stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of | Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of origin (gallbladder versus intrahepatic versus extrahepatic) with small strata collapsed as pre- specified in the sSAP. c One-sided p-value based on log-rank test stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of | Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of origin (gallbladder versus intrahepatic versus extrahepatic) with small strata collapsed as pre- specified in the sSAP. c One-sided p-value based on log-rank test stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of | Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of origin (gallbladder versus intrahepatic versus extrahepatic) with small strata collapsed as pre- specified in the sSAP. c One-sided p-value based on log-rank test stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of | Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of origin (gallbladder versus intrahepatic versus extrahepatic) with small strata collapsed as pre- specified in the sSAP. c One-sided p-value based on log-rank test stratified by geographic region (Asia versus Non-Asia), disease status (locally advanced versus metastatic), site of |

0 0

0 0

<div style=\"page-break-after: always\"></div>

## Analysis by combined positive score (CPS)

## CPS ≥10

## OS

Table 29 Analysis of Overall Survival (Participants with PD-L1 CPS &gt;=10, ITT population)

| Treatment                                                                                                                                                                              | N                                                                                                                                                                                      | Number of Events (%)                                                                                                                                                                   | Person- month                                                                                                                                                                          | Event Rate/ 100 Person- months                                                                                                                                                         | Median OS a (months) (95% CI)                                                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Chemotherapy                                                                                                                                                             | 203                                                                                                                                                                                    | 162 (79.8)                                                                                                                                                                             | 2678.7                                                                                                                                                                                 | 6.0                                                                                                                                                                                    | 11.0 (10.2,12.8)                                                                                                                                                                       |
| Placebo+Chemotherapy                                                                                                                                                                   | 186                                                                                                                                                                                    | 160 (86.0)                                                                                                                                                                             | 2261.5                                                                                                                                                                                 | 7.1                                                                                                                                                                                    | 10.3 (8.7, 11.4)                                                                                                                                                                       |
| PairwiseComparisons                                                                                                                                                                    | PairwiseComparisons                                                                                                                                                                    | PairwiseComparisons                                                                                                                                                                    | Hazard Ratiob(95%C1b                                                                                                                                                                   | Hazard Ratiob(95%C1b                                                                                                                                                                   | Hazard Ratiob(95%C1b                                                                                                                                                                   |
| Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                                                      | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                                                      | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                                                      | 0.84 (0.68,1.05)                                                                                                                                                                       | 0.84 (0.68,1.05)                                                                                                                                                                       | 0.84 (0.68,1.05)                                                                                                                                                                       |
| From product-limit(Kaplan-Meier)methodforcensored data. bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022 | From product-limit(Kaplan-Meier)methodforcensored data. bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022 | From product-limit(Kaplan-Meier)methodforcensored data. bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022 | From product-limit(Kaplan-Meier)methodforcensored data. bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022 | From product-limit(Kaplan-Meier)methodforcensored data. bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022 | From product-limit(Kaplan-Meier)methodforcensored data. bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022 |

## PFS

Table 30 Analysis of Progression-free Survival at FA (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (Participants with PD-L1 CPS &gt;=10, ITT population)

| Treatment                                                                                                                                                                                                                    | N                                                                                                                                                                                                                            | Number of Events (%)                                                                                                                                                                                                         | Person- month                                                                                                                                                                                                                | Event Rate/ 100 Person- months                                                                                                                                                                                               | Median PFS a (months) (95% CI)                                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Chemotherapy                                                                                                                                                                                                   | 203                                                                                                                                                                                                                          | 164 (80.8)                                                                                                                                                                                                                   | 1464.6                                                                                                                                                                                                                       | 11.2                                                                                                                                                                                                                         | 5.8 (5.0, 7.2)                                                                                                                                                                                                               |
| Placebo+Chemotherapy                                                                                                                                                                                                         | 186                                                                                                                                                                                                                          | 155 (83.3)                                                                                                                                                                                                                   | 1208.4                                                                                                                                                                                                                       | 12.8                                                                                                                                                                                                                         | 5.4 (4.4,6.8)                                                                                                                                                                                                                |
| PairwiseComparisons                                                                                                                                                                                                          |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              | Hazard Ratiob (95% C1)b                                                                                                                                                                                                      | Hazard Ratiob (95% C1)b                                                                                                                                                                                                      | Hazard Ratiob (95% C1)b                                                                                                                                                                                                      |
| Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                                                                                            | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                                                                                            | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                                                                                            | 0.90 (0.72, 1.12)                                                                                                                                                                                                            | 0.90 (0.72, 1.12)                                                                                                                                                                                                            | 0.90 (0.72, 1.12)                                                                                                                                                                                                            |
| From product-limit (Kaplan-Meier) method for censored data. bBased onCoxregressionmodelwithEfron's method of tiehandlingwith treatment as a covariate. BICR=Blinded independent centralreview. DatabaseCutoffDate:15DEC2022. | From product-limit (Kaplan-Meier) method for censored data. bBased onCoxregressionmodelwithEfron's method of tiehandlingwith treatment as a covariate. BICR=Blinded independent centralreview. DatabaseCutoffDate:15DEC2022. | From product-limit (Kaplan-Meier) method for censored data. bBased onCoxregressionmodelwithEfron's method of tiehandlingwith treatment as a covariate. BICR=Blinded independent centralreview. DatabaseCutoffDate:15DEC2022. | From product-limit (Kaplan-Meier) method for censored data. bBased onCoxregressionmodelwithEfron's method of tiehandlingwith treatment as a covariate. BICR=Blinded independent centralreview. DatabaseCutoffDate:15DEC2022. | From product-limit (Kaplan-Meier) method for censored data. bBased onCoxregressionmodelwithEfron's method of tiehandlingwith treatment as a covariate. BICR=Blinded independent centralreview. DatabaseCutoffDate:15DEC2022. | From product-limit (Kaplan-Meier) method for censored data. bBased onCoxregressionmodelwithEfron's method of tiehandlingwith treatment as a covariate. BICR=Blinded independent centralreview. DatabaseCutoffDate:15DEC2022. |

## CPS &lt;10

## OS

Table 31 Analysis of Overall Survival (Participants with PD-L1 CPS &lt;10, ITT population)

| Treatment                                                                                                                                                                              | N                                                                                                                                                                                      | Number of Events (%)                                                                                                                                                                   | Person- month                                                                                                                                                                          | Event Rate/ 100Person- months                                                                                                                                                          | Median OS a (months) (95% CI)                                                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Chemotherapy                                                                                                                                                             | 273                                                                                                                                                                                    | 211 (77.3)                                                                                                                                                                             | 4009.4                                                                                                                                                                                 | 5.3                                                                                                                                                                                    | 13.1 (11.6, 14.9)                                                                                                                                                                      |
| Placebo+Chemotherapy                                                                                                                                                                   | 289                                                                                                                                                                                    | 236 (81.7)                                                                                                                                                                             | 3810.3                                                                                                                                                                                 | 6.2                                                                                                                                                                                    | 11.6 (10.2,13.6)                                                                                                                                                                       |
| PairwiseComparisons                                                                                                                                                                    |                                                                                                                                                                                        |                                                                                                                                                                                        | HazardRatiob(95%C1)b                                                                                                                                                                   | HazardRatiob(95%C1)b                                                                                                                                                                   | HazardRatiob(95%C1)b                                                                                                                                                                   |
| Pembrolizumab+ Chemotherapyvs.Placebo + Chemotherapy                                                                                                                                   | Pembrolizumab+ Chemotherapyvs.Placebo + Chemotherapy                                                                                                                                   | Pembrolizumab+ Chemotherapyvs.Placebo + Chemotherapy                                                                                                                                   | 0.84 (0.70, 1.01)                                                                                                                                                                      | 0.84 (0.70, 1.01)                                                                                                                                                                      | 0.84 (0.70, 1.01)                                                                                                                                                                      |
| Fromproduct-limit(Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022. | Fromproduct-limit(Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022. | Fromproduct-limit(Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022. | Fromproduct-limit(Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022. | Fromproduct-limit(Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022. | Fromproduct-limit(Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. DatabaseCutoffDate:15DEC2022. |

<div style=\"page-break-after: always\"></div>

## PFS

Table 32 Analysis of Progression-free Survival at FA (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (Participants with PD-L1 CPS &lt;10, ITT population)

| Treatment                                                                                                                                         | N                                                                                                                                                 | Number of Ev ents (%)                                                                                                                             | Person- month                                                                                                                                     | Event Rate/ 100 Person- months                                                                                                                    | Median PFS a (months) (95% CI)                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Chemotherapy                                                                                                                        | 273                                                                                                                                               | 220 (80.6)                                                                                                                                        | 2083.9                                                                                                                                            | 10.6                                                                                                                                              | 6.8 (5.7, 7.9)                                                                                                                                    |
| Placebo+Chemotherapy                                                                                                                              | 289                                                                                                                                               | 243 (84.1)                                                                                                                                        | 1931.2                                                                                                                                            | 12.6                                                                                                                                              | 5.7 (4.7, 6.9)                                                                                                                                    |
| PairwiseComparisons                                                                                                                               |                                                                                                                                                   |                                                                                                                                                   | Hazard Ratiob(95%CI)b                                                                                                                             | Hazard Ratiob(95%CI)b                                                                                                                             | Hazard Ratiob(95%CI)b                                                                                                                             |
| Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                 | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                 | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                 | 0.84 (0.70, 1.01)                                                                                                                                 | 0.84 (0.70, 1.01)                                                                                                                                 | 0.84 (0.70, 1.01)                                                                                                                                 |
| Fromproduct-limit(Kaplan-Meier)methodforcensored data. bBased onCoxregressionmodel withEfron'smethod of tie handlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. bBased onCoxregressionmodel withEfron'smethod of tie handlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. bBased onCoxregressionmodel withEfron'smethod of tie handlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. bBased onCoxregressionmodel withEfron'smethod of tie handlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. bBased onCoxregressionmodel withEfron'smethod of tie handlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. bBased onCoxregressionmodel withEfron'smethod of tie handlingwith treatmentas a covariate. |

## CPS &lt;1

## OS

Figure 13 Kaplan-Meier Estimates of Overall Survival (Participants with PD-L1 CPS &lt; 1, ITT Population)

<!-- image -->

## Numberofparticipantsatrisk

Pembrolizumab+

0 0

Chemotherapy

Placebo+Chemotherapy

4 3 0 0

<div style=\"page-break-after: always\"></div>

## CPS ≥ 1

OS Figure 14 Kaplan-Meier Estimates of Overall Survival (Participants with PD-L1 CPS ≥

<!-- image -->

1, ITT Population)

<!-- image -->

## Number ofparticipants atrisk

Pembrolizumab + Chemotherapy

363338314286251213175152130115947161362010752 0 0

Placebo+Chemotherapy

36534231026523619315614111896765136271613104（ 0 0 0

## Analysis by Age

## OS

Table 33 Analysis of Overall Survival (Age &lt;65 Years) (ITT population)

| Treatment                                                                                                                                                  | N                                                                                                                                                          | Number of Events (%)                                                                                                                                       | Person- month                                                                                                                                              | Event Rate/ 100 Person- months                                                                                                                             | Median OS a (months) (95% CI)                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Chemotherapy                                                                                                                                 | 269                                                                                                                                                        | 210 (78.1)                                                                                                                                                 | 3741.2                                                                                                                                                     | 5.6                                                                                                                                                        | 12.8 (11.6, 14.1)                                                                                                                                          |
| Placebo+Chemotherapy                                                                                                                                       | 298                                                                                                                                                        | 242 (81.2)                                                                                                                                                 | 3853.0                                                                                                                                                     | 6.3                                                                                                                                                        | 10.9 (9.7, 12.0)                                                                                                                                           |
| PairwiseComparisons                                                                                                                                        | PairwiseComparisons                                                                                                                                        | PairwiseComparisons                                                                                                                                        | Hazard Ratiob (95% C1)b                                                                                                                                    | Hazard Ratiob (95% C1)b                                                                                                                                    | p-Value                                                                                                                                                    |
| Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                          | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                          | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                          | 0.88 (0.73, 1.05)                                                                                                                                          | 0.88 (0.73, 1.05)                                                                                                                                          | 0.0790c                                                                                                                                                    |
| From product-limit (Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. | From product-limit (Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. | From product-limit (Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. | From product-limit (Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. | From product-limit (Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. | From product-limit (Kaplan-Meier)method forcensored data. bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate. |

<div style=\"page-break-after: always\"></div>

Table 34 Analysis of Overall Survival (Age 65-74 Years) (ITT population)

| Treatment                                                                                                                                                    | N                                                                                                                                                            | Number of Events (%)                                                                                                                                         | Person- month                                                                                                                                                | Event Rate/ 100 Person- months                                                                                                                               | Median OS a (months) (95% CI)                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab + Chemotherapy                                                                                                                                 | 196                                                                                                                                                          | 154 (78.6)                                                                                                                                                   | 2845.4                                                                                                                                                       | 5.4                                                                                                                                                          | 13.2 (11.0, 14.6)                                                                                                                                            |
| Placebo+ Chemotherapy                                                                                                                                        | 181                                                                                                                                                          | 153 (84.5)                                                                                                                                                   | 2292.4                                                                                                                                                       | 6.7                                                                                                                                                          | 11.1 (9.6, 13.9)                                                                                                                                             |
| Pairwise Comparisons                                                                                                                                         |                                                                                                                                                              |                                                                                                                                                              | Hazard Ratiob (95% CI)b                                                                                                                                      |                                                                                                                                                              | p-Value                                                                                                                                                      |
| Pembrolizumab + Chemotherapy vs.Placebo + Chemotherapy                                                                                                       | Pembrolizumab + Chemotherapy vs.Placebo + Chemotherapy                                                                                                       | Pembrolizumab + Chemotherapy vs.Placebo + Chemotherapy                                                                                                       | 0.79 (0.63, 0.99)                                                                                                                                            | 0.79 (0.63, 0.99)                                                                                                                                            | 0.0201c                                                                                                                                                      |
| From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate. | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate. | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate. | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate. | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate. | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate. |

Table 35 Analysis of Overall Survival (Age &gt;=75 Years) (ITT population)

| Treatment                                           | N                                                   | Number of Events (%)                                | Person- month           | Event Rate/ 100 Person- months   | Median OS a (months) (95% CI)   |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-------------------------|----------------------------------|---------------------------------|
| Pembrolizumab + Chemotherapy                        | 68                                                  | 50 (73.5)                                           | 886.7                   | 5.6                              | 9.0 (7.9, 14.9)                 |
| Placebo + Chemotherapy                              | 57                                                  | 48 (84.2)                                           | 654.2                   | 7.3                              | 9.4 (6.4, 14.0)                 |
| Pairwise Comparisons                                | Pairwise Comparisons                                | Pairwise Comparisons                                | Hazard Ratio* (95% CI)b | Hazard Ratio* (95% CI)b          | p-Value                         |
| Pembrolizumab+ Chemotherapyvs.Placebo+ Chemotherapy | Pembrolizumab+ Chemotherapyvs.Placebo+ Chemotherapy | Pembrolizumab+ Chemotherapyvs.Placebo+ Chemotherapy | 0.81 (0.54, 1.20)       | 0.81 (0.54, 1.20)                | 0.1423c                         |

## PFS

Table 36 Analysis of Progression-free Survival at FA (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (Age &lt;65 Years) (ITT population)

<!-- image -->

| Treatment                                                   | N                                                           | Number of Events (%)                                        | Person- month         | Event Rate/ 100 Person- months   | Median PFS a (months) (95% C1)   |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-----------------------|----------------------------------|----------------------------------|
| Pembrolizumab + Chemotherapy                                | 269                                                         | 217 (80.7)                                                  | 1845.3                | 11.8                             | 6.4 (5.6, 6.9)                   |
| Placebo+Chemotherapy                                        | 298                                                         | 246 (82.6)                                                  | 1962.2                | 12.5                             | 5.6 (5.2, 6.9)                   |
| PairwiseComparisons                                         |                                                             |                                                             | Hazard Ratiob(95%CI)b |                                  | p-Value                          |
| Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy           | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy           | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy           | 0.95 (0.79, 1.14)     | 0.95 (0.79, 1.14)                | 0.29249                          |
| From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. |                       |                                  |                                  |

Table 37 Analysis of Progression-free Survival at FA (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (Age 65 - 74 Years) (ITT population)

| Treatment                                                   | N                                                           | Number of Events (%)                                        | Person- month                                               | Event Rate/ 100 Person- months                              | Median PFS a (months) (95% CI)                              |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Pembrolizumab + Chemotherapy                                | 196                                                         | 152 (77.6)                                                  | 1599.9                                                      | 9.5                                                         | 7.4 (5.7, 8.3)                                              |
| Placebo +Chemotherapy                                       | 181                                                         | 153 (84.5)                                                  | 1173.4                                                      | 13.0                                                        | 5.6 (4.4, 6.9)                                              |
| Pairwise Comparisons                                        | Pairwise Comparisons                                        | Pairwise Comparisons                                        | Hazard Ratiob (95% CI)b                                     | Hazard Ratiob (95% CI)b                                     | p-Value                                                     |
| Pembrolizumab+Chemotherapyvs.Placebo +Chemotherapy          | Pembrolizumab+Chemotherapyvs.Placebo +Chemotherapy          | Pembrolizumab+Chemotherapyvs.Placebo +Chemotherapy          | 0.74 (0.59, 0.93)                                           | 0.74 (0.59, 0.93)                                           | 0.0041c                                                     |
| From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. |

<div style=\"page-break-after: always\"></div>

Table 38 Analysis of Progression-free Survival at FA (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (Age &gt;=75 Years) (ITT population)

| Treatment                                                                                                                                        | N                                                                                                                                                | Number of Events (%)                                                                                                                             | Person- month                                                                                                                                    | Event Rate/ 100 Person- months                                                                                                                   | Median PFS a (months) (95% C1)                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Chemotherapy                                                                                                                       | 68                                                                                                                                               | 59 (86.8)                                                                                                                                        | 486.6                                                                                                                                            | 12.1                                                                                                                                             | 5.5 (3.3, 7.7)                                                                                                                                   |
| Placebo+Chemotherapy                                                                                                                             | 57                                                                                                                                               | 49 (86.0)                                                                                                                                        | 396.7                                                                                                                                            | 12.4                                                                                                                                             | 4.3 (3.4, 7.2)                                                                                                                                   |
| PairwiseComparisons                                                                                                                              |                                                                                                                                                  |                                                                                                                                                  | Hazard Ratiob (95%C1)b                                                                                                                           |                                                                                                                                                  | p-Value                                                                                                                                          |
| Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy                                                                                                | 1.00 (0.68, 1.46)                                                                                                                                | 1.00 (0.68, 1.46)                                                                                                                                | 0.4901c                                                                                                                                          |
| Fromproduct-limit(Kaplan-Meier)methodforcensored data. Based on CoxregressionmodelwithEfron's method of tiehandlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. Based on CoxregressionmodelwithEfron's method of tiehandlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. Based on CoxregressionmodelwithEfron's method of tiehandlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. Based on CoxregressionmodelwithEfron's method of tiehandlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. Based on CoxregressionmodelwithEfron's method of tiehandlingwith treatmentas a covariate. | Fromproduct-limit(Kaplan-Meier)methodforcensored data. Based on CoxregressionmodelwithEfron's method of tiehandlingwith treatmentas a covariate. |

## ORR

Table 39 Analysis of Objective Response with Confirmation at FA Based on BICR Assessment per RECIST 1.1 (Age &lt;65 Years) (ITT population)

| Treatment                                                                                                                                                                               | N                                                                                                                                                                                       | Number of                                                                                                                                                                               | Objective Response Rate                                                                                                                                                                 | Difference in %vs. Placebo + Chemotherapy                                                                                                                                               | Difference in %vs. Placebo + Chemotherapy                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                         |                                                                                                                                                                                         | Objective Responses                                                                                                                                                                     | (%) (95% CI)                                                                                                                                                                            | Estimate (95% CI)                                                                                                                                                                       | p-Valueb                                                                                                                                                                                |
| Pembrolizumab + Chemotherapy                                                                                                                                                            | 269                                                                                                                                                                                     | 80                                                                                                                                                                                      | 29.7 (24.3,35.6)                                                                                                                                                                        | 1.2 (-6.3, 8.7)                                                                                                                                                                         | 0.3752                                                                                                                                                                                  |
| Placebo+Chemotherapy                                                                                                                                                                    | 298                                                                                                                                                                                     | 85                                                                                                                                                                                      | 28.5 (23.5,34.0)                                                                                                                                                                        |                                                                                                                                                                                         |                                                                                                                                                                                         |
| BasedonMiettinen&Nurminenmethod. b One-sided p-value for testing.H0: difference in %0versus Hl: difference in %> 0. BICR-Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminenmethod. b One-sided p-value for testing.H0: difference in %0versus Hl: difference in %> 0. BICR-Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminenmethod. b One-sided p-value for testing.H0: difference in %0versus Hl: difference in %> 0. BICR-Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminenmethod. b One-sided p-value for testing.H0: difference in %0versus Hl: difference in %> 0. BICR-Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminenmethod. b One-sided p-value for testing.H0: difference in %0versus Hl: difference in %> 0. BICR-Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminenmethod. b One-sided p-value for testing.H0: difference in %0versus Hl: difference in %> 0. BICR-Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. |

Table 40 Analysis of Objective Response with Confirmation at FA Based on BICR Assessment per RECIST 1.1 (Age 65-74 Years) (ITT population)

| Treatment                                                                                                                                                                              | N                                                                                                                                                                                      | Number of                                                                                                                                                                              | Objective Response Rate                                                                                                                                                                | Difference in % vs.Placebo + Chemotherapy                                                                                                                                              | Difference in % vs.Placebo + Chemotherapy                                                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                        |                                                                                                                                                                                        | Objective Responses                                                                                                                                                                    | (%) (95% CI)                                                                                                                                                                           | Estimate (95% CI)*                                                                                                                                                                     | p-Valueb                                                                                                                                                                               |
| Pembrolizumab+Chemotherapy                                                                                                                                                             | 196                                                                                                                                                                                    | 62                                                                                                                                                                                     | 31.6 (25.2, 38.6)                                                                                                                                                                      | 2.9 (-6.4, 12.1)                                                                                                                                                                       | 0.2701                                                                                                                                                                                 |
| Placebo+Chemotherapy                                                                                                                                                                   | 181                                                                                                                                                                                    | 52                                                                                                                                                                                     | 28.7 (22.3,35.9)                                                                                                                                                                       |                                                                                                                                                                                        |                                                                                                                                                                                        |
| BasedonMiettinen&Nurminen method. One-sided p-valuefor testing.H0: difference in%=0 versus Hl: difference in %> 0. BICR=Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. One-sided p-valuefor testing.H0: difference in%=0 versus Hl: difference in %> 0. BICR=Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. One-sided p-valuefor testing.H0: difference in%=0 versus Hl: difference in %> 0. BICR=Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. One-sided p-valuefor testing.H0: difference in%=0 versus Hl: difference in %> 0. BICR=Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. One-sided p-valuefor testing.H0: difference in%=0 versus Hl: difference in %> 0. BICR=Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. One-sided p-valuefor testing.H0: difference in%=0 versus Hl: difference in %> 0. BICR=Blindedindependentcentralreview. DatabaseCutoffDate:15DEC2022. |

Table 41 Analysis of Objective Response with Confirmation at FA Based on BICR Assessment per RECIST 1.1 (Age &gt;=75 Years) (ITT population)

| Treatment                                                                                                                                                                                     | N                                                                                                                                                                                             | Number of                                                                                                                                                                                     | Objective Response Rate                                                                                                                                                                       | Difference in % vs. Placebo + Chemotherapy                                                                                                                                                    | Difference in % vs. Placebo + Chemotherapy                                                                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                               |                                                                                                                                                                                               | Objective Responses                                                                                                                                                                           | (%) (95% CI)                                                                                                                                                                                  | Estimate (95% CI)*                                                                                                                                                                            | p-Valueb                                                                                                                                                                                      |
| Pembrolizumab+Chemotherapy                                                                                                                                                                    | 68                                                                                                                                                                                            | 14                                                                                                                                                                                            | 20.6 (11.7,32.1)                                                                                                                                                                              | -5.7 (-21.0, 9.1)                                                                                                                                                                             | 0.7741                                                                                                                                                                                        |
| Placebo+Chemotherapy                                                                                                                                                                          | 57                                                                                                                                                                                            | 15                                                                                                                                                                                            | 26.3 (15.5, 39.7)                                                                                                                                                                             |                                                                                                                                                                                               |                                                                                                                                                                                               |
| BasedonMiettinen&Nurminen method. b One-sided p-value for testing. H0: difference in %0 versus Hl: difference in % > 0. BICR-Blindedindependent centralreview. Database CutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. b One-sided p-value for testing. H0: difference in %0 versus Hl: difference in % > 0. BICR-Blindedindependent centralreview. Database CutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. b One-sided p-value for testing. H0: difference in %0 versus Hl: difference in % > 0. BICR-Blindedindependent centralreview. Database CutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. b One-sided p-value for testing. H0: difference in %0 versus Hl: difference in % > 0. BICR-Blindedindependent centralreview. Database CutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. b One-sided p-value for testing. H0: difference in %0 versus Hl: difference in % > 0. BICR-Blindedindependent centralreview. Database CutoffDate:15DEC2022. | BasedonMiettinen&Nurminen method. b One-sided p-value for testing. H0: difference in %0 versus Hl: difference in % > 0. BICR-Blindedindependent centralreview. Database CutoffDate:15DEC2022. |

<div style=\"page-break-after: always\"></div>

## Subsequent therapies

Table 42 Summary of Subsequent Oncologic Therapies (ITT population)

|                                                                       | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   |
|-----------------------------------------------------------------------|--------------------------------|--------------------------------|------------------------|------------------------|
|                                                                       | n                              | (%)                            |                        | (%)                    |
| Participants in population                                            | 533                            |                                | 536                    |                        |
| Participants inone ormoresubsequent oncologic therapies               | 253                            | (47.5)                         | 261                    | (48.7)                 |
| Chemotherapy                                                          | 230                            | (43.2)                         | 230                    | (42.9)                 |
| CAPECITABINE                                                          | 49                             | (9.2)                          | 51                     | (9.5)                  |
| CAPECITABINE;OXALIPLATIN                                              | 2                              | (0.4)                          | 1                      | (0.2)                  |
| CARBOPLATIN                                                           | 6                              | (1.1)                          | 4                      | (0.7)                  |
| CISPLATIN                                                             | 50                             | (9.4)                          | 56                     | (10.4)                 |
| CISPLATIN;GEMCITABINE                                                 | 2                              | (0.4)                          | 0                      | (0.0)                  |
| DOCETAXEL                                                             | 0                              | (0.0)                          | 1                      | (0.2)                  |
| FLUOROURACIL                                                          | 126                            | (23.6)                         | 127                    | (23.7)                 |
| GEMCITABINE                                                           | 41                             | (7.7)                          | 42                     | (7.8)                  |
| GEMCITABINEHYDROCHLORIDE                                              | 9                              | (1.7)                          | 8                      | (1.5)                  |
| GIMERACIL:OTERACILPOTASSIUM;TEGAFUR                                   | 37                             | (6.9)                          | 33                     | (6.2)                  |
| IRINOTECAN                                                            | 45                             | (8.4)                          | 42                     | (7.8)                  |
| IRINOTECANHYDROCHLORIDE                                               | 8                              | (1.5)                          | 12                     | (2.2)                  |
| IRINOTECANHYDROCHLORIDETRIHYDRATE                                     | 5                              | (0.9)                          | 3                      | (0.6)                  |
| LIPOSOMAL MITOMYCIN                                                   | 0                              | (0.0)                          | 1                      | (0.2)                  |
| OXALIPLATIN                                                           | 109                            | (20.5)                         | 111                    | (20.7)                 |
| PACLITAXEL                                                            | 7                              | (1.3)                          | 5                      | (0.9)                  |
| PACLITAXEL NANOPARTICLE ALBUMIN-BOUND                                 | 14                             | (2.6)                          | 15                     | (2.8)                  |
| PEMETREXEDDISODIUM                                                    | 1                              | (0.2)                          | 1                      | (0.2)                  |
| RALTITREXED                                                           | 0                              | (0.0)                          | 1                      | (0.2)                  |
| TEGAFUR                                                               | 3                              | (0.6)                          | 0                      | (0.0)                  |
| ImmuneCheckpointInhibitors                                            | 26                             | (4.9)                          | 38                     | (7.1)                  |
| ATEZOLIZUMAB                                                          | 1                              | (0.2)                          | 1                      | (0.2)                  |
| CAMRELIZUMAB                                                          | 2                              | (0.4)                          | 2                      | (0.4)                  |
| DURVALUMAB                                                            | 3                              | (0.6)                          | 4                      | (0.7)                  |
| ENVAFOLIMAB                                                           | 1                              | (0.2)                          | 1                      | (0.2)                  |
| IPILIMUMAB                                                            | 0                              | (0.0)                          | 4                      | (0.7)                  |
| NIVOLUMAB                                                             | 8                              | (1.5)                          | 18                     | (3.4)                  |
| PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1)INHIBITORS | 1                              | (0.2)                          | 0                      | (0.0)                  |
| PEMBROLIZUMAB                                                         | 4                              | (0.8)                          | 5                      | (0.9)                  |
| PEMBROLIZUMAB;VIBOSTOLIMAB                                            | 0                              | (0.0)                          | 2                      | (0.4)                  |
| SINTILIMAB                                                            | 3                              | (0.6)                          | 3                      | (0.6)                  |
| SPARTALIZUMAB                                                         | 1                              | (0.2)                          | 0                      | (0.0)                  |
| TISLELIZUMAB                                                          | 2                              | (0.4)                          | 1                      | (0.2)                  |
| TORIPALIMAB                                                           | 1                              | (0.2)                          | 1                      | (0.2)                  |
| TREMELIMUMAB                                                          | 0                              | (0.0)                          | 3                      | (0.6)                  |
| TargetedTherapy                                                       | 6                              | (1.1)                          | 18                     | (3.4)                  |
| ERDAFITINIB                                                           | 0                              | (0.0)                          | 1                      | (0.2)                  |

<div style=\"page-break-after: always\"></div>

|                                                                 | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   |
|-----------------------------------------------------------------|--------------------------------|--------------------------------|------------------------|------------------------|
|                                                                 | n                              | (%)                            | n                      | (%)                    |
| TargetedTherapy                                                 | 6                              | (1.1)                          | 18                     | (3.4)                  |
| FIBROBLAST GROWTHFACTORRECEPTOR (FGFR) TYROSINEKINASEINHIBITORS | 0                              | (0.0)                          | 3                      | (0.6)                  |
| HMPL 306                                                        | 0                              | (0.0)                          | 2                      | (0.4)                  |
| INFIGRATINIB                                                    | 0                              | (0.0)                          | 1                      | (0.2)                  |
| IVOSIDENIB                                                      | 4                              | (0.8)                          | 3                      | (0.6)                  |
| PEMIGATINIB                                                     | 2                              | (0.4)                          | 8                      | (1.5)                  |
| Other                                                           | 43                             | (8.1)                          | 50                     | (9.3)                  |
| ANTINEOPLASTICAGENTS                                            | 2                              | (0.4)                          | 1                      | (0.2)                  |
| ASCIMINIB                                                       | 0                              | (0.0)                          | 1                      | (0.2)                  |
| BELZUTIFAN                                                      | 0                              | (0.0)                          | 1                      | (0.2)                  |
| BEVACIZUMAB                                                     | 1                              | (0.2)                          | 4                      | (0.7)                  |
| BEXMARILIMAB                                                    | 1                              | (0.2)                          | 0                      | (0.0)                  |
| BI905711                                                        | 0                              | (0.0)                          | 1                      | (0.2)                  |
| BINIMETINIB                                                     | 1                              | (0.2)                          | 0                      | (0.0)                  |
| CATEQUENTINIBHYDROCHLORIDE                                      | 5                              | (0.9)                          | 2                      | (0.4)                  |
| CERITINIB                                                       | 0                              | (0.0)                          | 1                      | (0.2)                  |
| CETUXIMAB                                                       | 1                              | (0.2)                          | 0                      | (0.0)                  |
| DABRAFENIB DABRAFENIBMESILATE                                   | 3 0                            | (0.6) (0.0)                    | 1 1                    | (0.2) (0.2)            |
| DASATINIB                                                       | 0                              | (0.0)                          | 1                      | (0.2)                  |
| DONAFENIB                                                       | 1                              | (0.2)                          | 1                      | (0.2)                  |
| ENCORAFENIB                                                     | 1                              | (0.2)                          | 0                      | (0.0)                  |
| ERLOTINIBHYDROCHLORIDE                                          | 2                              | (0.4)                          | 1                      | (0.2)                  |
| FRUQUINTINIB                                                    | 1                              | (0.2)                          | 0                      | (0.0)                  |
| IMATINIBMESILATE                                                | 0                              | (0.0)                          | 1                      | (0.2)                  |
| INVESTIGATIONALDRUG                                             | 3                              | (0.6)                          | 2                      | (0.4)                  |
| LENVATINIB                                                      | 5                              | (0.9)                          | 8                      | (1.5)                  |
| LENVATINIBMESILATE                                              | 7                              | (1.3)                          | 4                      | (0.7)                  |
| LY 3410738                                                      | 0                              | (0.0)                          | 1                      | (0.2)                  |
| OLAPARIB                                                        | 0                              | (0.0)                          | 1                      | (0.2)                  |
| OTHERANTINEOPLASTICAGENTS                                       | 2                              | (0.4)                          | 0                      | (0.0)                  |
| OTHERIMMUNOSTIMULANTS                                           | 0                              | (0.0)                          | 1                      | (0.2)                  |
| OTHERMONOCLONALANTIBODIESANDANTIBODY DRUGCONJUGATES             | 2                              | (0.4)                          | 2                      | (0.4)                  |
| OTHERPROTEINKINASEINHIBITORS                                    | 1                              | (0.2)                          | 1                      | (0.2)                  |
| OTHERTHERAPEUTICPRODUCTS                                        | 1                              | (0.2)                          | 1                      | (0.2)                  |
| PALBOCICLIB                                                     | 1                              | (0.2)                          | 0                      | (0.0)                  |
| PERTUZUMAB                                                      | 1                              | (0.2)                          | 3                      | (0.6)                  |
| REGORAFENIB                                                     | 1                              | (0.2)                          | 2                      | (0.4)                  |
| RIVOCERANIB                                                     | 0                              | (0.0)                          | 2                      | (0.4)                  |
| RIVOCERANIBMESYLATE                                             | 1                              | (0.2)                          | 1                      | (0.2)                  |
| RXC 004                                                         | 1                              | (0.2)                          | 0 0                    | (0.0)                  |
| SURUFATINIB                                                     | 1                              | (0.2)                          |                        | (0.0)                  |
| TRAMETINIB                                                      | 3                              | (0.6)                          | 4                      | (0.7)                  |
| TNO 155                                                         | 1                              | (0.2)                          | 0                      | (0.0)                  |
| TRASTUZUMAB TRASTUZUMABANNS                                     | 3 0                            | (0.6) (0.0)                    | 7 1                    | (1.3) (0.2)            |
| TRASTUZUMAB DERUXTECAN NXKI                                     | 0                              | (0.0)                          | 1                      | (0.2)                  |
| TUCATINIB                                                       | 0                              | (0.0)                          | 1                      | (0.2)                  |

Every participantis counted a single time for each applicable specific oncologic treatment.A participant with multiple oncologic

WHO-DDGLOBALB3Sep22wasusedinthereportingof this study.

DatabaseCutoffDate:15DEC2022.

<div style=\"page-break-after: always\"></div>

Table 43 Subsequent local therapies for liver disease after PD (ITT Population)

|                                  | Pembrolizumab + Chemotherapy     | Pembrolizumab + Chemotherapy     | Placebo + Chemotherapy           | Placebo + Chemotherapy           |
|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                  | n                                | (%)                              | n                                | (%)                              |
| Participants in population       | 533                              |                                  | 536                              |                                  |
| Surgery                          | 1                                | (0.2)                            | 0                                | (0.0)                            |
| Radiotherapy                     | 2                                | (0.4)                            | 6                                | (1.1)                            |
| Locoregional therapy             | 3                                | (0.6)                            | 6                                | (1.1)                            |
| Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. | Database Cutoff Date: 15DEC2022. |

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 44 Summary of Efficacy for trial KEYNOTE-966

| Title: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma   | Title: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma   | Title: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma   | Title: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                        | IND: 123482; EudraCT: 2019-000944-82                                                                                                                                                                                                    | IND: 123482; EudraCT: 2019-000944-82                                                                                                                                                                                                    | IND: 123482; EudraCT: 2019-000944-82                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                  | Phase 3, randomized, double-blind, placebo-controlled                                                                                                                                                                                   | Phase 3, randomized, double-blind, placebo-controlled                                                                                                                                                                                   | Phase 3, randomized, double-blind, placebo-controlled                                                                                                                                                                                                   |
| Hypothesis                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                             | Superiority                                                                                                                                                                                                                             | Superiority                                                                                                                                                                                                                                             |
| Treatments groups                                                                                                                                                                                                                       | Pembrolizumab + Chemotherapy                                                                                                                                                                                                            | Pembrolizumab + Chemotherapy                                                                                                                                                                                                            | Pembrolizumab 200 mg Day 1 of each cycle, up to 35 administrations + gemcitabine 1000 mg/m2, Day 1 and Day 8 of each cycle, until PD or unacceptable toxicity + cisplatin 25 mg/m2 Day 1 and Day 8 of each cycle, up to 8 cycles number randomized: 533 |
| Treatments groups                                                                                                                                                                                                                       | Placebo + Chemotherapy                                                                                                                                                                                                                  | Placebo + Chemotherapy                                                                                                                                                                                                                  | Placebo Day 1 of each cycle, up to 35 administrations + gemcitabine 1000 mg/m2, Day 1 and Day 8 of each cycle, until PD or unacceptable toxicity + cisplatin 25 mg/m2 Day 1 and Day 8 of each cycle, up to 8 cycles number randomized: 536              |
| Endpoints and definitions                                                                                                                                                                                                               | Primary endpoint                                                                                                                                                                                                                        | OS                                                                                                                                                                                                                                      | Time from randomization to death due to any cause                                                                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                                      | PFS                                                                                                                                                                                                                                     | Time from randomization to PD, based upon RECIST 1.1 by BICR or death, whichever occurred earlier                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                                      | ORR DoR                                                                                                                                                                                                                                 | proportion of subjects who have a confirmed CR or PR by BICR time from first documented evidence of CR or PR until disease progression or death                                                                                                         |
| Database cut off                                                                                                                                                                                                                        | 15-DEC-2022 (FA)                                                                                                                                                                                                                        | 15-DEC-2022 (FA)                                                                                                                                                                                                                        | 15-DEC-2022 (FA)                                                                                                                                                                                                                                        |
| Database lock                                                                                                                                                                                                                           | 19-JAN-2023 (FA)                                                                                                                                                                                                                        | 19-JAN-2023 (FA)                                                                                                                                                                                                                        | 19-JAN-2023 (FA)                                                                                                                                                                                                                                        |
| Results and Analysis                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                    |
| Analysis description                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                        |
| Analysis population and time point description                                                                                                                                                                                          | Intent to treat                                                                                                                                                                                                                         | Intent to treat                                                                                                                                                                                                                         | Intent to treat                                                                                                                                                                                                                                         |

536

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                                                                     | Pembrolizumab + Chemotherapy                                                                                                                                                                                        | Placebo + Chemotherapy                                                                                                                                                                                              |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                   | Number of subject                                                                                                                                                                                                   | 533                                                                                                                                                                                                                 | 536                                                                                                                                                                                                                 |
|                                                   | OS (median months)                                                                                                                                                                                                  | 12.7                                                                                                                                                                                                                | 10.9                                                                                                                                                                                                                |
|                                                   | 95% CI                                                                                                                                                                                                              | 11.5, 13.6                                                                                                                                                                                                          | 9.9, 11.6                                                                                                                                                                                                           |
|                                                   | PFS (median months)                                                                                                                                                                                                 | 6.5                                                                                                                                                                                                                 | 5.6                                                                                                                                                                                                                 |
|                                                   | 95% CI                                                                                                                                                                                                              | 5.7, 6.9                                                                                                                                                                                                            | 5.1, 6.6                                                                                                                                                                                                            |
|                                                   | ORR (CR+PR) (%)                                                                                                                                                                                                     | 28.7                                                                                                                                                                                                                | 28.5                                                                                                                                                                                                                |
|                                                   | DOR (median months)                                                                                                                                                                                                 | 9.7 (1.2+ - 22.7+)                                                                                                                                                                                                  | 6.9 (0.0+ - 19.2+)                                                                                                                                                                                                  |
| Effect estimate per comparison                    | Primary endpoint                                                                                                                                                                                                    | Pembrolizumab+chemotherapy vs placebo+chemotherapy                                                                                                                                                                  | OS                                                                                                                                                                                                                  |
|                                                   |                                                                                                                                                                                                                     | HR                                                                                                                                                                                                                  | 0.83                                                                                                                                                                                                                |
|                                                   |                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                              | (0.72, 0.95)                                                                                                                                                                                                        |
|                                                   |                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                             | 0.0034                                                                                                                                                                                                              |
|                                                   | Secondary endpoint                                                                                                                                                                                                  | Pembrolizumab+chemotherapy vs placebo+chemotherapy                                                                                                                                                                  | PFS                                                                                                                                                                                                                 |
|                                                   |                                                                                                                                                                                                                     | HR                                                                                                                                                                                                                  | 0.86                                                                                                                                                                                                                |
|                                                   |                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                              | 0.75, 1.00                                                                                                                                                                                                          |
|                                                   |                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                             | 0.0225                                                                                                                                                                                                              |
| Notes                                             | Primary efficacy endpoint of OS was analysed at FA (DCO for FA is 15-DEC-2022). The analyses of PFS, ORR, and DOR (secondary endpoints) were prespecified in the protocol to be based on IA1 data (15-DEC-2021 DCO) | Primary efficacy endpoint of OS was analysed at FA (DCO for FA is 15-DEC-2022). The analyses of PFS, ORR, and DOR (secondary endpoints) were prespecified in the protocol to be based on IA1 data (15-DEC-2021 DCO) | Primary efficacy endpoint of OS was analysed at FA (DCO for FA is 15-DEC-2022). The analyses of PFS, ORR, and DOR (secondary endpoints) were prespecified in the protocol to be based on IA1 data (15-DEC-2021 DCO) |

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

KEYNOTE-966 was a superiority trial designed to demonstrate advantage of pembrolizumab in association with gemcitabine plus cisplatin over duplex chemotherapy alone as first-line therapy in patients with locally advanced (unresectable) or metastatic BTC (intra- or extrahepatic cholangiocarcinoma or gallbladder).

Based on the inclusion/exclusion criteria, a broad population in terms of cancer site and hepatitis status was eligible for recruitment, although limited to relatively fit patients (PS 0-1). Histologically confirmed diagnosis of BTC was requested. Exposure to prior systemic therapies was an exclusion criterion, with the exception of neo-adjuvant/adjuvant treatments not containing gemcitabine and/or cisplatin. Participants who received prior neoadjuvant/adjuvant therapy with R2 resection were excluded. Overall, the study population can be considered representative of the advanced/metastatic BTC setting.

Pembrolizumab was tested at a dose of 200 mg IV Q3W, in line with the licensed posology for KEYTRUDA as monotherapy and combination with chemotherapy. Pembrolizumab was administrated on top of a backbone therapy with gemcitabine plus cisplatin. The chemotherapeutic scheme adopted in KEYNOTE966 can be considered standard and in line with current clinical recommendations. The association of gemcitabine and cisplatin represents the most common front-line approach in BTC patients, although other gemcitabine-based regimens are available. However, the study population recruited in KEYNOTE966 does not provide representativeness of alternative chemotherapeutic schemes generally used in cisplatin-unfit patients carrying a worse prognosis and reduced effect of therapies; moreover, the tolerability in association with pembrolizumab cannot be predicted in this more frail subgroup that have

<div style=\"page-break-after: always\"></div>

not been included in the pivotal trial. The wording in section 4.1 of the SmPC was revised  to clearly reflect the tested chemotherapeutic agents adopted in the pivotal trial: KEYTRUDA, in combination with gemcitabine-based chemotherapy gemcitabine and cisplatin , is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults .

The primary endpoint was OS, which is endorsed in an aggressive disease setting such as BTC. Secondary endpoints include PFS per RECIST 1.1, ORR (CR or PR) and DoR as assessed by BICR, which are also supported for the efficacy evaluation. Among tertiary endpoints , PFS, ORR and DoR as evaluated by Investigators, disease control (DC) rate, time-to-deterioration (TTT) and Quality of Life (QOL) questionnaires, are considered adequate. Efficacy by PD-L1 status (CPS ≥ 1 versus &lt;1, and additional cutoff ≥ 10) was not pre-specified but rather included in the exploratory outcomes. The primary efficacy endpoint of OS was analysed at FA. The PFS, ORR, and DOR (secondary endpoints) were prespecified in the protocol to be evaluated on the basis of IA1 data (15 DEC-2021 data cutoff). The median time from randomization to DCO in the ITT population was 25.6 months (range 18.3 to 38.4 months) for the FA and 13.6 months (range 6.3 to 26.4 months) for the IA1.

Approximately 1048 participants were expected to be randomized 1:1 into pembrolizumab plus gemcitabine plus cisplatin or placebo plus gemcitabine plus cisplatin. After the enrollment of the global portion was complete, the study remained open to enrolment in China alone for the China extension cohort of 46 participants until a total of 158 participants had been enrolled across the global and extension parts to meet local regulatory requirements in China. This report describes the global portion of the study. The sample size calculation is comprehensible and reproducible. Of the six amendments to the protocol, only amendment 2 (08-DEC-2020) affected the sample size and power calculation; the sample size was increased from the initial 788 to 1048 participants to maintain study timelines and statistical power. The final number of randomized participants was 1069.

The ITT population served as the population for the primary efficacy analyses of OS. All randomly assigned participants were included in this population. The efficacy analyses of OS in this submission were based on FA (DCO 15-DEC-2022), which was the third analysis of OS. At the FA data cut-off, descriptive analyses for key secondary endpoints of PFS and ORR were provided since the final analyses for these endpoints were performed at IA1 (DCO 15-DEC-2021).

Statistical methods were well reported in the protocol section and in the Amendment 04 of supplemental SAP (sSAP) dated 13-JUN-2022, which represents its latest version. Overall, statistical methods are considered appropriate: the overall type I error over the primary endpoints (OS) and the key secondary endpoint (PFS and ORR) is strongly controlled at 2.5% (one-sided), with initially 2.5% allocated to OS (H1); by using the graphical approach of Mauer and Bretz if OS hypothesis was rejected, the corresponding alpha was reallocated equally to PFS and ORR; if the PFS hypothesis was rejected, the corresponding alpha was reallocated to ORR; if the ORR hypothesis was rejected, the corresponding alpha was reallocated to PFS.

There were six protocol amendments over the study course, among these only amendments 2, 4 and 5 affected the SAP language. Amendment 2 (08-DEC-2020) brought the most significant changes, since the primary endpoints of the study were modified, a more conservative hazard ratio assumption for OS was made accounting for possible delayed treatment effect and, consequently, the sample size was increased from the initial 788 to 1048 participants, in order to maintain study timelines and statistical power. The rationale for these amendments was exhaustively explained.

Important protocol deviations were within acceptable limits (8.9%); the most frequently reported reason among those considered of clinical relevance (2.8%), was the improper storage of study drug (1.4%). One case of serious GCP breach without safety impact was reported, due to the use of incorrect ALT reference ranges that caused the erroneous recruitment of a patient not meeting the eligibility criteria. Overall, no concerns arise as regards the conduct of the study.

<div style=\"page-break-after: always\"></div>

Sensitivity analyses were adequate.

## Efficacy data and additional analyses

The current application is based on the FA (DCO: 15-DEC-2022) of study KEYNOTE-966 for the primary endpoint OS, while secondary endpoints were formally tested at IA1 (DCO: 15-DEC-2021) although descriptive statistics were provided at the final analysis.

As of the data cutoff for FA (15-DEC-2022), 1564 subjects were screened with 1069 being randomized (533 to pembrolizumab plus gemcitabine/cisplatin and 536 to placebo plus gemcitabine plus cisplatin), while 495 (31.6%) non-randomized participants were screen failures since they did not meet all inclusion/exclusion criteria. A total of 6 participants (pembrolizumab arm: 4; placebo arm: 2) were randomized but did not receive the study treatment. The screen failure rate was higher than expected, mostly associated with inappropriate organ function (haematological, renal and liver) as defined by the inclusion criteria. Concomitant disease-associated liver dysfunction at baseline was the main reason for screen failure in KEYNOTE-966, as it was for the TOPAZ-1 trial testing durvalumab combination in the same indication. It is common practice that gemcitabine administration in patients with liver dysfunction needs to be carefully monitored due to the anticipated liver toxicity that in a combination therapy is expected to increase. Yet, treatment with gemcitabine-based chemotherapy is not contraindicated in the presence of liver dysfunction and there is a wide experience with the use of chemotherapy in this clinical setting. A specification of liver function of patients enrolled in KEYNOTE-966 (serum bilirubin levels ( ≤ 1.5 x ULN or direct bilirubin ≤ ULN for participants with total bilirubin levels &gt; 1.5 × ULN) and resolved clinically significant biliary obstruction) as defined in the protocol has been reported in section 5.1 of the SmPC for an appropriate information to treating physicians.

At the time of FA (15-DEC-2022) median time to data cut-off was of 25.6 months (range: 18.3; 38.4), with a median follow-up of 12.7 (range: 0.2; 37.5) and 10.9 (range: 0.2; 36.2) months in the experimental and control arm, respectively. In total, 857 OS events over 818 required were observed (414 in pembrolizumab + chemotherapy arm and 443 in placebo + chemotherapy arm), based on which the study can be considered mature.

The 80.4% of the population underwent discontinuation from the trial, (77.7% vs 83.2% in the pembrolizumab and placebo group, respectively), the main reason being death in both treatment groups (76.7% vs 82.6%).  Discontinuation from study medication was registered in 93.4% of participants, occurring at an almost equal rate in both arms (92.4% vs 94.4 in the pembrolizumab and placebo group, respectively). Progressive disease was the most common reason (61.2% and 66.3% in the pembrolizumab and placebo group, respectively) while adverse events contributed to only a minority of cases (12.7% vs 11.4% in the pembrolizumab and placebo group, respectively). At the time of FA, treatment was ongoing in 4.7% of the ITT (5.1% vs 4.3% in the pembrolizumab and placebo, respectively).

Baseline and disease characteristics were well balanced between groups. In the recruited population, there was a slight predominance of male patients (51.6% vs 48.4% for female sex), age was 64.0 years in median. Asians and non-Asians were almost equally represented, but Western Europe was a minority (28.3%) among regions, with a dominance of Rest of the World (63.8%). The prevailing tumour site was intrahepatic (59.2%) compared to the gallbladder (21.8%) and extrahepatic location (19%). Metastatic was more frequent than advanced disease (88.2% vs 11.8%, respectively). No major differences could be observed between treatment arms in the anatomical distribution of metastases. Liver (58.9% and 56%) and lymph nodes (58.2% and 54.7%) were the prevailing sites in both groups, followed by respiratory (29.8% and 27.2%) and peritoneum (24.4% and 24.3%). Other locations were also similarly affected, with the exception of a slightly higher prevalence of metastases in the abdomen cavity wall and organs

<div style=\"page-break-after: always\"></div>

(other than liver) in the placebo group (7.9% and 10.6%).All these baseline characteristics are expected according with the disease epidemiology. Patients were almost all HCV negative (96.7%) with only a minority having a prior HCV infection (2.9%); the majority of the population was HBV negative (68.5%), 28% had a clinically resolved prior infection and 2.8% a chronic HBV infection. In terms of tumour hallmarks, the PDL-1 status was similar between groups, with a higher frequency of CPS≥1 (68.1%) than CPS&lt;1 (20.9%); in a not negligible portion of tumours, CPS remained indeterminate (11%). At the MSI characterisation, the majority of the population was MSS (80%; it was indeterminate in 19.1%). Overall, the study population can be considered representative of the whole target population.

Pembrolizumab, in addition to gemcitabine+cisplatin, provided advantage compared to gemcitabine+cisplatin alone on the primary endpoint OS (HR=0.83; 95% CI: 0.72; 0.95; p=0.0034), with a gain in median survival of 1.8 months (12.7 vs 10.9). These results are similar to the magnitude of effect that was reported for durvalumab on top of gemcitabine+cisplatin in the TOPAZ-1 trial (HR= 0.80; 95% CI: 0.66, 0.97; p-value 0.021; median OS gain ~1.5 months) (see Imfinzi SmPC).

The secondary endpoint PFS did not meet statistically significance. It showed a trend towards improvement in the experimental vs the control arm (HR=0.86; 95% CI: 0.75,1; p=0.0225) at IA1, that was confirmed at the FA (HR=0.87; 95% CI: 0.76, 0.99; p=0.0171). The ORR was unchanged by pembrolizumab treatment (28.7% vs 28.5% in the pembrolizumab and placebo arm, respectively at IA1; 29.3% vs 28.4% in the pembrolizumab and placebo arm, respectively at FA), although a slightly longer duration of response was registered in the experimental arm compared to control (9.7 vs 6.9 months at IA1; 8.3 vs 6.8 months at FA).

Among exploratory endpoints , PROs were comparable between arms.

Subgroup analysis demonstrated consistency across the main prespecified subgroups, with the exception of a lower performance of pembrolizumab in OS for the gallbladder (HR=0.96; 95% CI:0.73, 1.26) and extrahepatic (HR=0.99; 95% CI:0.73,1.35) tumour, compared to the intrahepatic cancer (HR=0.76; 95% CI:0.64,0.91). A similar behaviour was reported for durvalumab in the TOPAZ-1 trial. The PFS and ORR followed the same trend, with the PFS reaching a HR&gt;1 in the extrahepatic localisation, and ORR showing even disadvantage of pembrolizumab vs placebo in the extrahepatic and gallbladder cancer sites. Due to the availability of limited clinical data and poor knowledge around peculiarities in biological/clinical features that might impact response to immunomodulators, no firm conclusions can be derived on the reasons and biological plausibility underlying inconsistency in treatment effect across tumour locations. Considering the absence of a detrimental effect in these subgroups on the basis of the survival primary endpoint, it can be concluded that a positive B/R of pembrolizumab in association to chemotherapy applies regardless of anatomical classification.

The efficacy evaluation by CPS score, either by using 1 or 10 as cut-off point, demonstrated similar results in the different subgroups regardless of the PD-L1 status.

OS and PFS were consistent in Asians and non-Asians , although ORR was enhanced by pembrolizumab in Asians (difference between pembrolizumab and placebo of 4) but reduced by treatment in non-Asians (difference between pembrolizumab and placebo of -3). The TOPAZ-1 trial reported increased efficacy of durvalumab in countries known to be fluke-endemic compared to the ITT population. This pattern was not replicated in KEYNOTE-966, where response to treatment was even more attenuated in this geographically determined subgroup (HR=0.92; 95% CI: 0.72;1.17) compared to the overall population, though not indicative of a clear detrimental effect. The OS by hepatitis status was generally consistent with the treatment performance registered in the overall population.

Efficacy by age was generally comparable in the different patient categories, in terms of OS and PFS. However, the ORR was reduced by pembrolizumab relative to placebo in patients aged ≥75 years compared to the youngest population (9.0 vs 9.4 for pembrolizumab plus chemotherapy and placebo plus

<div style=\"page-break-after: always\"></div>

chemotherapy, respectively). No clear signs of detrimental effect emerged in the oldest. In any case, a warning for the use of pembrolizumab in the elderly population, particularly in combination with chemotherapy, is already included in the SmPC as a general consideration, which also applies to the current clinical setting (see SmPC section 4.4).

There were no substantial differences in the list of subsequent therapies between groups, since cytotoxic agents were equally received by patients (43.2% vs 42.9% in the pembrolizumab vs placebo arm) with a prevailing use of the FOLFOX regimen (&gt;20% in both arms); as expected, a slightly more frequent administration of checkpoint inhibitors was reported in the placebo arm (7.1% vs 4.9% in the pembrolizumab arm). The use of localised therapy after disease progression was very limited in the study population (0.2-1.1%), overall balanced between treatment arms.

## 2.4.4. Conclusions on the clinical efficacy

Overall, the efficacy evaluation supported a modest survival advantage of pembrolizumab versus placebo on top of gemcitabicine plus cisplatin in the first-line treatment of the advanced BTC disease setting. The final indication wording was updated to clearly reflect that the backbone therapy used was gemcitabine plus cisplatin.

## 2.5. Clinical safety

## Introduction

KEYNOTE-966 is an ongoing Phase 3, randomized, double-blind study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy in participants with locally advanced unresectable or metastatic biliary tract carcinoma. Safety analyses used the All Participants as Treated (APaT) population of all participants who received at least 1 dose of study intervention, as of the FA DCO date of 15-DEC2022. Pooled safety data from studies of pembrolizumab in combination with chemotherapy in NSCLC (KEYNOTE-021 Cohorts A, C, and G, KEYNOTE-189, and KEYNOTE-407), HNSCC (KEYNOTE-048), TNBC (KEYNOTE-355), and esophageal carcinoma (KEYNOTE-590) are included to provide a point of reference on the safety profile of pembrolizumab in combination with chemotherapy. Participants in the Pooled Combination Dataset received pembrolizumab along with one or more chemotherapeutic agents. These chemotherapies included platinum-based chemotherapy, 5-fluorouracil, paclitaxel/nab-paclitaxel, gemcitabine, and pemetrexed. The safety results are presented for the following 4 datasets (see table below):

Table 45 Safety Datasets and Treatment Group Nomenclature

| Dataset                                                                  | Population                                                                                                                           | Nomenclature in Tables             | Nomenclature in Text                  |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|---------------------------------------|
| KEYNOTE-966 pembrolizumab plus chemotherapy (gemcitabine plus cisplatin) | (N=529): Participants from KEYNOTE-966 who received at least 1 dose of pembrolizumab in combination with chemotherapy in KEYNOTE-966 | KN966 Pembrolizumab + Chemotherapy | pembrolizumab plus chemotherapy group |
| KEYNOTE-966 placebo plus chemotherapy                                    | (N=534): Participants from KEYNOTE-966 who received at least 1 dose of placebo in combination with chemotherapy in KEYNOTE-966       | KN966 Placebo + Chemotherapy       | placebo plus chemotherapy group       |

<div style=\"page-break-after: always\"></div>

| (gemcitabine plus cisplatin)                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab plus chemotherapy                                                                                                                                                                                                                                                         | (N=2,033): Pooled safety data from participants treated with pembrolizumab plus platinum-based chemotherapy, including 791 participants with NSCLC from KEYNOTE-021, KEYNOTE-189, KEYNOTE-407, 276 participants with HNSCC from KEYNOTE-048, 370 participants with esophageal cancer from KEYNOTE- 590, and 596 participants with TNBC from KEYNOTE- 355                                                                                                                                                                                                                                                                                                                                                                     | Pooled Safety Dataset for Pembrolizumab + Chemotherapy                                                                                                                                                                                                                                  | Pooled Combination Dataset                                                                                                                                                                                                                                                              |
| Pembrolizumab monotherapy reference safety                                                                                                                                                                                                                                              | (N=7,631): Pooled safety data from participants treated with pembrolizumab monotherapy, including 2559 participants with advanced melanoma from KEYNOTE-001, KEYNOTE-002, KEYNOTE-006, KEYNOTE-054, and KEYNOTE-716; 2022 participants with NSCLC from KEYNOTE-001, KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042; 909 participants with HNSCC from KEYNOTE-012, KEYNOTE-040, KEYNOTE-048, and KEYNOTE-055; 636 participants with bladder cancer from KEYNOTE-045, and KEYNOTE-052; 488 participants with RCC from KEYNOTE-564; 475 participants with MSI-H tumors from KEYNOTE-158 and KEYNOTE-164; 389 participants with HL from KEYNOTE-013, KEYNOTE- 087, and KEYNOTE-204; 153 participants with MSI-H CRC from KEYNOTE-177. | RSD for Pembrolizumab                                                                                                                                                                                                                                                                   | RSD                                                                                                                                                                                                                                                                                     |
| Abbreviations: CRC=colorectal cancer; HL= Hodgkin lymphoma; HNSCC=head and neck squamous cell carcinoma; MSI-H=microsatellite instability-high; N=number; NSCLC=non-small cell lung cancer; RCC=renal cell carcinoma; RSD=reference safety dataset; TNBC=triple-negative breast cancer. | Abbreviations: CRC=colorectal cancer; HL= Hodgkin lymphoma; HNSCC=head and neck squamous cell carcinoma; MSI-H=microsatellite instability-high; N=number; NSCLC=non-small cell lung cancer; RCC=renal cell carcinoma; RSD=reference safety dataset; TNBC=triple-negative breast cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                      | Abbreviations: CRC=colorectal cancer; HL= Hodgkin lymphoma; HNSCC=head and neck squamous cell carcinoma; MSI-H=microsatellite instability-high; N=number; NSCLC=non-small cell lung cancer; RCC=renal cell carcinoma; RSD=reference safety dataset; TNBC=triple-negative breast cancer. | Abbreviations: CRC=colorectal cancer; HL= Hodgkin lymphoma; HNSCC=head and neck squamous cell carcinoma; MSI-H=microsatellite instability-high; N=number; NSCLC=non-small cell lung cancer; RCC=renal cell carcinoma; RSD=reference safety dataset; TNBC=triple-negative breast cancer. |

Table 46 Participant characteristics (APaT Population)

|                            | KN966 Pembrolizumab + Chemotherapy d   | KN966 Pembrolizumab + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|----------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                            | n                                      | (%)                                    | n                                | (%)                              | n                                                          | (%)                                                        | n                                                      | (%)                                                    |
| Participants in population | 529                                    |                                        | 534                              |                                  | 2,033                                                      |                                                            | 7,631                                                  |                                                        |
| Sex                        |                                        |                                        |                                  |                                  |                                                            |                                                            |                                                        |                                                        |
| Male                       | 279                                    | (52.7)                                 | 270                              | (50.6)                           | 1,041                                                      | (51.2)                                                     | 4,889                                                  | (64.1)                                                 |
| Female                     | 250                                    | (47.3)                                 | 264                              | (49.4)                           | 992                                                        | (48.8)                                                     | 2,742                                                  | (35.9)                                                 |
| Age (Years)                |                                        |                                        |                                  |                                  |                                                            |                                                            |                                                        |                                                        |
| <65                        | 266                                    | (50.3)                                 | 296                              | (55.4)                           | 1,218                                                      | (59.9)                                                     | 4,524                                                  | (59.3)                                                 |
| >=65                       | 263                                    | (49.7)                                 | 238                              | (44.6)                           | 815                                                        | (40.1)                                                     | 3,107                                                  | (40.7)                                                 |
| Mean                       | 63.3                                   |                                        | 61.9                             |                                  | 60.2                                                       |                                                            | 59.9                                                   |                                                        |
| SD                         | 10.3                                   |                                        | 11.0                             |                                  | 11.4                                                       |                                                            | 13.4                                                   |                                                        |

(64.1)

(35.9)

(59.3)

(40.7)

59.9

13.4

<div style=\"page-break-after: always\"></div>

62.0

94

59

(0.8)

826

(10.8)

146

(1.9)

86

(1.1)

5

(76.5)

671

(8.8)

604

(79.5)

808

(10.6)

145

(1.9)

10

(59.3)

(28.5)

824

(10.8)

110

(52.6)

(45.1)

175

(35.0)

(37.4)

(27.6)

| Median Range                              | 64.0 23 to   |        | 63.0 28 to   |        | 62.0 20 to   |        | 62.0     |        |
|-------------------------------------------|--------------|--------|--------------|--------|--------------|--------|----------|--------|
|                                           | 85           |        | 84           |        | 94           |        | 15 to 94 |        |
| Race                                      |              |        |              |        |              |        |          |        |
| American Indian Or Alaska Native          | 2            | (0.4)  | 1            | (0.2)  | 23           | (1.1)  | 59       | (0.8)  |
| Asian                                     | 243          | (45.9) | 249          | (46.6) | 472          | (23.2) | 826      | (10.8) |
| Black Or African American                 | 11           | (2.1)  | 3            | (0.6)  | 66           | (3.2)  | 146      | (1.9)  |
| Multiracial                               | 5            | (0.9)  | 2            | (0.4)  | 19           | (0.9)  | 86       | (1.1)  |
| Native Hawaiian Or Other Pacific Islander | 1            | (0.2)  | 0            | (0.0)  | 1            | (0.0)  | 5        | (0.1)  |
| White                                     | 254          | (48.0) | 267          | (50.0) | 1,416        | (69.7) | 5,838    | (76.5) |
| Missing                                   | 13           | (2.5)  | 12           | (2.2)  | 36           | (1.8)  | 671      | (8.8)  |
| Ethnicity                                 |              |        |              |        |              |        |          |        |
| Hispanic Or Latino                        | 58           | (11.0) | 52           | (9.7)  | 235          | (11.6) | 604      | (7.9)  |
| Not Hispanic Or Latino                    | 431          | (81.5) | 447          | (83.7) | 1,695        | (83.4) | 6,064    | (79.5) |
| Not Reported                              | 31           | (5.9)  | 31           | (5.8)  | 54           | (2.7)  | 808      | (10.6) |
| Unknown                                   | 5            | (0.9)  | 3            | (0.6)  | 46           | (2.3)  | 145      | (1.9)  |
| Missing                                   | 4            | (0.8)  | 1            | (0.2)  | 3            | (0.1)  | 10       | (0.1)  |
| Age Category (year)                       |              |        |              |        |              |        |          |        |
| <65                                       | 266          | (50.3) | 296          | (55.4) | 1,218        | (59.9) | 4,524    | (59.3) |
| 65-74                                     | 195          | (36.9) | 181          | (33.9) | 653          | (32.1) | 2,173    | (28.5) |
| 75-84                                     | 67           | (12.7) | 57           | (10.7) | 157          | (7.7)  | 824      | (10.8) |
| >=85                                      | 1            | (0.2)  | 0            | (0.0)  | 5            | (0.2)  | 110      | (1.4)  |
| ECOG Performance Status                   |              |        |              |        |              |        |          |        |
| [0] Normal Activity                       | 257          | (48.6) | 226          | (42.3) | 913          | (44.9) | 4,016    | (52.6) |
| [1] Symptoms, but ambulatory              | 271          | (51.2) | 308          | (57.7) | 1,116        | (54.9) | 3,440    | (45.1) |
| Other/Missing                             | 1            | (0.2)  | 0            | (0.0)  | 4            | (0.2)  | 175      | (2.3)  |
| Geographic Region                         |              |        |              |        |              |        |          |        |
| North America                             | 45           | (8.5)  | 40           | (7.5)  | 431          | (21.2) | 2,669    | (35.0) |
| Western Europe                            | 150          | (28.4) | 150          | (28.1) | 690          | (33.9) | 2,856    | (37.4) |
| Rest of the World                         | 334          | (63.1) | 344          | (64.4) | 912          | (44.9) | 2,106    | (27.6) |

d  Includes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.

e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.

f  Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407 and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN021 cohort A/C/GNSCLC: 19AUG2019, KN024: 10JUL2017, KN042: 04SEP2018, KN189-NSCLC: 20MAY2019, KN407NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B:  9SEP2019, KN177: 19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC: 14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

<div style=\"page-break-after: always\"></div>

## Patient exposure

Table 47 Drug Exposure Summary (APaT Population)

|                              | KN966 Pembrolizumab + Chemotherapy d (N=529)   | KN966 Placebo + Chemotherapy d (N=534)   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f (N=2033)   | Pembrolizumab Monotherapy Reference Safety Dataset e (N=7631)   |
|------------------------------|------------------------------------------------|------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|
| Duration of Exposure (month) |                                                |                                          |                                                                     |                                                                 |
| Mean Median SD Range         | 8.04 6.37 6.868 0.03 to 36.40                  | 7.29 5.54 6.319 0.03 to 30.62            | 9.02 6.28 7.802 0.03 to 48.00                                       | 7.85 5.78 6.907 0.03 to 38.01                                   |
| Number of Administrations    |                                                |                                          |                                                                     |                                                                 |
| Mean Median SD               | 20.35 16.00                                    | 18.89 16.00 15.474                       | NA NA NA                                                            | 12.33 9.00 10.116                                               |
|                              | 16.276                                         |                                          |                                                                     |                                                                 |
| Range                        | 1.00 to 102.00                                 | 1.00 to 80.00                            | NA                                                                  | 1.00 to 59.00                                                   |

Duration of exposure is the time from the first dose date to the last dose date.

d  Includes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.

- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.
- f  Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407 and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN021 cohort A/C/GNSCLC: 19AUG2019, KN024: 10JUL2017, KN042: 04SEP2018, KN189-NSCLC: 20MAY2019, KN407NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B:  9SEP2019, KN177: 19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC: 14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

7.85

5.78

6.907

0.03 to 38.01

12.33

10.116

1.00 to 59.00

<div style=\"page-break-after: always\"></div>

Table 48 Exposure by duration (APaT population)

|                            | KN966 Pembrolizumab + Chemotherapyd (N=529)   | KN966 Pembrolizumab + Chemotherapyd (N=529)   | KN966 Pembrolizumab + Chemotherapyd (N=529)   | KN966 Placebo + Chemotherapyd (N=534)   | KN966 Placebo + Chemotherapyd (N=534)   | KN966 Placebo + Chemotherapyd (N=534)   | PooledSafetyDatasetfor Pembrolizumab+Chemotherapyf (N=2033)   | PooledSafetyDatasetfor Pembrolizumab+Chemotherapyf (N=2033)   | PooledSafetyDatasetfor Pembrolizumab+Chemotherapyf (N=2033)   | PembrolizumabMonotherapy Reference Safety Dataset (N=7631)   | PembrolizumabMonotherapy Reference Safety Dataset (N=7631)   | PembrolizumabMonotherapy Reference Safety Dataset (N=7631)   |
|----------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
|                            | n                                             | (%)                                           | Person-months                                 | n                                       | (%)                                     | Person-months                           | n                                                             | (%)                                                           | Person-months                                                 | n                                                            | (%)                                                          | Person-months                                                |
| DurationofExposure (month) |                                               |                                               |                                               |                                         |                                         |                                         |                                                               |                                                               |                                                               |                                                              |                                                              |                                                              |
| >0                         | 529                                           | (100.0)                                       | 4,252.6                                       | 534                                     | (100.0)                                 | 3,895.0                                 | 2,033                                                         | (100.0)                                                       | 18,344.0                                                      | 7,631                                                        | (100.0)                                                      | 59,940.3                                                     |
| ≥1                         | 471                                           | (89.0)                                        | 4,226.9                                       | 480                                     | (89.9)                                  | 3,871.9                                 | 1,846                                                         | (90.8)                                                        | 18,268.7                                                      | 6,637                                                        | (87.0)                                                       | 59,548.3                                                     |
| ≥3                         | 388                                           | (73.3)                                        | 4,056.6                                       | 374                                     | (70.0)                                  | 3,659.9                                 | 1,562                                                         | (76.8)                                                        | 17,678.4                                                      | 5,023                                                        | (65.8)                                                       | 56,316.8                                                     |
| ≥6                         | 274                                           | (51.8)                                        | 3,549.7                                       | 249                                     | (46.6)                                  | 3,089.3                                 | 1,068                                                         | (52.5)                                                        | 15,460.9                                                      | 3,781                                                        | (49.5)                                                       | 50,879.4                                                     |
| ≥12                        | 117                                           | (22.1)                                        | 2,193.4                                       | 105                                     | (19.7)                                  | 1,896.9                                 | 550                                                           | (27.1)                                                        | 11,085.6                                                      | 1,673                                                        | (21.9)                                                       | 30,706.1                                                     |

Each participant is counted once on each applicable duration category row.

Duration of exposure is the time from the first dose date to the last dose date.

dIncludes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2,F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.

f Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048,KN189,KN355,KN407and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014,KN002: 28FEB2015,KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN021 cohort A/C/G-NSCLC: 19AUG2019, KN024: 10JUL2017,KN042:04SEP2018, KN189-NSCLC: 20MAY2019,KN407-NSCLC:09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoff datefor cHL(KN013cohort3:28SEP2018,KN087:15MAR2021,KN204:16JAN2020)

Database cutoff date for Bladder (KN045:26OCT2017,KN052: 26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B: 9SEP2019,KN177:19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC:14JUN2021)

Database cutoff date for TNBC (KN355:11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966:15DEC2022)

## Adverse events

## Table 49 Adverse Event Summary (APaT Population)

|                                                                   | KN966 Pembrolizumab + Chemotherapyd   | KN966 Pembrolizumab + Chemotherapyd   | KN966Placebo+Chemotherapy   | KN966Placebo+Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+Chemotherapy   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-------------------------------------------------------------------|---------------------------------------|---------------------------------------|-----------------------------|-----------------------------|--------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                   | n                                     | (%)                                   | n                           | (%)                         | n                                                      | (%)                                                    | n                                                    | (%)                                                  |
| Participants in population                                        | 529                                   |                                       | 534                         |                             | 2,033                                                  |                                                        | 7,631                                                |                                                      |
| with one or more adverse events                                   | 524                                   | (99.1)                                | 532                         | (99.6)                      | 2,015                                                  | (99.1)                                                 | 7,375                                                | (96.6)                                               |
| with no adverse event                                             | 5                                     | (0.9)                                 | 2                           | (0.4)                       | 18                                                     | (0.9)                                                  | 256                                                  | (3.4)                                                |
| with drug-related adverse events                                  | 493                                   | (93.2)                                | 500                         | (93.6)                      | 1,948                                                  | (95.8)                                                 | 5,462                                                | (71.6)                                               |
| with toxicity grade3-5 adverse events                             | 451                                   | (85.3)                                | 449                         | (84.1)                      | 1,583                                                  | (77.9)                                                 | 3,514                                                | (46.0)                                               |
| with toxicity grade 3-5 drug-related adverse events               | 377                                   | (71.3)                                | 370                         | (69.3)                      | 1,285                                                  | (63.2)                                                 | 1,208                                                | (15.8)                                               |
| with serious adverse events                                       | 276                                   | (52.2)                                | 263                         | (49.3)                      | 962                                                    | (47.3)                                                 | 2,742                                                | (35.9)                                               |
| with serious drug-related adverse events                          | 121                                   | (22.9)                                | 84                          | (15.7)                      | 550                                                    | (27.1)                                                 | 840                                                  | (11.0)                                               |
| who died                                                          | 31                                    | (5.9)                                 | 49                          | (9.2)                       | 139                                                    | (6.8)                                                  | 346                                                  | (4.5)                                                |
| who died due to a drug-related adverse event                      | 8                                     | (1.5)                                 | 3                           | (0.6)                       | 43                                                     | (2.1)                                                  | 42                                                   | (0.6)                                                |
| discontinued any drug due to an adverse event                     | 138                                   | (26.1)                                | 122                         | (22.8)                      | 551                                                    | (27.1)                                                 | 1,066                                                | (14.0)                                               |
| discontinued pembrolizumab or placebo                             | 77                                    | (14.6)                                | 66                          | (12.4)                      | 345                                                    | (17.0)                                                 | 1,066                                                | (14.0)                                               |
| discontinued any chemotherapy                                     | 124                                   | (23.4)                                | 113                         | (21.2)                      | 424                                                    | (20.9)                                                 | 0                                                    | (0.0)                                                |
| discontinued any drug due to a drug-related adverse event         | 102                                   | (19.3)                                | 81                          | (15.2)                      | 434                                                    | (21.3)                                                 | 639                                                  | (8.4)                                                |
| discontinued pembrolizumab or placebo                             | 47                                    | (8.9)                                 | 26                          | (4.9)                       | 234                                                    | (11.5)                                                 | 639                                                  | (8.4)                                                |
| discontinued any chemotherapy                                     | 90                                    | (17.0)                                | 73                          | (13.7)                      | 334                                                    | (16.4)                                                 | 0                                                    | (0.0)                                                |
| discontinued any drug due to a serious adverse event              | 76                                    | (14.4)                                | 61                          | (11.4)                      | 327                                                    | (16.1)                                                 | 714                                                  | (9.4)                                                |
| discontinued pembrolizumab or placebo                             | 61                                    | (11.5)                                | 54                          | (10.1)                      | 268                                                    | (13.2)                                                 | 714                                                  | (9.4)                                                |
| discontinued any chemotherapy                                     | 67                                    | (12.7)                                | 52                          | (9.7)                       | 228                                                    | (11.2)                                                 | 0                                                    | (0.0)                                                |
| discontinued any drug due to a serious drug-related adverse event | 41                                    | (7.8)                                 | 20                          | (3.7)                       | 220                                                    | (10.8)                                                 | 347                                                  | (4.5)                                                |
| discontinued pembrolizumab or placebo                             | 32                                    | (6.0)                                 | 14                          | (2.6)                       | 167                                                    | (8.2)                                                  | 347                                                  | (4.5)                                                |
| discontinued any chemotherapy                                     | 35                                    | (6.6)                                 | 17                          | (3.2)                       | 148                                                    | (7.3)                                                  | 0                                                    | (0.0)                                                |

Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Grades are based on NCI CTCAE version 4.03, with the exception of KN966 (version 5.0)

dIncludes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.

KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407 and KN590.

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN021 cohort A/C/G-NSCLC: 19AUG2019, KN024: 10JUL2017, KN042: 04SEP2018, KN189-NSCLC: 20MAY2019, KN407NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016,KN040: 15MAY2017,KN048:25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045:26OCT2017,KN052:26SEP2018)

Database cutoff date for CRC (KN164cohort A+B:9SEP2019,KN177:19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC: 14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

<div style=\"page-break-after: always\"></div>

Table 50 Exposure-Adjusted Adverse Event Summary (Including Multiple Occurrences of Events) (APaT Population)

|                                                               | Event Count andRate(Events/100person-months)a   | Event Count andRate(Events/100person-months)a   | Event Count andRate(Events/100person-months)a          | Event Count andRate(Events/100person-months)a    |
|---------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|
|                                                               | KN966Pembrolizumab + Chemotherapyd              | KN966 Placebo + Chemotherapyd                   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapyf | PembrolizumabMonotherapy ReferenceSafetyDatasete |
| Number of Participants exposed                                | 529                                             | 534                                             | 2033                                                   | 7631                                             |
| Total exposureb in person-months                              | 4757.41                                         | 4405.50                                         | 20266.55                                               | 66840.89                                         |
| Total events (rate)                                           |                                                 |                                                 |                                                        |                                                  |
| adverse events                                                | 10282 (216.13)                                  | 10031 (227.69) 6046 (137.24)                    | 40308 (198.89) 23303 (114.98) 6238 (30.78)             | 77451 (115.87) 24852 (37.18)                     |
| drug-related adverse events                                   | 6434 (135.24)                                   |                                                 |                                                        |                                                  |
| toxicity grade3-5adverse events                               | 2066 (43.43)                                    | 2012 (45.67)                                    |                                                        | 7376 (11.04)                                     |
| toxicity grade 3-5drug-related adverse events                 | 1450 (30.48)                                    | 1350 (30.64)                                    | 4288 (21.16)                                           | 1760 (2.63)                                      |
| serious adverse events                                        | 556 (11.69)                                     | 506 (11.49)                                     | 1939 (9.57)                                            | 4796 (7.18)                                      |
| seriousdrug-related adverse events                            | 172 (3.62)                                      | 118 (2.68)                                      | 887 (4.38)                                             | 1117 (1.67)                                      |
| adverse eventsleading todeath                                 | 31 (0.65)                                       | 49 (1.11)                                       | 143 (0.71)                                             | 353 (0.53)                                       |
| drug-related adverse eventsleading to death                   | 8 (0.17)                                        | 3 (0.07)                                        | 43 (0.21)                                              | 42 (0.06)                                        |
| adverseeventsresultingindrugdiscontinuation                   | 163 (3.43)                                      | 140 (3.18)                                      | 656 (3.24)                                             | 1149 (1.72)                                      |
| drug-related adverse events resulting in drug discontinuation | 124 (2.61)                                      | 92 (2.09)                                       | 515 (2.54)                                             | 699 (1.05)                                       |
| serious adverseeventsresultingindrugdiscontinuation           | 78 (1.64)                                       | 63 (1.43)                                       | 363 (1.79)                                             | 746 (1.12)                                       |

|                                                                    | Event Count and Rate(Events/100 person-months)a   | Event Count and Rate(Events/100 person-months)a   | Event Count and Rate(Events/100 person-months)a        | Event Count and Rate(Events/100 person-months)a   |
|--------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------------|---------------------------------------------------|
|                                                                    | KN966 Pembrolizumab + Chemotherapyd               | KN966 Placebo + Chemotherapyd                     | Pooled Safety Dataset for Pembrolizumab+ Chemotherapyf | PembrolizumabMonotherapy ReferenceSafetyDatasete  |
| serious drug-relatedadverse eventsresultingin drug discontinuation | 43 (0.90)                                         | 21 (0.48)                                         | 242 (1.19)                                             | 362 (0.54)                                        |

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Grades are based on NCI CTCAE version 4.03, with the exception of KN966 (version 5.0)

dIncludes all participants who received at least one dose of pembrolizumab or chemotherapy inKN966.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1,B2, B3, D,C,F1,F2,F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.

f Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048,KN189, KN355, KN407 and KN590.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006: 03MAR2015, KN054:03APR2020, KN716:21JUN2021)

Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010:30SEP2015,KN021 cohort A/C/G-NSCLC:19AUG2019,KN024:10JUL2017,KN042:04SEP2018,KN189-NSCLC: 20MAY2019, KN407-NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018,KN087:15MAR2021,KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052:26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B:9SEP2019,KN177:19FEB2021)

Database cutoff date for MSI-H(KN158 cohort K:05OCT2020)

Database cutoff date forRCC (KN564-RCC:14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal(KN590:02JUL2020)

Database cutoff date forHBC (KN966:15DEC2022)

Table 51 Participants With Adverse Events by Decreasing Incidence (Incidence ≥ 10% in One or More Treatment Groups) (APaT Population)

(96.6)

256

(3.4)

53

(12.9)

(20.1)

95

(31.0)

(15.5)

(17.2)

70

|                                                    | KN966 Pembrolizumab + Chemotherapy d   | KN966 Pembrolizumab + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|----------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                    | n                                      | (%)                                    | n                                | (%)                              | n                                                          | (%)                                                        | n                                                      | (%)                                                    |
| Participants in population with one or more events | 529                                    |                                        | 534                              |                                  | 2,033                                                      |                                                            | 7,631                                                  |                                                        |
| adverse                                            | 524                                    | (99.1)                                 | 532                              | (99.6)                           | 2,015                                                      | (99.1)                                                     | 7,375                                                  | (96.6)                                                 |
| with no adverse events                             | 5                                      | (0.9)                                  | 2                                | (0.4)                            | 18                                                         | (0.9)                                                      | 256                                                    | (3.4)                                                  |
| Neutrophil count decreased                         | 330                                    | (62.4)                                 | 327                              | (61.2)                           | 374                                                        | (18.4)                                                     | 53                                                     | (0.7)                                                  |
| Anaemia                                            | 323                                    | (61.1)                                 | 313                              | (58.6)                           | 1,053                                                      | (51.8)                                                     | 982                                                    | (12.9)                                                 |
| Nausea                                             | 233                                    | (44.0)                                 | 246                              | (46.1)                           | 1,051                                                      | (51.7)                                                     | 1,534                                                  | (20.1)                                                 |
| Platelet count decreased                           | 211                                    | (39.9)                                 | 212                              | (39.7)                           | 250                                                        | (12.3)                                                     | 95                                                     | (1.2)                                                  |
| Fatigue                                            | 187                                    | (35.3)                                 | 172                              | (32.2)                           | 744                                                        | (36.6)                                                     | 2,368                                                  | (31.0)                                                 |
| Constipation                                       | 186                                    | (35.2)                                 | 190                              | (35.6)                           | 692                                                        | (34.0)                                                     | 1,179                                                  | (15.5)                                                 |
| Decreased appetite                                 | 144                                    | (27.2)                                 | 155                              | (29.0)                           | 611                                                        | (30.1)                                                     | 1,312                                                  | (17.2)                                                 |
| White blood cell count decreased                   | 141                                    | (26.7)                                 | 127                              | (23.8)                           | 314                                                        | (15.4)                                                     | 70                                                     | (0.9)                                                  |

<div style=\"page-break-after: always\"></div>

934

(12.2)

945

(12.4)

(22.0)

674

(8.8)

(15.4)

538

572

184

(2.4)

(18.8)

880

(11.5)

630

358

118

847

(11.1)

(14.8)

946

(12.4)

628

163

(2.1)

324

937

(12.3)

528

298

(3.9)

(18.8)

(18.2)

225

(2.9)

564

111

52

201

146

487

82

117

| Pyrexia                              |   139 | (26.3)   |   104 | (19.5)   |   354 | (17.4)   | 934   | (12.2)   |
|--------------------------------------|-------|----------|-------|----------|-------|----------|-------|----------|
| Vomiting                             |   122 | (23.1)   |   128 | (24.0)   |   560 | (27.5)   | 945   | (12.4)   |
| Diarrhoea                            |   103 | (19.5)   |    98 | (18.4)   |   644 | (31.7)   | 1,678 | (22.0)   |
| Abdominal pain                       |    92 | (17.4)   |   122 | (22.8)   |   161 | (7.9)    | 674   | (8.8)    |
| Rash                                 |    90 | (17.0)   |    49 | (9.2)    |   363 | (17.9)   | 1,175 | (15.4)   |
| Aspartate aminotransferase increased |    88 | (16.6)   |    98 | (18.4)   |   269 | (13.2)   | 538   | (7.1)    |
| Alanine aminotransferase increased   |    87 | (16.4)   |   113 | (21.2)   |   283 | (13.9)   | 572   | (7.5)    |
| Hypomagnesaemia                      |    79 | (14.9)   |    79 | (14.8)   |   165 | (8.1)    | 184   | (2.4)    |
| Pruritus                             |    77 | (14.6)   |    51 | (9.6)    |   283 | (13.9)   | 1,435 | (18.8)   |
| Asthenia                             |    75 | (14.2)   |    95 | (17.8)   |   379 | (18.6)   | 880   | (11.5)   |
| Oedema peripheral                    |    73 | (13.8)   |    85 | (15.9)   |   251 | (12.3)   | 630   | (8.3)    |
| Blood creatinine increased           |    57 | (10.8)   |    58 | (10.9)   |   241 | (11.9)   | 358   | (4.7)    |
| Alopecia                             |    55 | (10.4)   |    68 | (12.7)   |   449 | (22.1)   | 118   | (1.5)    |
| Back pain                            |    54 | (10.2)   |    73 | (13.7)   |   228 | (11.2)   | 847   | (11.1)   |
| Dyspnoea                             |    53 | (10.0)   |    55 | (10.3)   |   306 | (15.1)   | 1,130 | (14.8)   |
| Headache                             |    53 | (10.0)   |    46 | (8.6)    |   290 | (14.3)   | 946   | (12.4)   |
| Weight decreased                     |    51 | (9.6)    |    63 | (11.8)   |   275 | (13.5)   | 628   | (8.2)    |
| Blood bilirubin increased            |    50 | (9.5)    |    65 | (12.2)   |    31 | (1.5)    | 163   | (2.1)    |
| Hypokalaemia                         |    48 | (9.1)    |    67 | (12.5)   |   216 | (10.6)   | 324   | (4.2)    |
| Hypothyroidism                       |    46 | (8.7)    |    14 | (2.6)    |   260 | (12.8)   | 937   | (12.3)   |
| Insomnia                             |    41 | (7.8)    |    41 | (7.7)    |   206 | (10.1)   | 528   | (6.9)    |
| Abdominal pain upper                 |    40 | (7.6)    |    57 | (10.7)   |   126 | (6.2)    | 298   | (3.9)    |
| Arthralgia                           |    39 | (7.4)    |    41 | (7.7)    |   355 | (17.5)   | 1,436 | (18.8)   |
| Cough                                |    36 | (6.8)    |    37 | (6.9)    |   426 | (21.0)   | 1,392 | (18.2)   |
| Dyspepsia                            |    33 | (6.2)    |    55 | (10.3)   |   108 | (5.3)    | 225   | (2.9)    |
| Dizziness                            |    32 | (6.0)    |    50 | (9.4)    |   224 | (11.0)   | 564   | (7.4)    |
| Mucosal inflammation                 |    28 | (5.3)    |    23 | (4.3)    |   230 | (11.3)   | 111   | (1.5)    |
| Leukopenia                           |    26 | (4.9)    |    15 | (2.8)    |   229 | (11.3)   | 52    | (0.7)    |
| Stomatitis                           |    26 | (4.9)    |    35 | (6.6)    |   288 | (14.2)   | 201   | (2.6)    |
| Neuropathy peripheral                |    21 | (4.0)    |    29 | (5.4)    |   221 | (10.9)   | 146   | (1.9)    |
| Pneumonia                            |    16 | (3.0)    |    20 | (3.7)    |   218 | (10.7)   | 487   | (6.4)    |
| Neutropenia                          |     1 | (0.2)    |     0 | (0.0)    |   663 | (32.6)   | 82    | (1.1)    |
| Thrombocytopenia                     |     0 | (0.0)    |     0 | (0.0)    |   401 | (19.7)   | 117   | (1.5)    |

Every participant is counted a single time for each applicable row and column.

- A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
- A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
- Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

d  Includes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.

- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.
- f  Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407 and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN021 cohort A/C/GNSCLC: 19AUG2019, KN024: 10JUL2017, KN042: 04SEP2018, KN189-NSCLC: 20MAY2019, KN407NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020) Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B:  9SEP2019, KN177: 19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC: 14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

<div style=\"page-break-after: always\"></div>

Table 52 Participants With Drug-Related Adverse Events by Decreasing Incidence (Incidence ≥ 5% in One or More Treatment Groups) (APaT Population)

(71.6)

2,169

(28.4)

34

234

43

675

(19.3)

34

525

248

184

884

(11.6)

336

314

(4.1)

57

904

(11.8)

1,143

(15.0)

491

37

(0.5)

312

810

(10.6)

105

(1.4)

126

(1.7)

55

(0.7)

79

(1.0)

32

57

35

(0.5)

64

(0.8)

103

54

(0.7)

148

(1.9)

312

(4.1)

661

(8.7)

49

56

|                                                            | KN966 Pembrolizumab + Chemotherapy d   | KN966 Pembrolizumab + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|------------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                            | n (%)                                  | n (%)                                  | n (%)                            | n (%)                            | (%)                                                        | (%)                                                        | n (%)                                                  | n (%)                                                  |
| Participants in population with one or more adverse events | 529                                    | 529                                    | 534                              | 534                              | 2,033                                                      | 2,033                                                      | 7,631                                                  | 7,631                                                  |
|                                                            | 493                                    | (93.2)                                 | 500                              | (93.6)                           | 1,948                                                      | (95.8)                                                     | 5,462                                                  | (71.6)                                                 |
| with no adverse events                                     | 36                                     | (6.8)                                  | 34                               | (6.4)                            | 85                                                         | (4.2)                                                      | 2,169                                                  | (28.4)                                                 |
| Neutrophil count decreased                                 | 321                                    | (60.7)                                 | 320                              | (59.9)                           | 362                                                        | (17.8)                                                     | 34                                                     | (0.4)                                                  |
| Anaemia                                                    | 278                                    | (52.6)                                 | 269                              | (50.4)                           | 887                                                        | (43.6)                                                     | 234                                                    | (3.1)                                                  |
| Platelet count decreased                                   | 199                                    | (37.6)                                 | 197                              | (36.9)                           | 240                                                        | (11.8)                                                     | 43                                                     | (0.6)                                                  |
| Nausea                                                     | 195                                    | (36.9)                                 | 219                              | (41.0)                           | 914                                                        | (45.0)                                                     | 675                                                    | (8.8)                                                  |
| Fatigue                                                    | 154                                    | (29.1)                                 | 147                              | (27.5)                           | 639                                                        | (31.4)                                                     | 1,476                                                  | (19.3)                                                 |
| White blood cell count decreased                           | 139                                    | (26.3)                                 | 124                              | (23.2)                           | 297                                                        | (14.6)                                                     | 34                                                     | (0.4)                                                  |
| Decreased appetite                                         | 103                                    | (19.5)                                 | 104                              | (19.5)                           | 463                                                        | (22.8)                                                     | 525                                                    | (6.9)                                                  |
| Vomiting                                                   | 86                                     | (16.3)                                 | 101                              | (18.9)                           | 430                                                        | (21.2)                                                     | 248                                                    | (3.2)                                                  |
| Constipation                                               | 85                                     | (16.1)                                 | 74                               | (13.9)                           | 272                                                        | (13.4)                                                     | 184                                                    | (2.4)                                                  |
| Rash                                                       | 73                                     | (13.8)                                 | 37                               | (6.9)                            | 267                                                        | (13.1)                                                     | 884                                                    | (11.6)                                                 |
| Alanine aminotransferase increased                         | 56                                     | (10.6)                                 | 71                               | (13.3)                           | 219                                                        | (10.8)                                                     | 336                                                    | (4.4)                                                  |
| Pyrexia                                                    | 55                                     | (10.4)                                 | 35                               | (6.6)                            | 137                                                        | (6.7)                                                      | 314                                                    | (4.1)                                                  |
| Alopecia                                                   | 53                                     | (10.0)                                 | 65                               | (12.2)                           | 430                                                        | (21.2)                                                     | 57                                                     | (0.7)                                                  |
| Diarrhoea                                                  | 53                                     | (10.0)                                 | 55                               | (10.3)                           | 431                                                        | (21.2)                                                     | 904                                                    | (11.8)                                                 |
| Pruritus                                                   | 52                                     | (9.8)                                  | 31                               | (5.8)                            | 202                                                        | (9.9)                                                      | 1,143                                                  | (15.0)                                                 |
| Asthenia                                                   | 51                                     | (9.6)                                  | 81                               | (15.2)                           | 273                                                        | (13.4)                                                     | 491                                                    | (6.4)                                                  |
| Hypomagnesaemia                                            | 49                                     | (9.3)                                  | 61                               | (11.4)                           | 100                                                        | (4.9)                                                      | 37                                                     | (0.5)                                                  |
| Aspartate aminotransferase increased                       | 45                                     | (8.5)                                  | 60                               | (11.2)                           | 207                                                        | (10.2)                                                     | 312                                                    | (4.1)                                                  |
| Hypothyroidism                                             | 41                                     | (7.8)                                  | 11                               | (2.1)                            | 220                                                        | (10.8)                                                     | 810                                                    | (10.6)                                                 |
| Blood creatinine increased                                 | 39                                     | (7.4)                                  | 39                               | (7.3)                            | 174                                                        | (8.6)                                                      | 105                                                    | (1.4)                                                  |
| Oedema peripheral                                          | 31                                     | (5.9)                                  | 32                               | (6.0)                            | 91                                                         | (4.5)                                                      | 126                                                    | (1.7)                                                  |
| Malaise                                                    | 30                                     | (5.7)                                  | 27                               | (5.1)                            | 98                                                         | (4.8)                                                      | 55                                                     | (0.7)                                                  |
| Dysgeusia                                                  | 29                                     | (5.5)                                  | 27                               | (5.1)                            | 158                                                        | (7.8)                                                      | 79                                                     | (1.0)                                                  |
| Leukopenia                                                 | 25                                     | (4.7)                                  | 12                               | (2.2)                            | 220                                                        | (10.8)                                                     | 32                                                     | (0.4)                                                  |
| Mucosal inflammation                                       | 24                                     | (4.5)                                  | 23                               | (4.3)                            | 207                                                        | (10.2)                                                     | 57                                                     | (0.7)                                                  |
| Peripheral sensory neuropathy                              | 24                                     | (4.5)                                  | 21                               | (3.9)                            | 154                                                        | (7.6)                                                      | 35                                                     | (0.5)                                                  |
| Lymphocyte count decreased                                 | 20                                     | (3.8)                                  | 27                               | (5.1)                            | 82                                                         | (4.0)                                                      | 64                                                     | (0.8)                                                  |
| Stomatitis                                                 | 19                                     | (3.6)                                  | 27                               | (5.1)                            | 256                                                        | (12.6)                                                     | 103                                                    | (1.3)                                                  |
| Neuropathy peripheral                                      | 16                                     | (3.0)                                  | 23                               | (4.3)                            | 180                                                        | (8.9)                                                      | 54                                                     | (0.7)                                                  |
| Weight decreased                                           | 16                                     | (3.0)                                  | 24                               | (4.5)                            | 134                                                        | (6.6)                                                      | 148                                                    | (1.9)                                                  |
| Myalgia                                                    | 15                                     | (2.8)                                  | 12                               | (2.2)                            | 107                                                        | (5.3)                                                      | 312                                                    | (4.1)                                                  |
| Arthralgia                                                 | 9                                      | (1.7)                                  | 11                               | (2.1)                            | 141                                                        | (6.9)                                                      | 661                                                    | (8.7)                                                  |
| Neutropenia                                                | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 641                                                        | (31.5)                                                     | 49                                                     | (0.6)                                                  |
| Thrombocytopenia                                           | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 376                                                        | (18.5)                                                     | 56                                                     | (0.7)                                                  |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

<div style=\"page-break-after: always\"></div>

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

- d  Includes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.
- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.
- f  Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407 and KN590.
- Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN021 cohort A/C/GNSCLC: 19AUG2019, KN024: 10JUL2017, KN042: 04SEP2018, KN189-NSCLC: 20MAY2019, KN407NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B:  9SEP2019, KN177: 19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC: 14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

Table 53 Participants With Grade 3-5 Adverse Events by Decreasing Incidence (Incidence ≥ 5% in One or More Treatment Groups) (APaT Population)

(46.0)

(54.0)

10

275

10

(0.1)

5

(0.1)

5

(0.1)

166

(2.2)

270

(3.5)

21

23

(0.3)

|                                  | KN966 Pembrolizumab + Chemotherapy d   | KN966 Pembrolizumab + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|----------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                  | n                                      | (%)                                    | n                                | (%)                              | n                                                          | (%)                                                        | n                                                      | (%)                                                    |
| Participants in population       | 529                                    |                                        | 534                              |                                  | 2,033                                                      |                                                            | 7,631                                                  |                                                        |
| with one or more adverse events  | 451                                    | (85.3)                                 | 449                              | (84.1)                           | 1,583                                                      | (77.9)                                                     | 3,514                                                  | (46.0)                                                 |
| with no adverse events           | 78                                     | (14.7)                                 | 85                               | (15.9)                           | 450                                                        | (22.1)                                                     | 4,117                                                  | (54.0)                                                 |
| Neutrophil count decreased       | 257                                    | (48.6)                                 | 253                              | (47.4)                           | 254                                                        | (12.5)                                                     | 10                                                     | (0.1)                                                  |
| Anaemia                          | 152                                    | (28.7)                                 | 154                              | (28.8)                           | 374                                                        | (18.4)                                                     | 275                                                    | (3.6)                                                  |
| Platelet count decreased         | 94                                     | (17.8)                                 | 107                              | (20.0)                           | 71                                                         | (3.5)                                                      | 10                                                     | (0.1)                                                  |
| White blood cell count decreased | 61                                     | (11.5)                                 | 47                               | (8.8)                            | 136                                                        | (6.7)                                                      | 5                                                      | (0.1)                                                  |
| Cholangitis                      | 29                                     | (5.5)                                  | 23                               | (4.3)                            | 2                                                          | (0.1)                                                      | 5                                                      | (0.1)                                                  |
| Fatigue                          | 26                                     | (4.9)                                  | 22                               | (4.1)                            | 117                                                        | (5.8)                                                      | 166                                                    | (2.2)                                                  |
| Pneumonia                        | 9                                      | (1.7)                                  | 10                               | (1.9)                            | 138                                                        | (6.8)                                                      | 270                                                    | (3.5)                                                  |
| Neutropenia                      | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 413                                                        | (20.3)                                                     | 21                                                     | (0.3)                                                  |
| Thrombocytopenia                 | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 157                                                        | (7.7)                                                      | 23                                                     | (0.3)                                                  |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

<div style=\"page-break-after: always\"></div>

- d  Includes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.
- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.
- f  Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407 and KN590.
- Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN021 cohort A/C/GNSCLC: 19AUG2019, KN024: 10JUL2017, KN042: 04SEP2018, KN189-NSCLC: 20MAY2019, KN407NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B:  9SEP2019, KN177: 19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC: 14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

Table 54 Participants With Grade 3-5 Drug-Related Adverse Events by Decreasing Incidence (Incidence ≥ 5% in One or More Treatment Groups) (APaT Population)

(15.8)

(84.2)

6

33

2

(0.0)

2

(0.0)

13

11

(0.1)

|                                  | KN966 Pembrolizumab + Chemotherapy d   | KN966 Pembrolizumab + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|----------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                  | n                                      | (%)                                    | n                                | (%)                              | n                                                          | (%)                                                        | n                                                      | (%)                                                    |
| Participants in population       | 529                                    |                                        | 534                              |                                  | 2,033                                                      |                                                            | 7,631                                                  |                                                        |
| with one or more adverse events  | 377                                    | (71.3)                                 | 370                              | (69.3)                           | 1,285                                                      | (63.2)                                                     | 1,208                                                  | (15.8)                                                 |
| with no adverse events           | 152                                    | (28.7)                                 | 164                              | (30.7)                           | 748                                                        | (36.8)                                                     | 6,423                                                  | (84.2)                                                 |
| Neutrophil count decreased       | 247                                    | (46.7)                                 | 246                              | (46.1)                           | 242                                                        | (11.9)                                                     | 6                                                      | (0.1)                                                  |
| Anaemia                          | 123                                    | (23.3)                                 | 131                              | (24.5)                           | 307                                                        | (15.1)                                                     | 33                                                     | (0.4)                                                  |
| Platelet count decreased         | 85                                     | (16.1)                                 | 99                               | (18.5)                           | 68                                                         | (3.3)                                                      | 2                                                      | (0.0)                                                  |
| White blood cell count decreased | 61                                     | (11.5)                                 | 46                               | (8.6)                            | 130                                                        | (6.4)                                                      | 2                                                      | (0.0)                                                  |
| Neutropenia                      | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 403                                                        | (19.8)                                                     | 13                                                     | (0.2)                                                  |
| Thrombocytopenia                 | 0                                      | (0.0)                                  | 0                                | (0.0)                            | 143                                                        | (7.0)                                                      | 11                                                     | (0.1)                                                  |

Every participant is counted a single time for each applicable row and column.

- A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
- A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

- d  Includes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.
- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.
- f  Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407 and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006:

03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN021 cohort A/C/G-

NSCLC: 19AUG2019, KN024: 10JUL2017, KN042: 04SEP2018, KN189-NSCLC: 20MAY2019, KN407-

NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B:  9SEP2019, KN177: 19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC: 14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

Table 55 Participants With Adverse Events Resulting in Death by Decreasing Incidence (Incidence &gt; 0% in One or More Treatment Groups of KEYNOTE-966) (APaT Population)

346

(4.5)

(95.5)

40

(0.5)

49

(0.6)

11

(0.1)

0

(0.0)

1

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

9

(0.1)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

4

(0.1)

6

(0.1)

1

(0.0)

8

(0.1)

0

(0.0)

8

(0.1)

10

(0.1)

11

(0.1)

0

(0.0)

3

(0.0)

1

(0.0)

0

(0.0)

1

(0.0)

1

(0.0)

|                                         | KN966 Pembrolizumab + Chemotherapy d   | KN966 Pembrolizumab + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|-----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                         | n                                      | (%)                                    | n                                | (%)                              | n                                                          | (%)                                                        | n                                                      | (%)                                                    |
| Participants in population more adverse | 529                                    |                                        | 534                              |                                  | 2,033                                                      |                                                            | 7,631                                                  |                                                        |
| with one or events                      | 31                                     | (5.9)                                  | 49                               | (9.2)                            | 139                                                        | (6.8)                                                      | 346                                                    | (4.5)                                                  |
| with no adverse events                  | 498                                    | (94.1)                                 | 485                              | (90.8)                           | 1,894                                                      | (93.2)                                                     | 7,285                                                  | (95.5)                                                 |
| Pneumonia                               | 4                                      | (0.8)                                  | 0                                | (0.0)                            | 15                                                         | (0.7)                                                      | 40                                                     | (0.5)                                                  |
| Death                                   | 3                                      | (0.6)                                  | 5                                | (0.9)                            | 15                                                         | (0.7)                                                      | 49                                                     | (0.6)                                                  |
| Sepsis                                  | 3                                      | (0.6)                                  | 6                                | (1.1)                            | 6                                                          | (0.3)                                                      | 11                                                     | (0.1)                                                  |
| Biliary tract infection                 | 2                                      | (0.4)                                  | 0                                | (0.0)                            | 0                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| Euthanasia                              | 2                                      | (0.4)                                  | 1                                | (0.2)                            | 0                                                          | (0.0)                                                      | 1                                                      | (0.0)                                                  |
| Abdominal abscess                       | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 0                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| Abdominal infection                     | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 0                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| COVID-19                                | 1                                      | (0.2)                                  | 4                                | (0.7)                            | 1                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| Cardiac arrest                          | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 9                                                          | (0.4)                                                      | 9                                                      | (0.1)                                                  |
| Cholangitis                             | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 0                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| Fungal sepsis                           | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 0                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| Gastrointestinal haemorrhage            | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 0                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| Lower respiratory tract infection       | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 0                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| Malignant neoplasm progression          | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 0                                                          | (0.0)                                                      | 4                                                      | (0.1)                                                  |
| Myocardial infarction                   | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 3                                                          | (0.1)                                                      | 6                                                      | (0.1)                                                  |
| Pneumocystis jirovecii pneumonia        | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 1                                                          | (0.0)                                                      | 1                                                      | (0.0)                                                  |
| Pneumonia aspiration                    | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 5                                                          | (0.2)                                                      | 8                                                      | (0.1)                                                  |
| Pneumonia viral                         | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 1                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| Pneumonitis                             | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 4                                                          | (0.2)                                                      | 8                                                      | (0.1)                                                  |
| Pulmonary embolism                      | 1                                      | (0.2)                                  | 3                                | (0.6)                            | 3                                                          | (0.1)                                                      | 10                                                     | (0.1)                                                  |
| Septic shock                            | 1                                      | (0.2)                                  | 1                                | (0.2)                            | 8                                                          | (0.4)                                                      | 11                                                     | (0.1)                                                  |
| Shock haemorrhagic                      | 1                                      | (0.2)                                  | 0                                | (0.0)                            | 1                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| Acute kidney injury                     | 0                                      | (0.0)                                  | 2                                | (0.4)                            | 4                                                          | (0.2)                                                      | 3                                                      | (0.0)                                                  |
| Acute myocardial infarction             | 0                                      | (0.0)                                  | 1                                | (0.2)                            | 2                                                          | (0.1)                                                      | 1                                                      | (0.0)                                                  |
| Biliary sepsis                          | 0                                      | (0.0)                                  | 1                                | (0.2)                            | 0                                                          | (0.0)                                                      | 0                                                      | (0.0)                                                  |
| COVID-19 pneumonia                      | 0                                      | (0.0)                                  | 2                                | (0.4)                            | 0                                                          | (0.0)                                                      | 1                                                      | (0.0)                                                  |
| Cerebral haemorrhage                    | 0                                      | (0.0)                                  | 1                                | (0.2)                            | 0                                                          | (0.0)                                                      | 1                                                      | (0.0)                                                  |

<div style=\"page-break-after: always\"></div>

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

1

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

17

(0.2)

0

(0.0)

1

(0.0)

| Cerebral infarction                |   0 | (0.0)   |   3 | (0.6)   |   1 | (0.0)   |   0 | (0.0)   |
|------------------------------------|-----|---------|-----|---------|-----|---------|-----|---------|
| Cerebral venous sinus thrombosis   |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Cholangitis infective              |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Cholecystitis                      |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Diarrhoea                          |   0 | (0.0)   |   1 | (0.2)   |   1 | (0.0)   |   1 | (0.0)   |
| Hepatic infection                  |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Hepatorenal syndrome               |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Ileus                              |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Liver abscess                      |   0 | (0.0)   |   2 | (0.4)   |   0 | (0.0)   |   0 | (0.0)   |
| Lung abscess                       |   0 | (0.0)   |   1 | (0.2)   |   1 | (0.0)   |   0 | (0.0)   |
| Oesophageal varices haemorrhage    |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Pneumococcal sepsis                |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Pneumonia acinetobacter            |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Pneumonia bacterial                |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Post procedural complication       |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Respiratory failure                |   0 | (0.0)   |   1 | (0.2)   |   5 | (0.2)   |  17 | (0.2)   |
| Spontaneous bacterial peritonitis  |   0 | (0.0)   |   1 | (0.2)   |   0 | (0.0)   |   0 | (0.0)   |
| Upper gastrointestinal haemorrhage |   0 | (0.0)   |   2 | (0.4)   |   1 | (0.0)   |   1 | (0.0)   |

Every participant is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

d  Includes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.

- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.
- f  Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407 and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN021 cohort A/C/GNSCLC: 19AUG2019, KN024: 10JUL2017, KN042: 04SEP2018, KN189-NSCLC: 20MAY2019, KN407NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B:  9SEP2019, KN177: 19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC: 14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

Deaths due to drug-related AEs were reported in 1.5% of the pembrolizumab plus chemotherapy group and 0.6% of the placebo plus chemotherapy group; no drug-related AEs resulting in death were reported in more than 1 participant. In KEYNOTE-966, a total of 8 participants died of a drug-related AE, as assessed by the investigator, in the pembrolizumab plus chemotherapy group. Of the 8 deaths in the pembrolizumab plus chemotherapy group considered by the investigator as related to the study intervention, 5 were considered related to chemotherapy (cholangitis, lower respiratory tract infection,

<div style=\"page-break-after: always\"></div>

myocardial infarction, pneumonia viral, septic shock), 2 were considered related to pembrolizumab (abdominal abscess and malignant neoplasm progression), and 1 was related to both chemotherapy and pembrolizumab (pneumonitis) (data not shown).

Table 56 Participants With Serious Adverse Events by Decreasing Incidence (Incidence ≥ 5% in One or More Treatment Groups) (APaT Population)

(35.9)

(64.1)

5

(0.1)

79

(1.0)

272

(3.6)

|                            | KN966 Pembrolizumab + Chemotherapy d   | KN966 Pembrolizumab + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | KN966 Placebo + Chemotherapy d   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|----------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                            | n                                      | (%)                                    | n                                | (%)                              | n                                                          | (%)                                                        | n                                                      | (%)                                                    |
| Participants in population | 529                                    |                                        | 534                              |                                  | 2,033                                                      |                                                            | 7,631                                                  |                                                        |
| with one or more adverse   | 276                                    | (52.2)                                 | 263                              | (49.3)                           | 962                                                        | (47.3)                                                     | 2,742                                                  | (35.9)                                                 |
| with no adverse events     | 253                                    | (47.8)                                 | 271                              | (50.7)                           | 1,071                                                      | (52.7)                                                     | 4,889                                                  | (64.1)                                                 |
| Cholangitis                | 31                                     | (5.9)                                  | 24                               | (4.5)                            | 2                                                          | (0.1)                                                      | 5                                                      | (0.1)                                                  |
| Pyrexia                    | 30                                     | (5.7)                                  | 12                               | (2.2)                            | 35                                                         | (1.7)                                                      | 79                                                     | (1.0)                                                  |
| Pneumonia                  | 8                                      | (1.5)                                  | 8                                | (1.5)                            | 137                                                        | (6.7)                                                      | 272                                                    | (3.6)                                                  |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

d  Includes all participants who received at least one dose of pembrolizumab or chemotherapy in KN966.

- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.
- f  Includes all participants who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407 and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN021 cohort A/C/GNSCLC: 19AUG2019, KN024: 10JUL2017, KN042: 04SEP2018, KN189-NSCLC: 20MAY2019, KN407NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 15MAR2021, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN164 cohort A+B:  9SEP2019, KN177: 19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC: 14JUN2021)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

The proportion of participants with 1 or more drug-related SAEs was generally similar in the pembrolizumab plus chemotherapy group compared with the placebo plus chemotherapy group (22.9% vs 15.7%). The most frequently reported drug related SAEs (incidence ≥1%) were platelet count decreased, neutrophil count decreased, pyrexia, anemia, febrile neutropenia, and pneumonitis in the pembrolizumab plus chemotherapy group, and platelet count decreased and febrile neutropenia in the

<div style=\"page-break-after: always\"></div>

placebo plus chemotherapy group. No meaningful differences in the frequency of specific drug related SAEs were observed between the treatment groups (data not shown).

The proportion of participants with drug-related SAEs in the pembrolizumab plus chemotherapy group (22.9%) was generally similar to the Pooled Combination Dataset (27.1%) and higher compared with the RSD (11.0%) (data not shown).

Adverse Events of Special Interest (AEOSI) are immune-mediated events and infusion-related reactions causally associated with pembrolizumab. When adjusted for exposure, the overall AEOSI rate was 3.32 events/100 person-months in the pembrolizumab plus chemotherapy group, 4.20 events/100 person-months in the Pooled Combination Dataset, and 4.55 events/100 person-months in the RSD.

For 14.9% of participants in the pembrolizumab plus chemotherapy group in KEYNOTE-966, the maximum grade of AEOSI was Grade 1 or 2; for 7.2% of participants, the maximum Grade was 3 to 5. There was 1 fatal AEOSI (pneumonitis) in the pembrolizumab plus chemotherapy group considered related to both chemotherapy (gemcitabine) and pembrolizumab by the investigator (data not shown).

The AEOSI outcome was reported as resolved or resolving for 37.6% and 18.8% of participants, respectively, in the pembrolizumab plus chemotherapy group of KEYNOTE-966 at the time of data cutoff.

The most frequently reported AEOSI categories in the pembrolizumab plus chemotherapy group were hypothyroidism (8.7%), pneumonitis (4.9%), and hyperthyroidism (3.6%). The proportion of participants with an event in the AEOSI category of hepatitis in the pembrolizumab plus chemotherapy group was (1.7%) compared with the Pooled Combination Dataset (1.2%) and the RSD (1.0%). There were no reported events of cholangitis sclerosing, autoimmune cholangitis, or immune-mediated cholangitis in the pembrolizumab plus chemotherapy group in KEYNOTE-966 (data not shown).

<div style=\"page-break-after: always\"></div>

Table 57 Adverse Event Summary for AEOSI (APaT Population)

|                                                                   | KN966Pembrolizumab + Chemotherapyd   | KN966Pembrolizumab + Chemotherapyd   | KN966 Placebo + Chemotherapyd   | KN966 Placebo + Chemotherapyd   | Pooled SafetyDataset for Pembrolizumab+ Chemotherapyf   | Pooled SafetyDataset for Pembrolizumab+ Chemotherapyf   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|-------------------------------------------------------------------|--------------------------------------|--------------------------------------|---------------------------------|---------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                                   | n                                    | (%)                                  | n                               | (%)                             | n                                                       | (%)                                                     | n                                                     | (%)                                                   |
| Participants in population                                        | 529                                  |                                      | 534                             |                                 | 2,033                                                   |                                                         | 7,631                                                 |                                                       |
| with one or more adverse events                                   | 117                                  | (22.1)                               | 69                              | (12.9)                          | 585                                                     | (28.8)                                                  | 2,047                                                 | (26.8)                                                |
| with no adverse event                                             | 412                                  | (77.9)                               | 465                             | (87.1)                          | 1,448                                                   | (71.2)                                                  | 5,584                                                 | (73.2)                                                |
| with drug-relatedadverse events                                   | 99                                   | (18.7)                               | 57                              | (10.7)                          | 513                                                     | (25.2)                                                  | 1,795                                                 | (23.5)                                                |
| with toxicity grade3-5adverse events                              | 38                                   | (7.2)                                | 21                              | (3.9)                           | 168                                                     | (8.3)                                                   | 527                                                   | (6.9)                                                 |
| with toxicity grade 3-5 drug-related adverse events               | 33                                   | (6.2)                                | 17                              | (3.2)                           | 150                                                     | (7.4)                                                   | 465                                                   | (6.1)                                                 |
| with serious adverse events                                       | 31                                   | (5.9)                                | 18                              | (3.4)                           | 142                                                     | (7.0)                                                   | 506                                                   | (6.6)                                                 |
| with serious drug-related adverse events                          | 26                                   | (4.9)                                | 15                              | (2.8)                           | 128                                                     | (6.3)                                                   | 453                                                   | (5.9)                                                 |
| who died                                                          | 1                                    | (0.2)                                | 0                               | (0.0)                           | 6                                                       | (0.3)                                                   | 13                                                    | (0.2)                                                 |
| who died due toa drug-related adverse event                       | 1                                    | (0.2)                                | 0                               | (0.0)                           | 6                                                       | (0.3)                                                   | 13                                                    | (0.2)                                                 |
| discontinued any drug due to an adverse event                     | 24                                   | (4.5)                                | 9                               | (1.7)                           | 116                                                     | (5.7)                                                   | 358                                                   | (4.7)                                                 |
| discontinuedpembrolizumaborplacebo                                | 23                                   | (4.3)                                | 9                               | (1.7)                           | 98                                                      | (4.8)                                                   | 358                                                   | (4.7)                                                 |
| discontinued any chemotherapy                                     | 14                                   | (2.6)                                | 4                               | (0.7)                           | 57                                                      | (2.8)                                                   | 0                                                     | (0.0)                                                 |
| discontinuedanydrugduetoadrug-relatedadverseevent                 | 24                                   | (4.5)                                | 9                               | (1.7)                           | 113                                                     | (5.6)                                                   | 352                                                   | (4.6)                                                 |
| discontinuedpembrolizumaborplacebo                                | 23                                   | (4.3)                                | 9                               | (1.7)                           | 95                                                      | (4.7)                                                   | 352                                                   | (4.6)                                                 |
| discontinued any chemotherapy                                     | 14                                   | (2.6)                                | 4                               | (0.7)                           | 55                                                      | (2.7)                                                   | 0                                                     | (0.0)                                                 |
| discontinued any drug due to a serious adverse event              | 13                                   | (2.5)                                | 4                               | (0.7)                           | 85                                                      | (4.2)                                                   | 227                                                   | (3.0)                                                 |
| discontinuedpembrolizumaborplacebo                                | 13                                   | (2.5)                                | 4                               | (0.7)                           | 78                                                      | (3.8)                                                   | 227                                                   | (3.0)                                                 |
| discontinued any chemotherapy                                     | 10                                   | (1.9)                                | 2                               | (0.4)                           | 39                                                      | (1.9)                                                   | 0                                                     | (0.0)                                                 |
| discontinued any drug due to a serious drug-related adverse event | 13                                   | (2.5)                                | 4                               | (0.7)                           | 82                                                      | (4.0)                                                   | 225                                                   | (2.9)                                                 |
| discontinuedpembrolizumaborplacebo                                | 13                                   | (2.5)                                | 4                               | (0.7)                           | 75                                                      | (3.7)                                                   | 225                                                   | (2.9)                                                 |
| discontinued any chemotherapy                                     | 10                                   | (61)                                 | 2                               | (0.4)                           | 37                                                      | (1.8)                                                   | 0                                                     | (0.0)                                                 |

Determined by theinvestigator toberelated to the drug.

Non-serious adverse eventsup to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms\"Neoplasm Progression\",\"Malignant Neoplasm Progression\"and\"DiseaseProgression\"not related to the drug are excluded.

Grades are based on NCI CTCAE version 4.03, with the exception of KN966 (version 5.0)

dIncludes all participantswhoreceived atleast one doseof pembrolizumaborchemotherapyinKN966.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2,B3, D, C,F1,F2,F3,KN002 (original phase),KN006,KN010,KN012 cohort B and B2,KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN158 cohort K, KN164 cohort A+B, KN177, KN204, KN564 and KN716.

f Includes all participants who received at least one dose of pembrolizumab combo therapy inKN021 cohort A/C/G,KN048,KN189,KN355,KN407 and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020, KN716: 21JUN2021)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015, KN021 cohort A/C/G-NSCLC:19AUG2019,KN024:10JUL2017,KN042:04SEP2018, KN189-NSCLC: 20MAY2019, KN407- NSCLC: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016,KN040: 15MAY2017, KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018,KN087: 15MAR2021,KN204: 16JAN2020)

Database cutoff date for CRC (KN164 cohort A+B:9SEP2019,KN177:19FEB2021)

Database cutoff date for MSI-H (KN158 cohort K: 05OCT2020)

Database cutoff date for RCC (KN564-RCC:14JUN2021)

Database cutoff date for TNBC (KN355:11DEC2019)

Database cutoff dateforEsophageal(KN590:02JUL2020)

Database cutoff date for HBC (KN966: 15DEC2022)

## Hepatic Events of Clinical Interest (HECI):

Patients with BTC are at risk for a range of complications that can cause hepatic laboratory abnormalities with or without clinical decompensation. For careful monitoring of participants' hepatic events of clinical interest (HECI) criteria were defined in the protocol and used by the investigators for assessment and reporting of events meeting these criteria. In KEYNOTE-966, the median time to onset of the first HECI was 88.0 days (range 3 to 711 days) in the pembrolizumab plus chemotherapy group and 146.0 (range 2 to 579 days) in the placebo plus chemotherapy group.

With regard to pre-existing viral hepatitis, KEYNOTE-966 allowed enrollment of participants with preexisting HBV/HCV, and these participants were monitored during the course of the study. No cases of viral hepatitis flares were observed.

<div style=\"page-break-after: always\"></div>

Table 58 Adverse Event Summary Hepatic Events of Clinical Interest (APaT population)

|                                                                   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                                                   | n                              | (%)                            | n                        | (%)                      |
| Participants in population                                        | 529                            |                                | 534                      |                          |
| with one or more adverse events                                   | 49                             | (9.3)                          | 57                       | (10.7)                   |
| with no adverse event                                             | 480                            | (90.7)                         | 477                      | (89.3)                   |
| with drug-related adverse events                                  | 17                             | (3.2)                          | 14                       | (2.6)                    |
| with toxicity grade 3-5 adverse events                            | 48                             | (9.1)                          | 52                       | (9.7)                    |
| with toxicity grade 3-5 drug-related adverse events               | 16                             | (3.0)                          | 13                       | (2.4)                    |
| with serious adverse events                                       | 36                             | (6.8)                          | 39                       | (7.3)                    |
| with serious drug-related adverse events                          | 8                              | (1.5)                          | 7                        | (1.3)                    |
| who died                                                          | 3                              | (0.6)                          | 3                        | (0.6)                    |
| who died due to a drug-related adverse event                      | 0                              | (0.0)                          | 0                        | (0.0)                    |
| discontinued any drug due to an adverse event                     | 15                             | (2.8)                          | 9                        | (1.7)                    |
| discontinued MK-3475/PLACEBO                                      | 12                             | (2.3)                          | 8                        | (1.5)                    |
| discontinued any chemotherapy                                     | 11                             | (2.1)                          | 4                        | (0.7)                    |
| discontinued all drugs                                            | 6                              | (1.1)                          | 1                        | (0.2)                    |
| discontinued any drug due to a drug-related adverse event         | 8                              | (1.5)                          | 5                        | (0.9)                    |
| discontinued MK-3475/PLACEBO                                      | 7                              | (1.3)                          |                          | (0.7)                    |
| discontinued any chemotherapy                                     | 5                              | (0.9)                          | 1                        | (0.2)                    |
| discontinued all drugs                                            | 3                              | (0.6)                          | 0                        | (0.0)                    |
| discontinued any drug due to a serious adverse event              | 11                             | (2.1)                          | 6                        | (1.1)                    |
| discontinued MK-3475/PLACEBO                                      | 9                              | (1.7)                          | 6                        | (1.1)                    |
| discontinued any chemotherapy                                     | 9                              | (1.7)                          | 3                        | (0.6)                    |
| discontinued all drugs                                            |                                | (0.9)                          | 1                        | (0.2)                    |
| discontinued any drug due to a serious drug-related adverse event | 4                              | (0.8)                          | 2                        | (0.4)                    |
| discontinued MK-3475/PLACEBO                                      | 4                              | (0.8)                          | 2                        | (0.4)                    |
| discontinued any chemotherapy                                     | 3                              | (0.6)                          | 0                        | (0.0)                    |
| discontinued all drugs                                            | 2                              | (0.4)                          | 0                        | (0.0)                    |

Grades are based on NCI CTCAE version 5.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA V25.1 preferred terms \"Neoplasm progression\",\"Malignantneoplasm progression\"and \"Disease progression\" not related to the drug are excluded.

Database Cutoff Date: 15DEC2022.

<div style=\"page-break-after: always\"></div>

Table 59 Participants with Adverse Events Hepatic Events of Clinical Interest by Decreasing incidence (Incidence &gt;0% in one or more treatment groups) (APaT population)

|                                                      | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placcbo + Chemotherapy   | Placcbo + Chemotherapy   |
|------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                                      | n                              | (%)                            | n                        | (%)                      |
| Participants in population                           | 529                            |                                | 534                      |                          |
| with one or more hepatic events of clinical interest | 49                             | (9.3)                          | 57                       | (10.7)                   |
| with no hepatic cvents of clinical interest          | 480                            | (90.7)                         | 477                      | (89.3)                   |
| Biliary obstruction                                  | 7                              | (1.3)                          | 6                        | (1.7)                    |
| Cholangitis                                          | 7                              | (1.3)                          | 7                        | (1.3)                    |
| Ascites                                              | 6                              | (1.1)                          | 2                        | (0.4)                    |
| Alanine aminotransferase incrcascd                   | 5                              | (0.9)                          | 4                        | (0.7)                    |
| Biliary tract infection                              | 5                              | (0.9)                          | 5                        | (0.9)                    |
| Blood bilirubin increased                            | 4                              | (0.8)                          | 7                        | (1.3)                    |
| Immune-mcdiated hepatitis                            | 4                              | (0.8)                          | 6                        | (1.1)                    |
| Transaminascs increased                              | 3                              | (0.6)                          | 2                        | (0.4)                    |
| Cholangitis acute                                    | 2                              | (0.4)                          | 0                        | (0.0)                    |
| Jaundice cholestatic                                 | 2                              | (0.4)                          | 4                        | (0.7)                    |
| Oesophageal varices hacmorrhage                      | 2                              | (0.4)                          | 0                        | (0.0)                    |
| Sepsis                                               | 2                              | (0.4)                          | 0                        | (0.0)                    |
| Autoimmune hepatitis                                 | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Biliary dilatation                                   | 1                              | (0.2)                          | 1                        | (0.2)                    |
| Cholestasis                                          | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Cholestatie liver injury                             | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Coombs negative haemolytic anaemia                   | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Device dislocation                                   | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Hepatic encephalopathy                               | 1                              | (0.2)                          | 1                        | (0.2)                    |
| Hepatic function abnormal                            | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Hepatic hacmorhage                                   | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Intestinal varices haemorrhagc                       | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Liver injury                                         | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Stent malfunction                                    | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Abdominal pain                                       | 0                              | (0.0)                          | 1                        | (0.2)                    |
| Biliary sepsis                                       | 0                              | (0.0)                          | 1                        | (0.2)                    |
| Cholangitis infective                                | 0                              | (0.0)                          | 2                        | (0.4)                    |
| Device occlusion                                     | 0                              | (0.0)                          | 1                        | (0.2)                    |
| Drug-induced liver injury                            | 0                              | (0.0)                          | 1                        | (0.2)                    |
| Hyperbilirubinaemia                                  | 0                              | (0.0)                          | 1                        | (0.2)                    |
| Hypertransaminasaemia                                | 0                              | (0.0)                          | 2                        | (0.4)                    |
| Jaundice                                             | 0                              | (0.0)                          | 1                        | (0.2)                    |
| Liver abscess                                        | 0                              | (0.0)                          | 2                        | (0.4)                    |
| Liver function test increascd                        | 0                              | (0.0)                          | 1                        | (0.2)                    |
| Steatohepatitis                                      | 0                              | (0.0)                          | 1                        | (0.2)                    |
| Upper gastrointestinal haemorrhage                   | 0                              | (0.0)                          | 1                        | (0.2)                    |

Every participant is counted a single time for cach applicable row and column.

MedDRA V25.1 preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Discase progression\" not related to the drug are excluded.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose arc included.

Database Cutoff Date: 15DEC2022.

<div style=\"page-break-after: always\"></div>

Figure 15 Between-Treatment comparisons in Hepatic Events of Clinical Interest Selected Adverse Events (&gt;=1% incidence) and sorted by Risk Difference (APaT population)

<!-- image -->

Table 60 Summary of Outcome for participants with hepatic events of clinical interest (Incidence &gt;0% in one or more treatment groups (APaT population)

|                                                   | Outcome      | Pembrolizumab+ Chemotherapy   | Placebo + Chemotherapy   |
|---------------------------------------------------|--------------|-------------------------------|--------------------------|
| Participants in population                        |              | 529                           | 534                      |
| With one ormorehepaticevents of clinical interest | Overall      | 49 (9.3)                      | 57 (10.7)                |
|                                                   | Fatal        | 3 (6.1)                       | 3 (5.3)                  |
|                                                   | Not Resolved | 12 (24.5)                     | 14 (24.6)                |
|                                                   | Resolving    | 5 (10.2)                      | 1 (1.8)                  |
|                                                   | Unknown      | 0 (0.0)                       | 0 (0.0)                  |
|                                                   | Sequelae     | 0 (0.0)                       | 1 (1.8)                  |
|                                                   | Resolved     | 29 (59.2)                     | 38 (66.7)                |

Data were provided regarding the risk of Cholangitis and/or Biliary Infections including in patients with biliary stent/biliary drain:

Table 61 Adverse Event Summary Cholangitis and/or Biliary Infections (APaT Population)

(10.3)

(89.7)

(0.6)

(9.0)

(0.6)

(9.2)

(0.6)

(0.4)

(0.0)

(1.1)

(1.1)

(0.9)

(0.6)

(0.4)

(0.4)

|                                                           | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-----------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                                           | n                              | (%)                            | n                        | (%)                      |
| Participants in population                                | 529                            |                                | 534                      |                          |
| with one or more adverse events                           | 59                             | (11.2)                         | 55                       | (10.3)                   |
| with no adverse event                                     | 470                            | (88.8)                         | 479                      | (89.7)                   |
| with drug-related a adverse events                        | 5                              | (0.9)                          | 3                        | (0.6)                    |
| with toxicity grade 3-5 adverse events                    | 52                             | (9.8)                          | 48                       | (9.0)                    |
| with toxicity grade 3-5 drug-related adverse events       | 4                              | (0.8)                          | 3                        | (0.6)                    |
| with serious adverse events                               | 53                             | (10.0)                         | 49                       | (9.2)                    |
| with serious drug-related adverse events                  | 4                              | (0.8)                          | 3                        | (0.6)                    |
| who died                                                  | 3                              | (0.6)                          | 2                        | (0.4)                    |
| who died due to a drug-related adverse event              | 1                              | (0.2)                          | 0                        | (0.0)                    |
| discontinued any drug due to an adverse event             | 6                              | (1.1)                          | 6                        | (1.1)                    |
| discontinued MK-3475/PLACEBO                              | 4                              | (0.8)                          | 6                        | (1.1)                    |
| discontinued any chemotherapy                             | 5                              | (0.9)                          | 5                        | (0.9)                    |
| discontinued all drugs                                    | 3                              | (0.6)                          | 3                        | (0.6)                    |
| discontinued any drug due to a drug-related adverse event | 1                              | (0.2)                          | 2                        | (0.4)                    |
| discontinued MK-3475/PLACEBO                              | 0                              | (0.0)                          | 2                        | (0.4)                    |

<div style=\"page-break-after: always\"></div>

(0.4)

(0.2)

(1.1)

(1.1)

(0.9)

(0.6)

(0.4)

(0.4)

(0.4)

(0.2)

| discontinued any chemotherapy                                      | 1   | (0.2)   | 2 (0.4)   |
|--------------------------------------------------------------------|-----|---------|-----------|
| discontinued all drugs                                             | 0   | (0.0)   | 1 (0.2)   |
| discontinued any drug due to a serious adverse                     | 5   | (0.9)   | 6 (1.1)   |
| event                                                              |     |         |           |
| discontinued MK-3475/PLACEBO                                       | 4   | (0.8)   | 6 (1.1)   |
| discontinued any chemotherapy                                      | 4   | (0.8)   | 5 (0.9)   |
| discontinued all drugs                                             | 3   | (0.6)   | 3 (0.6)   |
| discontinued any drug due to a serious drug- related adverse event | 0   | (0.0)   | 2 (0.4)   |
| discontinued MK-3475/PLACEBO                                       | 0   | (0.0)   | 2 (0.4)   |
| discontinued any chemotherapy                                      | 0   | (0.0)   | 2 (0.4)   |
| discontinued all drugs                                             | 0   | (0.0)   | 1 (0.2)   |

a  Determined by the investigator to be related to the drug.

Grades are based on NCI CTCAE version 5.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA V25.1 preferred terms 'Neoplasm progression', 'Malignant neoplasm progression' and 'Disease progression' not related to the drug are excluded.

Database Cutoff Date: 15DEC2022.

Table 62 Summary of Outcome for Participants With Cholangitis Or Biliary Infections (Incidence &gt; 0% in One or More Treatment Groups) (APaT Population)

|                                                    | Outcome      | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   |
|----------------------------------------------------|--------------|--------------------------------|--------------------------|
| Participants in population                         |              | 529                            | 534                      |
| With one or more cholangitis or biliary infections | Overall      | 59 (11.2)                      | 55 (10.3)                |
|                                                    | Fatal        | 3 (5.1)                        | 2 (3.6)                  |
|                                                    | Not Resolved | 8 (13.6)                       | 7 (12.7)                 |
|                                                    | Resolving    | 2 (3.4)                        | 3 (5.5)                  |
|                                                    | Unknown      | 0 (0.0)                        | 0 (0.0)                  |
|                                                    | Sequelae     | 1 (1.7)                        | 2 (3.6)                  |
|                                                    | Resolved     | 45 (76.3)                      | 41 (74.5)                |

Every participant is counted once according to the worst outcome; the ordering of the outcome is as follows: Fatal&gt;Not Resolved&gt;Resolving&gt;Unknown&gt;Sequelae&gt;Resolved.

\"Participants in population\" is used for percentage calculation for the Overall row in each section. Within each section, the overall total is used for percentage calculation for each outcome.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Database Cutoff Date: 15DEC2022.

Table 63 Adverse Event Summary Cholangitis and/or Biliary Infections (APaT Population - Biliary Stent/Biliary Drain)

(29.3)

(70.7)

(2.4)

(24.4)

(2.4)

|                                                     | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-----------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                                     | n                              | (%)                            | n                        | (%)                      |
| Participants in population                          | 33                             |                                | 41                       |                          |
| with one or more adverse events                     | 13                             | (39.4)                         | 12                       | (29.3)                   |
| with no adverse event                               | 20                             | (60.6)                         | 29                       | (70.7)                   |
| with drug-related a adverse events                  | 1                              | (3.0)                          | 1                        | (2.4)                    |
| with toxicity grade 3-5 adverse events              | 13                             | (39.4)                         | 10                       | (24.4)                   |
| with toxicity grade 3-5 drug-related adverse events | 1                              | (3.0)                          | 1                        | (2.4)                    |
| with serious adverse events                         | 12                             | (36.4)                         | 10                       | (24.4)                   |

<div style=\"page-break-after: always\"></div>

(2.4)

(0.0)

(0.0)

(2.4)

(2.4)

(2.4)

(0.0)

(2.4)

(2.4)

(2.4)

(0.0)

(2.4)

(2.4)

(2.4)

(0.0)

(2.4)

(2.4)

(2.4)

(0.0)

| with serious drug-related adverse events                           |   1 | (3.0)   |   1 | (2.4)   |
|--------------------------------------------------------------------|-----|---------|-----|---------|
| who died                                                           |   0 | (0.0)   |   0 | (0.0)   |
| who died due to a drug-related adverse event                       |   0 | (0.0)   |   0 | (0.0)   |
| discontinued any drug due to an adverse event                      |   2 | (6.1)   |   1 | (2.4)   |
| discontinued MK-3475/PLACEBO                                       |   2 | (6.1)   |   1 | (2.4)   |
| discontinued any chemotherapy                                      |   1 | (3.0)   |   1 | (2.4)   |
| discontinued all drugs                                             |   1 | (3.0)   |   0 | (0.0)   |
| discontinued any drug due to a drug-related adverse event          |   0 | (0.0)   |   1 | (2.4)   |
| discontinued MK-3475/PLACEBO                                       |   0 | (0.0)   |   1 | (2.4)   |
| discontinued any chemotherapy                                      |   0 | (0.0)   |   1 | (2.4)   |
| discontinued all drugs                                             |   0 | (0.0)   |   0 | (0.0)   |
| discontinued any drug due to a serious adverse event               |   2 | (6.1)   |   1 | (2.4)   |
| discontinued MK-3475/PLACEBO                                       |   2 | (6.1)   |   1 | (2.4)   |
| discontinued any chemotherapy                                      |   1 | (3.0)   |   1 | (2.4)   |
| discontinued all drugs                                             |   1 | (3.0)   |   0 | (0.0)   |
| discontinued any drug due to a serious drug- related adverse event |   0 | (0.0)   |   1 | (2.4)   |
| discontinued MK-3475/PLACEBO                                       |   0 | (0.0)   |   1 | (2.4)   |
| discontinued any chemotherapy                                      |   0 | (0.0)   |   1 | (2.4)   |
| discontinued all drugs                                             |   0 | (0.0)   |   0 | (0.0)   |

a  Determined by the investigator to be related to the drug.

Grades are based on NCI CTCAE version 5.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA V25.1 preferred terms 'Neoplasm progression', 'Malignant neoplasm progression' and 'Disease progression' not related to the drug are excluded.

Database Cutoff Date: 15DEC2022.

Table 64 Summary of Outcome for Participants With Cholangitis Or Biliary Infections (Incidence &gt; 0% in One or More Treatment Groups) (APaT Population - Biliary Stent/Biliary Drain)

|                                                    | Outcome      | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   |
|----------------------------------------------------|--------------|--------------------------------|--------------------------|
| Participants in population                         |              | 33                             | 41                       |
| With one or more cholangitis or biliary infections | Overall      | 13 (39.4)                      | 12 (29.3)                |
|                                                    | Fatal        | 0 (0.0)                        | 0 (0.0)                  |
|                                                    | Not Resolved | 2 (15.4)                       | 1 (8.3)                  |
|                                                    | Resolving    | 0 (0.0)                        | 2 (16.7)                 |
|                                                    | Unknown      | 0 (0.0)                        | 0 (0.0)                  |
|                                                    | Sequelae     | 0 (0.0)                        | 1 (8.3)                  |
|                                                    | Resolved     | 11 (84.6)                      | 8 (66.7)                 |

Every participant is counted once according to the worst outcome; the ordering of the outcome is as follows: Fatal&gt;Not Resolved&gt;Resolving&gt;Unknown&gt;Sequelae&gt;Resolved.

\"Participants in population\" is used for percentage calculation for the Overall row in each section. Within each section, the overall total is used for percentage calculation for each outcome.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Database Cutoff Date: 15DEC2022.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

No new safety concerns based on laboratory abnormalities were reported in the pembrolizumab plus chemotherapy group in KEYNOTE-966. The proportion of participants with abnormal laboratory findings were comparable in the pembrolizumab plus chemotherapy and placebo plus chemotherapy group, and higher than the RSD, reflecting chemotherapy-related toxicities and the study indication. There were no notable differences in laboratory abnormalities between the treatment groups in KEYNOTE-966 (tables not shown). Laboratory abnormalities (by maximum toxicity grade worsened from baseline) in the KEYNOTE-966 pembrolizumab plus chemotherapy group versus the RSD (≥20% difference) included ALT increased, AST increased, bilirubin increased, calcium decreased, creatinine increased, GGT increased, sodium decreased, hypomagnesemia, white blood cell count decreased, lymphocyte count decreased, neutrophil count decreased, platelet count decreased, hemoglobin decreased (anemia). The laboratory abnormalities listed above were primarily CTCAE Grade 1 and Grade 2 in severity. The most frequently observed (≥10%) Grade 3 or 4 laboratory abnormalities that were similar in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups were consistent with chemotherapy-related myelosuppression (WBC decreased, hemoglobin decreased, platelet count decreased, lymphocyte count decreased, neutrophil count decreased), or underlying advanced BTC (blood bilirubin increased) (tables not shown).

## Safety in special populations

## Age

Table 65 Adverse Event Summary by Age Category (&lt;65, 65-74, &gt;=75 years) (APaT population)

|                                                                           |       |               |       |               |       |               | KN966 Placebo + Chemotherapyd   | KN966 Placebo + Chemotherapyd   | KN966 Placebo + Chemotherapyd   | KN966 Placebo + Chemotherapyd   | KN966 Placebo + Chemotherapyd   | KN966 Placebo + Chemotherapyd   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   |
|---------------------------------------------------------------------------|-------|---------------|-------|---------------|-------|---------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                                           |       |               | 65-74 | 65-74         | >=75  | >=75          | <65                             | <65                             | 65-74                           | 65-74                           | >=75                            | >=75                            | <65                                                      | <65                                                      | 65-74                                                    | 65-74                                                    | >=75                                                     | >=75                                                     |
|                                                                           | n     | (%)           | n (%) | n (%)         | n (%) | n (%)         | n (%)                           | n (%)                           | n (%)                           | n (%)                           | (%)                             | (%)                             | (%)                                                      | (%)                                                      | (%)                                                      | (%)                                                      | n (%)                                                    | n (%)                                                    |
| Participants in population                                                | 266   |               | 195   |               | 68    |               | 296                             |                                 | 181                             |                                 | 57                              |                                 | 1,218                                                    |                                                          | 653                                                      |                                                          | 162                                                      |                                                          |
| with one or more adverse events                                           | 261 5 | (98.1) (61)   | 195 0 | (100.0)       | 68 0  | (100.0) (0.0) | 296 0                           | (100.0)                         | 179                             | (98.9) (1.1)                    | 57 0                            | (100.0) (0.0)                   | 1,207 11                                                 | (99.1) (0.9)                                             | 647 6                                                    | (99.1) (0.9)                                             | 161 1                                                    | (99.4) (0.6)                                             |
| with no adverse event with drug-related adverse events                    | 244   | (91.7)        | 186   | (0.0) (95.4)  | 63    | (92.6)        | 281                             | (0.0) (94.9)                    | 2 172                           | (95.0)                          | 47                              | (82.5)                          | 1,165                                                    | (95.6)                                                   | 629                                                      | (96.3)                                                   | 154                                                      | (95.1)                                                   |
| with toxicity grade 3-5 adverse events                                    | 224   | (84.2)        | 168   | (86.2)        | 59    | (86.8)        | 241                             | (81.4)                          | 158                             | (87.3)                          | 50                              | (87.7)                          | 940                                                      | (77.2)                                                   | 506                                                      | (77.5)                                                   | 137                                                      | (84.6)                                                   |
| with toxicity grade 3-5 drug-related adverse events                       | 179   | (67.3)        | 150   | (76.9)        | 48    | (70.6)        | 193                             | (65.2)                          | 138                             | (76.2)                          | 39                              | (68.4)                          | 760                                                      | (62.4)                                                   | 422                                                      | (64.6)                                                   | 103                                                      | (63.6)                                                   |
| with serious adverse events                                               | 128   | (48.1)        | 103   | (52.8)        | 45    | (66.2)        | 133                             | (44.9)                          | 93                              | (51.4)                          | 37                              | (64.9)                          | 512                                                      | (42.0)                                                   | 353                                                      | (54.1)                                                   | 97                                                       | (59.9)                                                   |
| with serious drug-related adverse events                                  | 61    | (22.9)        | 38    | (19.5)        | 22    | (32.4)        | 34                              | (11.5)                          | 39                              | (21.5)                          | 11                              | (19.3)                          | 289                                                      | (23.7)                                                   | 205                                                      | (31.4)                                                   | 56                                                       | (34.6)                                                   |
| with any dose modificationa due to an                                     | 211   | (79.3)        | 166   | (85.1)        | 57    | (83.8)        | 233                             | (78.7)                          | 158                             |                                 | 50                              | (87.7)                          | 016                                                      | (74.7)                                                   | 534                                                      | (81.8)                                                   | 137                                                      | (84.6)                                                   |
| adverse event pembrolizumab or placebo dose                               | 153   | (57.5)        | 128   | (65.6)        | 47    | (69.1)        | 177                             | (59.8)                          | 118                             | (87.3) (65.2)                   | 44                              | (77.2)                          | 706                                                      | (58.0)                                                   | 447                                                      | (68.5)                                                   | 117                                                      | (72.2)                                                   |
| modification any chemotherapy dose modification                           |       | (21.1)        | 45    | (23.1)        |       |               |                                 |                                 | 42                              |                                 |                                 |                                 |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
|                                                                           | 56    |               |       |               | 23    | (33.8)        | 45                              | (15.2)                          |                                 | (23.2)                          | 26                              | (45.6)                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| who died                                                                  |       | (4.1)         | 10    | (5.1)         | 10    | (14.7)        | 22                              | (7.4)                           | 15                              | (8.3)                           | 12                              | (21.1)                          | 58                                                       | (4.8)                                                    | 49                                                       | (7.5)                                                    | 32                                                       | (19.8)                                                   |
| who died due to a drug-related adverse event                              | 4     | (1.5)         | 2     | (1.0)         | 2     | (2.9)         | 0                               | (0.0)                           | 2                               | (1.1)                           | 1                               | (1.8)                           | 17                                                       | (1.4)                                                    | 15                                                       | (2.3)                                                    | 11                                                       | (6.8)                                                    |
| discontinued any drug due to an adverse event                             | 62    | (23.3)        | 51    | (26.2)        | 25    | (36.8)        | 52                              | (17.6)                          | 44                              | (24.3)                          | 26                              | (45.6)                          | 275                                                      | (22.6)                                                   | 209                                                      | (32.0)                                                   | 67                                                       | (41.4)                                                   |
| discontinued pembrolizumab or placcbo                                     | 33    | (12.4)        | 28    | (14.4)        | 16    | (23.5)        | 29                              | (9.8)                           | 21                              | (11.6)                          | 16                              | (28.1)                          | 162                                                      | (13.3)                                                   | 131                                                      | (20.1)                                                   | 52                                                       | (32.1)                                                   |
| discontinued any chemotherapy discontinued any drug due to a drug-related | 56 48 | (21.1) (18.0) | 45 37 | (23.1) (19.0) | 23 17 | (33.8) (25.0) | 45 36                           | (15.2) (12.2)                   | 42 31                           | (23.2) (17.1)                   | 26 14                           | (45.6) (24.6)                   | 228                                                      | (18.7)                                                   | 161                                                      | (24.7)                                                   | 45                                                       | (27.8)                                                   |
| adverse event discontinued pembrolizumab or placebo                       | 20    | (7.5)         | 19    | (9.7)         |       | (11.8)        | 16                              | (5.4)                           | 7                               | (3.9)                           | 3                               | (5.3)                           | 116                                                      |                                                          | 88                                                       |                                                          | 30                                                       | (18.5)                                                   |
| discontinued any chemotherapy                                             | 43    | (16.2)        |       |               | 8     |               | 30                              | (10.1)                          |                                 | (16.0)                          | 14                              | (24.6)                          |                                                          | (9.5)                                                    |                                                          | (13.5)                                                   |                                                          |                                                          |
| discontinued anydrug due toa serious adverse event                        | 35    | (13.2)        |       | (16.4) (11.8) | 15 18 | (22.1) (26.5) | 22                              | (7.4)                           | 22                              | (12.2)                          | 17                              | (29.8)                          | 154                                                      | (12.6)                                                   | 122                                                      | (18.7)                                                   | 51                                                       | (31.5)                                                   |
| discontinued pembrolizumab or placebo                                     | 29    | (10.9)        | 17    | (8.7)         | 15    | (22.1)        | 20                              | (6.8)                           | 19                              | (10.5)                          | 15                              | (26.3)                          | 120                                                      | (9.9)                                                    | 101                                                      | (15.5)                                                   | 47                                                       | (29.0)                                                   |
| discontinued any chemotherapy                                             | 30    | (11.3)        | 21    | (10.8)        | 16    | (23.5)        | 19                              | (6.4)                           | 17                              | (9.4)                           | 16                              | (28.1)                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| discontinued any drug due to a serious drug- related adverse event        | 23    | (8.6)         | 9     | (4.6)         | 9     | (13.2)        | 8                               | (2.7)                           | 8                               | (4.4)                           | 4                               | (7.0)                           | 112                                                      | (9.2)                                                    | 78                                                       | (11.9)                                                   | 30                                                       | (18.5)                                                   |
| discontinued pembrolizumab or placcbo                                     | 17    | (6.4)         | 8     | (4.1)         |       | (10.3)        |                                 | (2.4)                           | 5                               | (2.8)                           | 2                               | (3.5)                           | 79                                                       | (6.5)                                                    | 62                                                       | (9.5)                                                    | 26                                                       | (16.0)                                                   |

Sex . The AE profile in the pembrolizumab plus chemotherapy group in KEYNOTE-966 was generally similar between male and female participants (tables not shown). The AE profile was similar for both sexes in the Pooled Combination Dataset (with the exception of SAEs, which were more common in males) and the RSD (data not shown).

<div style=\"page-break-after: always\"></div>

ECOG Status . The AE profile in the pembrolizumab plus chemotherapy group in KEYNOTE-966 was generally similar between participants with an ECOG status of 0 and participants with an ECOG status of 1, except for a higher incidence of all causality SAEs in participants with an ECOG status of 1 (data not shown).

The same pattern (higher incidence of all causality SAEs in participants with an ECOG status of 1 vs 0) was generally observed in the Pooled Combination Dataset and the RSD. Additionally, the incidence of drug-related SAEs was higher in participants with ECOG status of 1 vs 0 in the Pooled Combination Dataset, the incidence of Grade 3 to 5 all causality AEs was higher in participants with ECOG status of 1 vs 0 in the RSD, and the incidence of drug-related AEs was higher in participants with ECOG status of 0 vs 1 in the RSD.

Region . The AE profile based on region in the pembrolizumab plus chemotherapy group in KEYNOTE-966 was generally consistent with both the Pooled Combination Dataset and the RSD. No notable differences in AE profile were observed between North America, Western Europe, and the rest of the world (data not shown).

Use in Pregnancy and Lactation . There were no reports of pregnancy in KEYNOTE-966.

## Safety related to drug-drug interactions and other interactions

As pembrolizumab is an IgG antibody that is administered parenterally and cleared by catabolism, food and drug-drug interaction (DDI) are not anticipated to influence exposure.

Drugs that affect the cytochrome P450 enzymes, and other metabolizing enzymes, are not expected to interfere with the metabolism of an IgG antibody. The IgG antibodies, in general, do not directly regulate the expression of cytochrome P450 enzymes, other enzymes, or transporters involved in drug elimination. Therefore, no dedicated DDI studies have been performed. In addition, in vitro experiments and studies conducted in preclinical species have been shown to have limited value in predicting DDI potential in humans. Therefore, no preclinical pharmacokinetic studies were conducted to assess the propensity of pembrolizumab to be a victim or perpetrator of pharmacokinetic DDIs. Similarly, the potential of DDI between pembrolizumab and chemotherapy agents is expected to be low. No impact of co-administered chemotherapy on pembrolizumab PK was observed in KEYNOTE-021 cohort G. Studies evaluating pharmacodynamic drug interactions with pembrolizumab have not been conducted. However, as systemic corticosteroids may be used in combination with pembrolizumab to ameliorate potential side effects, the potential for a pharmacokinetic DDI with pembrolizumab as a victim was assessed as part of the population pharmacokinetic analysis (data not shown). No relationship was observed between prolonged use of systemic corticosteroids and pembrolizumab exposure. Nevertheless, the use of systemic corticosteroids or other immunosuppressants before the start of pembrolizumab treatment should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab treatment to treat immune-mediated adverse reactions. Corticosteroids can also be used as premedication, when pembrolizumab is used in combination with chemotherapy, as antiemetic prophylaxis and/or to alleviate chemotherapy-related adverse reactions (see section 4.5 of the SmPC).

## Discontinuation due to adverse events

In KEYNOTE-966, the proportion of participants in the pembrolizumab plus chemotherapy group who experienced 1 or more AEs that led to discontinuation of any study treatment was generally similar compared with the placebo plus chemotherapy group (26.1% vs 22.8% (see Table 49), exposure adjusted 3.43 vs 3.18 (see Table 50)). The incidence of specific AEs was similar between both treatment

<div style=\"page-break-after: always\"></div>

groups in KEYNOTE-966 (see Table 51). The proportion of participants discontinuing any study treatment due to cholangitis was low in both the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups (0.4% and 0.6%, respectively) (data not shown).

The proportion of participants with AEs leading to discontinuations of any study treatment in the pembrolizumab plus chemotherapy group (26.1%) was similar to the Pooled Combination Dataset (27.1%) and higher compared with the RSD (14.0%) (see Table 49); differences between the pembrolizumab plus chemotherapy group and the RSD were driven partly by chemotherapy-related toxicities (neutrophil count decreased and platelet count decreased) (data not shown).

A similar percentage of participants in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups in KEYNOTE-966 experienced AEs leading to discontinuation of chemotherapy (23.4% and 21.2%, respectively). These percentages were also similar to the percentage of participants with AEs leading to discontinuation of chemotherapy in the Pooled Combination Dataset (20.9%) (see Table 49).

Discontinuation of pembrolizumab/placebo due to AEs occurred in a similar proportion of participants in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups (14.6% vs 12.4%). These percentages were also generally consistent with the Pooled Combination Dataset (17.0%) and the RSD (14.0%), with no clinically meaningful differences in AEs between the groups and indicate no new safety concern for pembrolizumab (see Table 49).

In KEYNOTE-966, the proportion of participants with drug-related AEs leading to discontinuation of any study treatment was generally similar in the pembrolizumab plus chemotherapy group compared with the placebo plus chemotherapy group (19.3% vs 15.2%) (see Table 49). The most frequently reported AEs (≥1% incidence) leading to discontinuation of any study treatment in both treatment groups were neutrophil count decreased, and blood creatinine increased (data not shown).

The proportion of participants with drug-related AEs leading to discontinuation of any study treatment in the pembrolizumab plus chemotherapy group (19.3%) was similar to the Pooled Combination Dataset (21.3%) and higher compared with the RSD (8.4%) (see Table 49). Differences in the pembrolizumab plus chemotherapy group compared with the RSD were partly driven by higher incidences of chemotherapy-associated AEs (e.g., neutrophil count decreased, platelet count decreased) (data not shown).

In KEYNOTE-966, the proportion of participants with drug-related AEs leading to discontinuation of pembrolizumab/placebo was generally similar in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups (8.9% vs 4.9%) (see Table 49). The most frequently reported drug-related AEs (≥2 participants) leading to discontinuation of pembrolizumab in the pembrolizumab plus chemotherapy group were pneumonitis, platelet count decreased, enterocolitis, pulmonary embolism, immune-mediated hepatitis, and autoimmune hepatitis (data not shown).

The proportion of participants in the pembrolizumab plus chemotherapy group with drug-related AEs leading to discontinuation of pembrolizumab (8.9%) was similar to those in the both the Pooled Combination Dataset (11.5%) and the RSD (8.4%) (see Table 49).

Participant narratives for participants in pembrolizumab plus chemotherapy group with drug-related AEs leading to discontinuation of intervention are provided in the CSR (data not shown). The proportion of participants who experienced 1 or more AEs that led to interruption of any study treatment was similar in the pembrolizumab plus chemotherapy group compared with the placebo plus chemotherapy group (70.5% vs 70.6%). The most frequently reported AEs (≥5%) in both groups were neutrophil count decreased, platelet count decreased, WBC count decreased, and anemia, reflecting common chemotherapy-related toxicities (data not shown).

<div style=\"page-break-after: always\"></div>

The proportion of participants with AEs leading to interruption of any study treatment in the pembrolizumab plus chemotherapy group (70.5%) was similar to the Pooled Combination Dataset (64.5%) and higher compared with the RSD (26.1%) (data not shown).

The proportion of participants with AEs resulting in treatment interruptions of pembrolizumab/placebo was similar in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups (55.0% vs 58.1%). The most frequently reported AEs (≥5% incidence) leading to pembrolizumab/placebo interruptions included neutrophil count decreased, platelet count decreased, and anemia, consistent with common chemotherapy-related toxicities (data not shown).

The proportion of participants with treatment interruptions of pembrolizumab due to AEs in the pembrolizumab plus chemotherapy group (55.0%) was similar to the Pooled Combination Dataset (54.9%) and higher compared with the RSD (26.1%). Differences between the pembrolizumab plus chemotherapy group and the RSD were partly driven by higher incidences of chemotherapy-associated AEs (neutrophil count decreased, platelet count decreased, and anemia) (data not shown).

The proportion of participants with drug-related AEs leading to interruption of any study treatment was similar in the pembrolizumab plus chemotherapy group compared with the placebo plus chemotherapy group (56.9% vs 57.1%). The most frequently reported drug-related AEs (≥5%) in both groups were neutrophil count decreased, platelet count decreased, WBC count decreased, and anemia, reflecting common chemotherapy-related toxicities. The proportion of participants with drug-related AEs leading to interruption of any study treatment in the pembrolizumab plus chemotherapy group was also similar to that observed in the Pooled Combination Dataset (54.5%) (data not shown).

The proportion of participants with treatment interruption due to drug-related AEs was higher in the pembrolizumab plus chemotherapy group compared with the RSD (56.9% vs 14.7%). Differences were partly driven by higher incidences of chemotherapy-associated AEs (neutrophil count decreased, platelet count decreased, WBC count decreased, and anemia) (data not shown).

The proportion of participants with treatment interruptions of pembrolizumab/placebo were similar in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups (38.6% vs 40.6%). The most frequently reported drug-related AEs (≥5% incidence) in these groups included neutrophil count decreased, platelet count decreased, and anemia, consistent with common chemotherapy-related toxicities (data not shown).

The proportion of participants with treatment interruptions of pembrolizumab due to drug-related AEs was higher in the pembrolizumab plus chemotherapy group compared with the RSD (38.6% vs 14.7%) (data not shown).

## Adverse drug reactions (ADRs)

Section 4.8 of the SmPC has been updated to reflect the addition of the KEYNOTE-966 population of BTC patients, receiving pembrolizumab in combination with gemcitabine and cisplatin, into the current 'pembrolizumab in combination with chemotherapy' pooled dataset (N=4787).

<div style=\"page-break-after: always\"></div>

T able 66 Adverse reactions in patients treated with pembrolizumab in combination with chemotherapy

|                                      |                                      | Combination Therapy (N=4787)         | Combination Therapy (N=4787)         |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
|                                      |                                      | All AEs % (n)                        | Gr 3-5 AEs                           |
| Infections and infestations          | Infections and infestations          | Infections and infestations          | Infections and infestations          |
| Common                               | Pneumonia                            | 7.3% (349)                           | 196                                  |
| Blood and lymphatie system disorders | Blood and lymphatie system disorders | Blood and lymphatie system disorders | Blood and lymphatie system disorders |
| Very common                          | Anaemia                              | 52.5% (2513)                         | 911                                  |
| Very common                          | Neutropenia                          | 27.5% (1318)                         | 808                                  |
| Very common                          | Thrombocytopenia                     | 14.8% (708)                          | 227                                  |
| Common                               | Febrile Neutropenia                  | 5.9% (284)                           | 274                                  |
| Common                               | Leukopenia                           | 9.4% (452)                           | 163                                  |
| Common                               | Lymphopenia                          | 3.0% (145)                           | 44                                   |
| Uncommon                             | Eosinophilia                         | 0.6% (28)                            | 2                                    |
| Rare                                 | Haemolytic Anaemia                   | 0.06% (3)                            | 2                                    |
| Rare                                 | Immune Thrombocytopenia              | 0.06% (3)                            | 2                                    |
| Immune system disorders              | Immune system disorders              | Immune system disorders              | Immune system disorders              |
| Common                               | Infusion Reactionsa                  | 7.4% (354)                           | 64                                   |
| Rare                                 | Sarcoidosis                          | 0.02% (1)                            | 0                                    |
| Endoerine disorders                  | Endoerine disorders                  | Endoerine disorders                  | Endoerine disorders                  |
| Very common                          | Hypothyroidismb                      | 13.3% (637)                          | 16                                   |
| Common                               | Adrenal Insufficiencyc               | 1.2% (57)                            | 24                                   |
| Common                               | Thyroiditisd                         | 1.2% (57)                            | 6                                    |
| Common                               | Hyperthyroidism                      | 5.2% (248)                           | 5                                    |
| Uncommon                             | Hypophysitise                        | 0.8% (37)                            | 19                                   |
| Rare                                 | Hypoparathyroidism                   | 0.04% (2)                            | 0                                    |
| Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   |
| Very common                          | Hypokalaemia                         | 11.6% (554)                          | 176                                  |
| Very common                          | Decreased Appetite                   | 27.9% (1335)                         | 107                                  |
| Common                               | Hyponatraemia                        | 7.7% (369)                           | 165                                  |
| Common                               | Hypocalcaemia                        | 4.4% (210)                           | 32                                   |
| Uncommon                             | Type I Diabetes Mellitusf            | 0.4% (17)                            | 16                                   |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                    | Combination Therapy (N=4787)   | Combination Therapy (N=4787)   |
|-------------------------------------------------|----------------------------------------------------|--------------------------------|--------------------------------|
|                                                 |                                                    | All AEs % (m)                  | Gr3-5 AEs                      |
| Psychiatrie disorders                           |                                                    |                                |                                |
| Very common                                     | Insomnia                                           | 10.5% (505)                    | 6                              |
| Nervous system disorders                        |                                                    |                                |                                |
| Very common                                     | Neuropathy Peripheral                              | 14.8% (708)                    | 51                             |
| Very common                                     | Headache                                           | 14.0% (672)                    | 15                             |
| Common                                          | Dizziness                                          | 9.8% (467)                     | 14                             |
| Common                                          | Dysgeusia                                          | 8.9% (424)                     | 2                              |
| Common                                          | Lethargy                                           | 1.2% (56)                      | 2                              |
| Uncommon                                        | Encephalitisg                                      | 0.1% (7)                       | 7                              |
| Uncommon                                        | Epilepsy                                           | 0.1% (7)                       | 3                              |
| Rare                                            | Myasthenic Syndrome                                | 0.06% (3)                      | 3                              |
| Rare                                            | Guillain-Banre Syndromeh                           | 0.04% (2)                      | 2                              |
| Rare                                            | Optic Neuritis                                     | 0.02% (1)                      | 1                              |
| Eye disorders                                   |                                                    |                                |                                |
| Common                                          | Dry Eye                                            | 3.1% (149)                     | 1                              |
| Uncommon                                        | Uveitisi                                           | 0.1% (5)                       | 0                              |
| Cardiae disorders                               |                                                    |                                |                                |
| Common                                          | Cardiac Arrhythmia (Including Atrial Fibrillation) | 3.6% (173)                     | 45                             |
| Uncommon                                        | Myocarditisk                                       | 0.2% (9)                       | 7                              |
| Uncommon                                        | Pericardial Effusion                               | 0.4% (19)                      | 7                              |
| Uncommon                                        | Pericarditis                                       | 0.1% (7)                       | 2                              |
| Vascular disorders                              |                                                    |                                |                                |
| Common                                          | Hypertension                                       | 6.2% (295)                     | 126                            |
| Uncommon                                        | Vasculitisl                                        | 0.6% (31)                      | 4                              |
| Respiratory, thoracie and mediastinal disorders | Respiratory, thoracie and mediastinal disorders    |                                |                                |
| Very common                                     | Dyspnoea                                           | 11.2% (535)                    | 60                             |
| Very common                                     | Cough                                              | 15.9% (762)                    | 5                              |

<div style=\"page-break-after: always\"></div>

|                                        |                                        | Combination Therapy (N-4787)           | Combination Therapy (N-4787)           |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|                                        |                                        | All AEs % (m)                          | Gr 3-5 AEs 11                          |
| Common                                 | Pneumonitism                           | 4.1% (196)                             | 72                                     |
| Gastrointestinal disorders             | Gastrointestinal disorders             | Gastrointestinal disorders             | Gastrointestinal disorders             |
| Very common                            | Diarrhoea                              | 34.2% (1637)                           | 197                                    |
| Very common                            | Vomiting                               | 28.9% (1384)                           | 173                                    |
| Very common                            | Nausea                                 | 51.4% (2460)                           | 163                                    |
| Very common                            | Abdominal Painn                        | 19.4% (929)                            | 66                                     |
| Very common                            | Constipation                           | 31.8% (1522)                           | 17                                     |
| Common                                 | Colitiso                               | 2.8% (136)                             | 68                                     |
| Common                                 | Gastritis                              | 2.1% (100)                             | 8                                      |
| Common                                 | Dry Mouth                              | 4.6% (218)                             | 1                                      |
| Uncommon                               | Pancreatitisp                          | 0.5% (22)                              | 17                                     |
| Uncommon                               | Gastrointestinal Ulcerationq           | 0.5% (22)                              | 3                                      |
| Rare                                   | Small Intestinal Perforation           | 0.04% (2)                              | 2                                      |
| Hepatobiliary disorders                | Hepatobiliary disorders                | Hepatobiliary disorders                | Hepatobiliary disorders                |
| Common                                 | Hepatitisr                             | 1.3% (60)                              | 45                                     |
| Rare                                   | Cholangitis Sclerosings                | 0.04% (2)                              | 2                                      |
| Skin and subeutaneous tissue disorders | Skin and subeutaneous tissue disorders | Skin and subeutaneous tissue disorders | Skin and subeutaneous tissue disorders |
| Very common                            | Alopecia                               | 24.7% (1181)                           | 6                                      |
| Very common                            | Pruritust                              | 14.3% (683)                            | 5                                      |
| Very common                            | Rashu                                  | 21.3% (1018)                           | 4                                      |
| Common                                 | Severe Skin Reactionsv                 | 2.6% (125)                             | 109                                    |
| Common                                 | Erythema                               | 3.8% (184)                             | 3                                      |
| Common                                 | Dermatitis                             | 1.5% (73)                              | 3                                      |
| Common                                 | Dry Skin                               | 5.3% (256)                             | 2                                      |
| Common                                 | Dermatitis Acneiform                   | 2.0% (97)                              | 2                                      |
| Common                                 | Eczema                                 | 1.2% (58)                              | 1                                      |
| Uncommon                               | Psoriasis                              | 0.4% (21)                              | 4                                      |
| Uncommon                               | Lichenoid Keratosisw                   | 0.1% (5)                               | 1                                      |
| Uncommon                               | Vitiligox                              | 0.6% (28)                              | 0                                      |
| Uncommon                               | Papule                                 | 0.2% (10)                              | 0                                      |
| Rare                                   | Stevens-Johnson Syndrome               | 0.04% (2)                              | 2                                      |

<div style=\"page-break-after: always\"></div>

|                                                     |                                                     | Combination Therapy (N-4787)                        | Combination Therapy (N-4787)                        |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                     |                                                     | All AEs % (m)                                       | Gr 3-5 AEs                                          |
| Rare                                                | Erythema Nodosum                                    | 0.08% (4)                                           | 0                                                   |
| Rare                                                | Hair Colour Changes                                 | 0.02% (1)                                           | 0                                                   |
| Musculoskeletal and connectivetissue disorders      | Musculoskeletal and connectivetissue disorders      | Musculoskeletal and connectivetissue disorders      | Musculoskeletal and connectivetissue disorders      |
| Very common                                         | Musculoskeletal Painy                               | 14.1% (677)                                         | 35                                                  |
| Very common                                         | Arthralgia                                          | 15.8% (756)                                         | 31                                                  |
| Common                                              | Myositisz                                           | 9.0% (432)                                          | 17                                                  |
| Common                                              | Pain In Extremity                                   | 7.1% (342)                                          | 6                                                   |
| Common                                              | Arthritisaa                                         | 1.6% (76)                                           | 7                                                   |
| Uncommon                                            | Tenosymovitisbb                                     | 0.4% (18)                                           | 1                                                   |
| Rare                                                | Sjogren's Syndrome                                  | 0.02% (1)                                           | 0                                                   |
| Renal and urinary disorders                         | Renal and urinary disorders                         | Renal and urinary disorders                         | Renal and urinary disorders                         |
| Common                                              | Acute Kidney Injury                                 | 3.5% (166)                                          | 83                                                  |
| Uncommon                                            | Nephritiscc                                         | 0.7% (35)                                           | 19                                                  |
| Uncommon                                            | Cystitis Noninfective                               | 0.2% (8)                                            | 0                                                   |
| General disorders and administration siteconditions | General disorders and administration siteconditions | General disorders and administration siteconditions | General disorders and administration siteconditions |
| Very common                                         | Fatigue                                             | 34.7% (1662)                                        | 239                                                 |
| Very common                                         | Asthenia                                            | 19.1% (912)                                         | 155                                                 |
| Very common                                         | Pyrexia                                             | 19.0% (911)                                         | 40                                                  |
| Common                                              | Oedemadd                                            | 4.6% (222)                                          | 8                                                   |
| Common                                              | Influenza Like Illness                              | 2.8% (133)                                          | 2                                                   |
| Common                                              | Chills                                              | 2.9% (140)                                          | 0                                                   |
| Investigations                                      | Investigations                                      | Investigations                                      | Investigations                                      |
| Very common                                         | Alanine Aminotransferase Increased                  | 17.7% (846)                                         | 154                                                 |
| Very common                                         | Aspartate Aminotransferase Increased                | 17.7% (847)                                         | 125                                                 |
| Common                                              | Blood Bilirubin Increased                           | 5.6% (270)                                          | 49                                                  |
| Common                                              | Blood Alkaline Phosphatase Increased                | 6.6% (318)                                          | 39                                                  |
| Common                                              | Blood Creatinine Increased                          | 9.1% (435)                                          | 24                                                  |
| Common                                              | Hypercalcaemia                                      | 1.7% (79)                                           | 20                                                  |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                              | Combination Therapy (N-4787)                                                                                                                                                                                                                                                 | Combination Therapy (N-4787)                                                                                                                                                                                                                                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                              | All AEs % (m)                                                                                                                                                                                                                                                                | Gr 3-5 AEs 11                                                                                                                                                                                                                                                                |
| Uncommon                                                                                                                                                                                                                                                                     | Amylase Increased                                                                                                                                                                                                                                                            | 0.6% (28)                                                                                                                                                                                                                                                                    | 9                                                                                                                                                                                                                                                                            |
| Every participant is counted a single time for each applicable row. a. Infusion Reactions (Anaphylactic Reaction, Cytokine Release Syndrome, Drug Hypersensitivity, Hypersensitivity, Infusion Related Hypersensitivity Reaction, Infusion Related Reaction, Serum Sickness) | Every participant is counted a single time for each applicable row. a. Infusion Reactions (Anaphylactic Reaction, Cytokine Release Syndrome, Drug Hypersensitivity, Hypersensitivity, Infusion Related Hypersensitivity Reaction, Infusion Related Reaction, Serum Sickness) | Every participant is counted a single time for each applicable row. a. Infusion Reactions (Anaphylactic Reaction, Cytokine Release Syndrome, Drug Hypersensitivity, Hypersensitivity, Infusion Related Hypersensitivity Reaction, Infusion Related Reaction, Serum Sickness) | Every participant is counted a single time for each applicable row. a. Infusion Reactions (Anaphylactic Reaction, Cytokine Release Syndrome, Drug Hypersensitivity, Hypersensitivity, Infusion Related Hypersensitivity Reaction, Infusion Related Reaction, Serum Sickness) |

## Post marketing experience

The safety profile of pembrolizumab was summarized in the Periodic Safety Update Report covering the period 04-SEP-2021 through 03-SEP-2022, specifically Appendix 20.3 (Numbers of Adverse Drug

<div style=\"page-break-after: always\"></div>

Reactions by Preferred Term from Postauthorization Sources). No revocation or withdrawal of pembrolizumab registration for safety reasons has occurred in any country.

## 2.5.1. Discussion on clinical safety

The safety profile of pembrolizumab in combination with cisplatin and gemcitabine in adult patients with locally advanced unresectable or metastatic biliary tract cancers has been assessed in the phase 3 randomized, placebo-controlled KEYNOTE-966 clinical trial. The safety analysis was presented as comparative of chemotherapy vs chemotherapy plus immunotherapy in the context of KEYNOTE-966. At data cut-off of 15-DEC-2022 (final analysis (FA)), all participants who received at least 1 dose of study intervention were included in the safety analysis (n=529 in the interventional arm; n=534 in the control arm). Additionally, the MAH provided safety data from the reference datasets of previous studies with pembrolizumab used as a single agent (n=7 631) or in combination with chemotherapy (n=2 033).

The KEYNOTE-966 trial population resulted enriched in subjects of Asian race (45.9% in the pembrolizumab plus chemotherapy group and 46.6% in the placebo plus chemotherapy group) as compared with the reference datasets of chemotherapy plus immunotherapy and immunotherapy alone (10.8 and23.2%, respectively). Such a difference is in part justified by the study indication, given the epidemiology of cholangiocarcinoma. The population was well balanced according to age, ECOG performance status and gender.

Exposure to the study drugs was similar in the pembrolizumab plus chemotherapy and chemotherapy plus placebo arms (median 6.37 vs 5.54 months), as it was for the mean number of administrations (20.35 vs 18.89 administrations). The slightly longer exposure in the pembrolizumab arm is likely a result of the longer progression-free survival.

The proportion of AEs reported in the two arms was comparable. However, treatment-related serious AEs were higher in subjects receiving pembrolizumab plus chemotherapy than chemotherapy alone (22.9% vs 15.7%). In addition, pruritus, rash and pyrexia were more common in patients receiving pembrolizumab; however, the incidence of these AEs was not higher than observed in the pooled datasets of pembrolizumab alone or in combination with various chemotherapies. Rash and pruritus have been associated with pembrolizumab. The differences in the safety profile between chemotherapy plus pembrolizumab and pembrolizumab alone were commonly ascribed to the chemo-related haematological toxicity, such as neutrophil count decreased, anaemia, platelet count decreased, nausea, white blood cell count (WBC) decreased, vomiting, constipation.

A higher proportion of participants in the pembrolizumab plus chemotherapy group experienced AEs of ALT increased and AST increased compared with the RSD, that could be associated with the study indication BTC. However, the frequency of ALT and AST increased was higher in the control arm of KEYNOTE-966 study.

A higher proportion of participants in the pembrolizumab plus chemotherapy group had Grade 3 to 4 AEs compared with the RSD, possibly due to chemotherapy and underlying malignancy in the KEYNOTE966 .

Overall, the proportion of participants in KEYNOTE-966 who experienced 1 or more drug-related AEs was similar between the pembrolizumab plus chemotherapy and the placebo plus chemotherapy groups (93.2% vs 93.6%). The most frequently reported drug-related AEs (incidence ≥ 10%) were similar between the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups. Consistently with the analysis of all AEs, pruritus, rash and hypothyroidism were more common in patients treated with pembrolizumab than placebo. The proportion of participants with drug-related AEs in the pembrolizumab plus chemotherapy group (93.2%) was similar to the Pooled Combination Dataset

<div style=\"page-break-after: always\"></div>

(95.8%) and higher than in the RSD (71.6%). Common drug-related AEs in the pembrolizumab plus chemotherapy group included common chemotherapy-related toxicities of neutrophil count decreased, anemia, platelet count decreased, nausea, WBC decreased, fatigue, decreased appetite, vomiting, constipation, and rash.

Grade 3 to 5 adverse events occurred in a comparable proportion in the two study arms (85.3% vs 84.1%). The most frequently reported Grade 3 to 5 AEs (incidence ≥5%) in the pembrolizumab plus chemotherapy group were neutrophil count decreased, anaemia, platelet count decreased, WBC count decreased, and cholangitis. The proportion of participants with 1 or more drug-related SAEs was higher in the pembrolizumab plus chemotherapy group compared with the placebo plus chemotherapy group (22.9% vs 15.7%). The most frequently reported drug-related SAEs (incidence ≥1%) were platelet count decreased, neutrophil count decreased, pyrexia, anaemia, febrile neutropenia, and pneumonitis in the pembrolizumab plus chemotherapy group, and platelet count decreased and febrile neutropenia in the placebo plus chemotherapy group. No meaningful differences in the frequency of specific drug-related SAEs were observed between the treatment groups.  Also, when compared with the reference pooled dataset of pembrolizumab, with or without chemotherapy, cholangitis emerged as a more common event in KEYNOTE-966; however, such a difference can still be interpreted based on the study indication, that is biliary cancers.

Fatal events occurred in 5.9% and 9.2% of subjects enrolled in the pembrolizumab and placebo arm, respectively. The most frequently reported AEs resulting in death (&gt;2 participants) in KEYNOTE-966 were pneumonia (0.8%), death (0.6%), and sepsis (0.6%) in the pembrolizumab plus chemotherapy group, and sepsis (1.1%), death (0.9%), COVID-19 (0.7%), cerebral infarction (0.6%), and pulmonary embolism (0.6%) in the placebo plus chemotherapy group. Deaths due to drug-related AEs were reported in 1.5% of the pembrolizumab plus chemotherapy group and 0.6% of the placebo plus chemotherapy group.

Clarifications were requested to the MAH on the event reported as 'death' in the control arm, as it was unclear if this was a case of thyroiditis in a patient with pre-existing risk of fatal arrythmia, not managed in the proper way. The additional data provided however did not allow to conclude on a reasonable possibility of a causality between pembrolizumab and the event of death given the underlying cardiovascular and pulmonary comorbidities, reported sudden onset of the event, and a lack of an autopsy report.

Additional clarification regarding the event of death due to 'viral pneumonia', based on the available data including fever, neutropenia, lymphopenia and CT imaging finding, it was agreed with the MAH that likely the event was secondary to an infectious process in the setting of underlying malignancy and administration of chemotherapy.

No new indication-specific AEOSI causally associated with pembrolizumab were identified in the pembrolizumab plus chemotherapy group in KEYNOTE-966.The frequency, severity, and types of AEOSI observed in the pembrolizumab plus chemotherapy group were generally consistent with pembrolizumab used as a single agent. The overall incidence of AEOSI was similar in the pembrolizumab plus chemotherapy group (22.1%) compared with Pooled Combination Dataset (28.8%) and the RSD (26.8%), and higher than chemotherapy alone (12.9%). There was 1 fatal AEOSI (pneumonitis) in the pembrolizumab plus chemotherapy group considered related to both chemotherapy (gemcitabine) and pembrolizumab by the investigator. Pneumonitis is a well-known adverse drug reaction of pembrolizumab, and the risk of fatal events of pneumonitis is already included in the SmPC. The proportion of participants with an event in the AEOSI category of hepatitis was similar in the pembrolizumab plus chemotherapy group (1.7%) compared with the Pooled Combination Dataset (1.2%) and the RSD (1.0%). Overall, there were no data suggesting any new safety concerns for known pembrolizumab AEOSI when combining pembrolizumab with chemotherapy.

<div style=\"page-break-after: always\"></div>

In KEYNOTE-966, the proportion of participants in the pembrolizumab plus chemotherapy group who experienced 1 or more AEs that led to discontinuation of any study treatment was generally similar compared with the placebo plus chemotherapy group (26.1% vs 22.8%).

Safety in special populations was described. The safety findings in the pembrolizumab plus chemotherapy group of KEYNOTE-966 based on age, sex, or ECOG performance status were generally consistent with the established safety profile of pembrolizumab monotherapy and the known safety profile of chemotherapy.

Age: The AE profile based on age in the pembrolizumab plus chemotherapy group was generally consistent with the RSD. The AE profile in the pembrolizumab plus chemotherapy group was generally similar between participants who were &lt;65 years and those ≥65 years with the exception of Grade 3 to 5 drug-related AEs, SAEs, and pembrolizumab dose modifications, which were more frequent in participants ≥65 years of age. A similar pattern was observed between the age groups in the Pooled Combination Dataset (with the exception of Grade 3 to 5 drug-related AEs) and the RSD.

The AE profile between age categories &lt;65 years, 65 to 74 years, and ≥75 years was generally similar in the pembrolizumab plus chemotherapy group, with the exception of SAEs (all causality and drug-related), deaths due to AEs, chemotherapy dose modifications, and discontinuations due to AEs, which were more frequent in participants ≥75 years of age compared with those &lt;65 years or 65 to 74 years. The summary of AEs by age groups (&lt;65, 65 to 74, and ≥75 years) in the results section shows that the proportion of participants in the pembrolizumab plus chemotherapy group who experienced AEs related to falling and cardiovascular events were generally comparable across age groups. Infections, cerebrovascular events, and central nervous system events were more frequent in the ≥75-year age group. Due to the relatively small number of participants in the ≥75-year age group, these results should be interpreted with caution.

Sex: The overall safety profile was similar in male and female individuals, with higher frequency of SAE reported in males.

ECOG status: Similarly, safety was comparable in ECOG 0 vs 1, with higher rates of SAEs in ECOG 1, which might be expected.

Region: No remarkable differences were reported across geographical regions.

Hepatic events of clinical interest (HECI) were specifically analysed in KEYNOTE-966, given the risk of hepatic events in patients with BTC. Reassuringly, in KEYNOTE-966, the rate of HECI was generally similar in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups (9.3% vs 10.7%); further, there were no reported events of AEOSI such as cholangitis sclerosing, autoimmune cholangitis, or immune-mediated cholangitis in the pembrolizumab plus chemotherapy group, and no cases of viral hepatitis flare were observed. The majority of HECI events were of CTCAE Grade 1 to 2 toxicity. The proportion of participants with Grade 3 to 5 HECI were similar in the pembrolizumab plus chemotherapy group (9.1%) and the placebo plus chemotherapy (9.7%). Most HECI were resolved or resolving in both intervention groups. The median time to onset of the first HECI was 88.0 days (range 3 to 711 days) in the pembrolizumab plus chemotherapy group and 146.0 (range 2 to 579 days) in the placebo plus chemotherapy group.

Nevertheless, the MAH was requested to further investigate the relation of hepatic events with biliary stent in view of the previous findings of TOPAZ-1 study and the corresponding warning in the SmPC for Imfinzi. The additional data provided showed that cholangitis and biliary infections are commonly and expectedly increased in the presence of a biliary drainage. The MAH reported that such an increase is 3 to 4-fold than in the lack of any drainage. While limited by the low number of patients in this subgroup analysis is acknowledged, still the risk of biliary complications appears higher when patients have a biliary drainage in the pembrolizumab rather than in the control arm (39% vs 29%) (see Table 63). In addition,

<div style=\"page-break-after: always\"></div>

the consistency with a very similar study may reinforce the finding. A warning has been included in section 4.4 of the SmPC to reflect the findings over the rate of biliary complications in patients with biliary stent and drains.

The MAH reported the rate of AEs separately for subjects with liver metastasis at the study enrolment. There is no increase of the liver specific AEs, including AEOSI or severe events.

The AEs leading to treatment interruption in the KEYNOTE-966 are consistent with the established safety profile of pembrolizumab monotherapy, chemotherapy and/or underlying BTC. The incremental toxicity when compared with RSD is expected when adding chemotherapy to pembrolizumab.

The drug-related AEs leading to treatment interruption in the KEYNOTE-966 treatment groups are consistent with the established safety profile of pembrolizumab monotherapy and the known safety profile of chemotherapy. The incremental toxicity when compared with the RSD is expected when adding chemotherapy to pembrolizumab.

## 2.5.2. Conclusions on clinical safety

The safety profile of pembrolizumab in combination with cisplatin and gemcitabine for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults in KEYNOTE966 study overall is consistent with the established safety profiles of pembrolizumab monotherapy, the chemotherapy doublet and the underlying BTC disease. No new safety concerns were identified.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The MAH submitted an updated RMP version (41.0 date of final sign off November 2023) with this application. The (main) proposed RMP changes were the following:

Addition of a new indication for pembrolizumab in combination with gemcitabine-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.

Addition of study KEYNOTE-966 in Modules SIII, SVII, and SVIII; no changes to the risk profile in Modules SIII, SVII, and SVIII.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 41.0 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 41.0 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related adverse reactions                                                                                                                                                                                                                                                                                  |
| Important potential risks    | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information          | None                                                                                                                                                                                                                                                                                                              |

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance studies that are required for pembrolizumab.

## Risk minimisation measures

| Safety Concern                                                                                                                                | Risk Minimisation Measure                                                                                                                                                                                                                                   | Pharmacovigilance Activities                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks: Immune-Related Adverse Reactions                                                                                   | Important Potential Risks: Immune-Related Adverse Reactions                                                                                                                                                                                                 | Important Potential Risks: Immune-Related Adverse Reactions                                                                                       |
| Immune-related adverse reactions                                                                                                              | Routine risk minimisation measures: • The risk of the immune-mediated adverse reactions associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Routine pharmacovigilance activities                                                                                                              |
|                                                                                                                                               | Additional risk minimisation measures: • Patient card                                                                                                                                                                                                       | Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types |
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                   | Important Potential Risks                                                                                                                         |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: • For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and                      | Routine pharmacovigilance activities Additional pharmacovigilance including:                                                                      |

<div style=\"page-break-after: always\"></div>

|                                                                                      | appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted                                                                                                                                                                      | • Safety monitoring in the ongoing HL trial (KN204).                                                                                                                                   |
|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GVHD after pembrolizumab administration in patients with a history of allogeneic SCT | Routine risk minimisation measures: • GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons: no changes of the package leaflet are foreseen impacting the safe use of the medicinal product.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The final indication is: KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the firstline treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.

The BTC comprises a heterogeneous group of malignancies affecting the biliary tree that are distinguished based on the anatomical localisation (gallbladder, intrahepatic, perihilar, and distal/periampullary). Given the rare frequency of these tumours, the different subtypes are generally pooled together although carrying different epidemiology, risk factors, clinical presentation, molecular features, and prognosis (Manne et al , 2021) 8 .

8 Manne, A., Woods, E., Tsung, A. and Mittra, A. (2021) 'Biliary tract cancers: treatment updates and future directions in the era of precision medicine and immuno-oncology', Frontiers in Oncology, 11, pp. 1-16. doi: 10.3389/fonc.2021.768009.

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

Chemotherapy has long been the SoC for first-line treatment of advanced BTC, and the cisplatin gemcitabine doublet is the most common therapy adopted in the advanced stage of cancer. On 16 December 2022, durvalumab in combination with gemcitabine and cisplatin was approved for the treatment of BTC based on a modest survival advantage compared to chemotherapy alone as observed in the TOPAZ-1 study (EMEA/H/C/004771/II/0046). This combination is recommended as first-line treatment of advanced BTC (ESMO 2023). However, prognosis remains extremely poor with a median OS below 1 year in treated patients (Valle et al ., 2010) 9 , which makes the BTC a condition of significant unmet medical need.

## 3.1.3. Main clinical studies

The current procedure is supported by one single pivotal phase III double-blind randomized KEYNOTE966 study comparing the efficacy and safety of pembrolizumab in combination with gemcitabine plus cisplatin to placebo in combination with gemcitabine plus cisplatin.

## 3.2. Favourable effects

- Pembrolizumab, in addition to gemcitabine plus cisplatin, provided advantage compared to placebo in addition to gemcitabine plus cisplatin on the primary endpoint OS (HR=0.83; 95% CI: 0.72, 0.95; p=0.0034), with a gain in median survival of 1.8 months (12.7 vs 10.9).
- Subgroup analysis demonstrated consistency across most of the prespecified subgroups: age, geographic region, locally advanced vs metastatic, ECOG PS, biliary stent/biliary drain, antibiotics within 1 month of study start, smoking status, prior chemotherapy, PD-L1 expression (CPS&gt;=1 vs &lt;1), PD-L1 expression (CPS &lt;10 vs &gt;=10), MSS, hepatitis B status, subsequent therapies.

## 3.3. Uncertainties and limitations about favourable effects

- The survival gain exerted by pembrolizumab over placebo was modest, with a 1.8 month increase in median OS compared to placebo.
- PFS did not meet statistical significance, although it showed a trend towards improvement in the experimental vs the control arm (HR=0.86; 95% CI: 0.75, 1; p=0.0225) at IA1 that was confirmed at the FA (HR=0.87; 95% CI: 0.76, 0.99; p=0.0171).
- It was observed a lower performance of pembrolizumab in OS for the gallbladder (HR=0.96; 95% CI: 0.73, 1.26) and extrahepatic (HR=0.99; 95% CI: 0.73, 1.35) tumour, compared to the intrahepatic cancer (HR=0.76; 95% CI:0.64,0.91). Due to the availability of limited clinical data and poor knowledge, no firm conclusions can be derived on the reasons and biological plausibility underlying inconsistency in treatment effect across tumour locations. Considering the absence of a detrimental effect in these subgroups, it can be concluded that a positive B/R of pembrolizumab in association to chemotherapy applies regardless of anatomical classification.
- The screen failure rate was higher than expected, mostly associated with inappropriate organ function as defined by the inclusion criteria. This questions the external representativeness of the study for the target population. The main reason for screen failure was concomitant disease-

9 Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721. PMID: 20375404.

<div style=\"page-break-after: always\"></div>

associated liver dysfunction at baseline. Although gemcitabine administration is not contraindicated in patients with liver dysfunction, it needs to be carefully monitored due to the anticipated liver toxicity. In order to inform the treating physicians, a statement including the specifications for liver function of patients enrolled in KEYNOTE-966 has been included in section 5.1 of the SmPC.

## 3.4. Unfavourable effects

- Treatment-related serious AEs were higher in subjects receiving pembrolizumab plus chemotherapy compared to chemotherapy alone (22.9% vs 15.7%). Pruritus, rash and pyrexia were more common in patients receiving pembrolizumab.
- Grade 3 to 5 adverse events occurred in a comparable proportion in the two study arms (85.3% vs 84.1%). The most frequently reported Grade 3 to 5 AEs (incidence ≥ 5%) in the pembrolizumab plus chemotherapy group were neutrophil count decreased, anaemia, platelet count decreased, WBC count decreased, and cholangitis.
- Deaths due to drug-related AEs were reported in 1.5% of the pembrolizumab plus chemotherapy group and 0.6% of the placebo plus chemotherapy group.
- The proportion of participants in the pembrolizumab plus chemotherapy group who experienced 1 or more AEs that led to discontinuation of any study treatment was generally similar compared with the placebo plus chemotherapy group (26.1% vs 22.8%).
- The frequency, severity, and types of AEOSI observed in the pembrolizumab plus chemotherapy group were generally consistent with pembrolizumab used as a single agent.
- Patients aged 65-year or older experienced more drug-related AEs and SAEs, resulting in a higher proportion of treatment discontinuations.
- The rate of HECI was generally similar in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups (9.3% vs 10.7%).

## 3.5. Uncertainties and limitations about unfavourable effects

- The assessment of safety in patients aged ≥ 75 years is hampered by the low number of patients in this age group (68 vs 57). In the SmPC, a general warning that pembrolizumab in combination with chemotherapy should be used with caution in patients ≥75 years after careful consideration of the potential benefit/risk on an individual basis is already included (see SmPC 5.1).
- With the addition of pembrolizumab, the rate of hepatic events (cholangitis and biliary infections) furtherly increased in patients with biliary stents/drainage (39% vs 29%). A warning to closely monitor patients with biliary stents/drainage has been included in section 4.4 of the SmPC.

## 3.6. Effects Table

Table 67 Effects table for KEYTRUDA in combination with cisplatin and gemcitabine in KEYNOTE-966 study (data cut-off: 15-DEC-2022)

| Effect             | Short description                                           | Unit               | Treatment          | Control            | Uncertainties / Strength of evidence         | References         |
|--------------------|-------------------------------------------------------------|--------------------|--------------------|--------------------|----------------------------------------------|--------------------|
| Favourable Effects | Favourable Effects                                          | Favourable Effects | Favourable Effects | Favourable Effects | Favourable Effects                           | Favourable Effects |
| OS                 | duration of survival from randomization to death regardless | month s (95%       | 12.7 (11.5, 13.6)  | 10.9 (9.9, 11.6)   | Subgroup analysis showed inconsistent effect | CSR                |

<div style=\"page-break-after: always\"></div>

| Effect               | Short description                                                                                   | Unit                 | Treatment            | Control              | Uncertainties / Strength of evidence                                   | References           |
|----------------------|-----------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|------------------------------------------------------------------------|----------------------|
|                      | of cause                                                                                            | CI)                  |                      |                      | across relevant BTC subtypes                                           |                      |
| PFS                  | duration of survival without progression from randomization to PD or death whichever occurred first | month s (95% CI)     | 6.5 (5.7, 6.9)       | 5.6 (4.9, 6.5)       | Did not meet statistical significance / Trend maintained in IA1 and FA |                      |
| ORR                  | Confirmed CR + PR                                                                                   | %                    | 29.3                 | 28.4                 | Did not meet statistical significance                                  |                      |
| DoR                  | Duration of CR/PR until documented PD                                                               | month s (95% CI)     | 8.3 (1.2+ -33.0+)    | 6.8 (1.1+ - 30.0+)   |                                                                        |                      |
| Unfavourable Effects | Unfavourable Effects                                                                                | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                   | Unfavourable Effects |
| summary              | G3-5 AEs                                                                                            | %                    | 71.3                 | 69.3                 | safety profile consistent with the known                               |                      |
|                      | SAE                                                                                                 | %                    | 52.2                 | 49.3                 |                                                                        |                      |
|                      | Discontinuation due to AEs                                                                          | %                    | 26.1                 | 22.8                 | safety profile of                                                      |                      |
|                      | AEOSI Hypothyroidism Pneumonitis Hyperthyroidism                                                    | %                    | 22.1 8.7 4.9 3.6     | 12.9 2.6 1.9 1.9     | pembrolizumab in combination with chemotherapy                         |                      |
|                      | HECI                                                                                                | %                    | 9.3                  | 10.7                 |                                                                        |                      |

Abbreviations: AE= adverse event; SAE=serious adverse event; AEOSI= adverse event of special interest; IRR=infusion related reaction; CRS=clinical study report; HECI= Hepatic events of clinical interest

Notes: not applicable

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Pembrolizumab, as add-on therapy to gemcitabine+cisplatin for the first-line treatment of locally advanced unresectable or metastatic BTC, provided advantage in OS compared to gemcitabine+cisplatin alone (HR=0.83; 95% CI: 0.72,0.95; p=0.0034). However, only a modest effect in terms of gain in median survival was obtained (i.e. 1.8 months; 12.7 vs 10.9). This finding is similar to what was observed with drugs of the same class in the same setting (durvalumab plus gemcitabine+cisplatin in the TOPAZ-1 trial). The secondary endpoint PFS showed a trend towards improvement in the experimental arm relative to control that did not meet statistical significance (HR=0.86; 95% CI:0.75,1; p=0.0225) at IA1, that was confirmed at the FA (HR=0.87; 95% CI: 0.76, 0.99; p=0.0171). The ORR was unchanged by pembrolizumab treatment (28.7% vs 28.5% in the pembrolizumab and placebo arm, respectively at IA1; 29.3% vs 28.4% in the pembrolizumab and placebo arm, respectively at FA), although a slightly longer duration of response was achieved in the experimental arm compared to control (9.7 vs 6.9 months at IA1; 8.3 vs 6.8 months at FA). The pre-specified subgroup analysis showed a lower performance of pembrolizumab in OS for the gallbladder (HR=0.96; 95% CI: 0.73, 1.26) and extrahepatic (HR=0.99; 95% CI: 0.73, 1.35) tumours, compared to the intrahepatic subtype (HR=0.76; 95% CI: 0.64, 0.91). The PFS and ORR followed the same trend, with PFS reaching a HR&gt;1 in the extrahepatic localisation, and ORR showing even disadvantage of pembrolizumab vs placebo in the extrahepatic and gallbladder cancer sites. However, considering the limited value of subgroup analyses and the absence of a detrimental effect in these subgroups based on OS data, it can be concluded that a favourable effect of pembrolizumab in association to chemotherapy applies regardless of primary tumour location.

<div style=\"page-break-after: always\"></div>

Overall, the safety profile of pembrolizumab in KEYNOTE-966 study is consistent with the established toxicity of pembrolizumab monotherapy, the chemotherapy doublet and the underlying BTC disease. No new safety concerns were identified.

## 3.7.2. Balance of benefits and risks

The benefit/risk ratio of pembrolizumab, as add-on therapy to gemcitabine+cisplatin for the first-line treatment of locally advanced unresectable or metastatic BTC, is considered positive.

## 3.7.3. Additional considerations on the benefit risk balance

None.

## 3.8. Conclusions

The overall B/R of KEYTRUDA is positive as add-on therapy to gemcitabine+cisplatin for the first-line treatment of locally advanced unresectable or metastatic BTC.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include KEYTRUDA in combination with gemcitabine and cisplatin for the firstline treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, based on final results from study KEYNOTE-966; this is a Phase 3 randomized, double blind study of Pembrolizumab plus Gemcitabine/Cisplatin versus Placebo plus Gemcitabine/Cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 41.0 of the RMP has also been submitted.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that KEYTRUDA is not similar to Pemazyre, Tibsovo and Lytgobi within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.